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Congenital diaphragmatic hernia (CDH) is a congenital anomaly that occurs in about 
1 per 2000-3000 live births1,2. The reported incidence rates vary worldwide, in part 
dependent on case selection and source of reporting, since abortions and stillbirths are 
not always taken into account. In the Netherlands, about 50 to 60 infants with CDH are 
born alive each year. The mortality rate varies from about 20 to 40%, depending on the 
presence of associated malformations such as cardiac defects2-4. Despite many advances 
in the treatment in recent decades, CDH remains clinically and scientifically a challeng-
ing condition.
BACKGroUnD
The first report by Pare of two cases with a traumatic diaphragmatic hernia dates 
from 15755. In 1672, Riverius described a diaphragm defect as an incidental finding 
during autopsy in a 24-year-old man6. In 1769, Morgagni had classified different types 
of congenital diaphragmatic defects7. Bochdalek in 1848 was the first who described 
the posterolateral defect and suggested that a surgical correction would be useful in 
the treatment next to recognizing the role of pulmonary hypoplasia on outcome8. The 
terms ‘Bochdalek hernia’ and ‘Morgagni hernia’ are still being used. The Bochdalek hernia 
on the left posterolateral side is seen in more than 90% of the cases, while a defect in 
the anterior part of the diaphragm, the Morgagni hernia, is rare9,10. In the early 20th 
century, Heidenhain was the first surgeon who successfully performed a surgical repair 
in an infant with CDH11, who survived into adulthood12. Despite this successful outcome, 
surgical correction of CDH remained uncommon for some decades.
In 1921, the importance of pulmonary hypoplasia related to CDH was recognized. 
Several decades later, pulmonary hypertension was considered the most challenging 
condition to treat. Because pulmonary hypertension affect the already vulnerable lungs 
of the neonate with CDH, finding the optimal ventilation management remained dif-
ficult13. Milestones in the treatment of CDH were the introduction of delayed surgical 
repair after initial stabilization14, and the availability of the ‘gentle ventilation strategy’ 
with permissive hypercapnia15,16. The introduction of prenatal ultrasonography17 al-
lowed for early recognition of the anomaly, enabling start of optimal treatment as soon 
as possible in individual cases.
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PrEDiCtion
Antenatal period
A marker, either a diagnostic/ monitoring biomarker or clinical prediction score, should 
add useful information to the already available information and would ideally have both 
a high sensitivity and specificity, a high predictive value, and high robustness18.
When prenatal ultrasound techniques became sufficiently powerful, the second 
trimester ultrasound screening test was introduced to detect congenital anomalies, 
including CDH19. In the Netherlands, the prenatal ultrasound screening test was intro-
duced relatively late (in 2007) compared with other countries in Europe. In case of a 
diaphragm defect, abdominal organs can be visualized when obtaining a four-chamber 
view of the heart. A mediastinal shift caused by herniation of the stomach, intestine or 
liver into the chest, is often seen. A left-sided diaphragmatic defect is easier to detect 
than a right-sided defect because in the latter case the liver is most often herniated. The 
liver is more echogenic than intestine or stomach, and therefore hard to distinguish from 
lung20. Next to recognizing the CDH, it is important to detect any associated anomalies 
because these can have an impact on prognosis.
Several antenatal predictive markers for CDH outcome in patients have been proposed, 
such as the lung-to-head circumference ratio (LHR) and the observed-to-expected 
LHR (O/E LHR). Metkus et al were the first to describe the LHR21. It is calculated as the 
length of the longest axis of the contralateral lung multiplied by the longest diameter 
perpendicular to it, divided by the head circumference. However, the LHR increases over 
gestational age since between 12 and 32 weeks of gestation normal lungs increase in 
size four times more than the head circumference22. Ba’ath et al examined the usefulness 
of the LHR (measured until 32 weeks of gestation) and found no significant difference in 
LHR between survivors and non-survivors23.
The O/E LHR is calculated by dividing the observed LHR as explained above by the 
expected LHR. The expected LHR using the longest diameter method is calculated by 
different formulas for left and right CDH23. Peralta et al found that it was more accurate 
to trace the lung contours in normal lungs22. If this method is chosen for CDH patients, 
other formulas are used, also different for left and right CDH24.
Other prenatal measures which have shown prognostic value are the position of the 
liver (either intra-abdominal or intrathoracic)25,26, the position of the stomach (either in-
tra-abdominal or intrathoracic)27, and the side of the defect. Next to prenatal ultrasound 
measurements, fetal MRI is suitable to accurately measure lung sizes20. Still we should 
be aware that none of these prenatal markers can be used alone as a predictor since the 
level of postnatal care is the main determinant of outcome of individual patients.
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Postnatal period
Because the outcome of CDH patients is highly variable, it would be ideal to be able to 
predict this as soon as possible. Since in prenatal measurements the transitional phase 
after birth obviously cannot be taken into account, postnatal clinical parameters might 
have more accurate predictive value. Many researchers have searched for reliable pre-
diction models, based on several different clinical parameters.
In 2001 the CDH Study Group developed a prediction model containing the 5 minute 
Apgar score and birth weight28. In 2007, Schultz et al developed a prediction model 
based on blood gas analysis obtained in the first 24 hours of life and found that their 
model had better predictive abilities than previous models29. However, Baird et al could 
not validate the model of Schultz et al in a different dataset30. Based on a study including 
2022 infants with CDH, Brindle et al recently developed a validated clinical prediction 
rule that could identify infants at low, intermediate and high risk of death at the time 
of the first postnatal echocardiogram31. Their model was based on the birth weight, 
Apgar score at 5 minutes of life, presence of severe pulmonary hypertension, presence 
of major cardiac anomaly, and the presence of chromosomal anomaly. Their study is 
limited as many values for at least one of the parameters are missing (most often Apgar 
score and presence of severe pulmonary hypertension when echocardiography was not 
performed). Second, patients were born in different centers and not treated according 
to a standardized treatment protocol. In CDH patients, retrospective studies have shown 
that SNAP-II scores were higher in patients with a worse outcome32,33. Those studies, 
however, included relatively few patients (47 and 88 patients) and one was performed 
before the introduction of a gentle ventilation strategy32.
Instead of clinical parameters, specific tests from blood or other body fluids might 
serve as better prognostic objective markers. Biomarkers are defined as characteristics 
that can objectively be measured and evaluated as indicators of normal biological 
processes, pathogenic processes, or pharmacologic responses to therapeutic interven-
tions34.
Various biomarkers have been studied in CDH patients in relation to pulmonary hyper-
tension. Kobayashi et al found that levels of ICAM-1, ELAM-1, and VCAM-1 liberated by 
activated vascular endothelium were higher in CDH patients with pulmonary hyperten-
sion than in CDH patients without pulmonary hypertension35. Keller et al investigated 
the predictive role of entohelin-1, which is dysregulated in pulmonary hypertension36. It 
appeared that non-survivors or patients discharged on oxygen had higher plasma ET1 
levels. Patel et al prospectively investigated the relationship between plasma vascular 
endothelial growth factor A (VEGFA) and placental growth factor (PLGF) and measures 
of pulmonary artery pressure, oxygenation, and cardiac function37. They found that in-
creased plasma VEGFA and reduced PLGF correlated with clinical severity of pulmonary 
vascular disease37. Fleck et al found that cord blood levels of epidermal growth factor, 
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platelet-derived growth factor, and several inflammatory mediators increased with 
higher severity of pulmonary hypertension38.
The predictive value of B-type natriuretic peptide (BNP) or N-terminal pro BNP was 
investigated in several studies. These biomarkers were found useful in predicting the 
severity of pulmonary hypertension, although those studies were limited in having a 
single center design with relatively low sample sizes39,40, or retrospective designs41.
trEAtmEnt
Also because findings from randomized clinical trials specifically for CDH patients were 
still lacking, centers in the past used widely varying treatment protocols, if any. In 1995, 
the CDH study group was founded42,43 and started to collect data in a large database 
enabling to evaluate treatment strategies and enhance further research. However, 
research based on these data is still limited by the lack of standardized therapy between 
centers. In 2006, a European cooperative network of tertiary centers with expertise in 
CDH was founded, named the CDH EURO Consortium. The Consortium acknowledged 
the need for standardized therapy and therefore a standardized neonatal treatment 
protocol was implemented in 2008. The protocol was based upon levels of evidence and 
expert opinion, and consensus was reached during a consensus meeting44. Recommen-
dations are given on prenatal management and delivery, management in the delivery 
room, management in the ICU including management of ventilation and pulmonary 
hypertension, criteria for extracorporeal membrane oxygenation (ECMO) and surgical 
repair, sedation and analgesia and fluid management (see appendix 1).
Since 2008, all infants with CDH born in one of the participating centers of the CDH 
EURO Consortium have been treated according to this protocol. After implementation of 
the protocol, survival rates significantly increased from 67% to 88% in the high-volume 
centers in Mannheim and Rotterdam (≥ 10 CDH cases a year45). This finding emphasizes 
that standardized treatment is of paramount importance. Most recommendations in 
the original protocol, however, were based on expert opinion or on nonanalytic studies 
such as case reports or case series. An urgent need for randomized clinical trials was 
acknowledged, therefore, and the consortium designated the issue of the optimal initial 
ventilation strategy as the most important remaining research question. Consequently, 
a randomized clinical trial of initial ventilation strategy was set up including inborn 
neonates with a prenatal diagnosis of CDH and born after more than 34 weeks of gesta-
tion46. Immediately after delivery, they were randomized for initial ventilation strategy 
(either conventional mechanical ventilation or high-frequency oscillation).
Nowadays all infants with CDH are routinely intubated immediately after birth. 
However, ventilator-induced lung injury (VILI) is associated with worse outcome in CDH, 
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which raises the question whether this practice should be maintained in CDH infants 
with a good expected prognosis. On the other hand, other strategies such as liquid 
ventilation might serve as better ventilation modes in the most severe CDH cases.
oUtComE
As mortality in CDH has decreased, attention for morbidity and long-term follow-up 
has been increased. Previous studies have shown that about 87% of CDH survivors 
had a kind of associated morbidity, mainly pulmonary or gastro-intestinally related47,48. 
Gastro-esophageal reflux may be treated both by antireflux medication and by surgical 
intervention49. No prospective studies are available on the specific type of preventive 
antireflux medication. Several studies have shown that CDH infants are also at risk for 
impaired growth, mainly at young age50-52.
Potentially even more importantly is the children’s neurodevelopment, which can be 
assessed in a standardized way. Of the various test instruments, the Bayley Scales of 
Infant Development (BSID) is often used, and in some countries population normative 
data are available. Several studies on neurodevelopment have been published in recent 
years. From 24% to 32% of children had delayed cognition, and from 23% to 73% had 
delayed motor function53-56. Most of these studies, however, were performed in single 
centers, had small case series and cross-sectional designs.
ConSiDErAtion
Despite standardized therapy, survival rates in the various centers still differ. One of the 
most important differences in treatment between centers is the availability of ECMO57. 
Even in the CDH EURO Consortium, ECMO is not available in all centers. ECMO treat-
ment is indicated for the most severely ill patients, and is initiated most often because 
of severe respiratory or cardiovascular failure not responding to conventional intensive 
care treatment due to suprasystemic pulmonary hypertension58. Either the venoarterial 
or venovenous ECMO mode can be used, but the former is still preferred for CDH59. The 
impact of choice of mode on survival, however, is subject of debate.
One of the determinants of outcome next to patient characteristics such as liver posi-
tion60, diaphragmatic defect size61, stomach position27, and O/E LHR62, is the expertise 
of the CDH center. Bucher et al found that high-volume CDH centers achieve better 
survival rates as compared to low-volume CDH centers45. It could be hypothesized that 
despite the use of a standardized treatment protocol, survival rates still differ between 
centers because of different patient populations.
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AimS AnD oUtlinE of tHiS tHESiS
The aim of this thesis is to evaluate several aspects of CDH after the introduction of the 
standardized neonatal treatment protocol from the CDH EURO Consortium.
In the fi rst place, clinical parameters and biomarkers with a potential predictive role 
are investigated. Second, one of the most important remaining questions in treatment, 
the optimal initial ventilation strategy, is studied. Lastly, diff erences in outcome such as 
survival and neurodevelopment between centers are studied. The content is divided 
into six parts; the fi gure below illustrates how these are related and what chapters fall 
under each part.
Part ii focuses on the predictive role of both clinical parameters and biochemical 
parameters. Chapter 2 deals with the usefulness of a prenatal ultrasound measurement 
figure 1 – Overview of chapters in this thesis
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(the O/E LHR) in the prediction of outcome in isolated left CDH. The predictive value of 
the Score for Neonatal Acute Physiology- II (SNAP-II score) in infants with CDH is inves-
tigated in chapter 3. The predictive role of sphingolipids, analyzed in tracheal aspirates 
from CDH infants, is evaluated in chapter 4. Chapter 5 evaluates blood biomarkers (hs-
TroponinT and NT-proBNP) associated with impaired outcome in prenatally diagnosed 
CDH infants.
Part iii describes different aspects of the treatment of CDH patients. Chapter 6 
describes the multicenter randomized clinical trial on ventilation strategies (VICI-trial). 
Prenatally diagnosed CDH infants were randomized to either conventional mechanical 
ventilation of high-frequency oscillation. In an editorial, the role of liquid ventilation is 
CDH patients is discussed (chapter 7). The clinical course of five prenatally diagnosed 
CDH infants with a very good expected prognosis, in whom routine postnatal intuba-
tion was not performed, is presented in chapter 8. Pharmacodynamic considerations in 
the treatment of pulmonary hypertension in infants, including CDH infants, are studied 
in chapter 9. In chapter 10 an update of the standardized postnatal management of 
infants with CDH is described. Consensus of optimal treatment was reached within the 
CDH EURO Consortium.
Part iV concerns the neurodevelopmental outcome in high-risk CDH infants at the 
ages of one and two years, assessed from psychomotor development and mental de-
velopment as evaluated in two prospective standardized follow-up programs from two 
high-volume centers (chapter 11).
In Part V the influence of patient characteristics and center specific differences on 
outcome is evaluated (chapter 12).
In Part Vi results of the studies are placed in a broader perspective, and areas of cur-
rent and future research projects are described in chapter 13. Results of the studies are 
summarized in chapter 14.
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APPEnDix 1
Prenatal diagnosis and delivery
Following prenatal diagnosis, the absolute and O/E LHR and the position of the liver should be evaluated.
Planned vaginal delivery or cesarean section after a gestational age of 37 weeks in a designated tertiary center 
should be pursued.
In case of preterm labor prior to 34 weeks of gestation, antenatal steroids should be given.
initial treatment and procedures in the delivery room
After delivery, the infant should be intubated immediately without bag and mask ventilation.
The goal of treatment in the delivery room is achieving acceptable preductal saturations levels between 80 and 
95%.
Ventilation in the delivery room may be done by conventional ventilator or ventilation bag with a peak 
pressure as low as possible, preferably below 25 cm H2O.
An oro- or nasogastric tube with continuous or intermittent suction should be placed.
Arterial blood pressure has to be maintained at a normal level for gestational age. In case of hypotension and/ 
or poor perfusion, 10-20 ml/kg NaCl 0.9% should be administered 1-2 times and inotropic agents should be 
considered.
Sedatives and analgesics should be given.
No routine use of surfactant in either term or preterm infants with CDH.
Ventilation management in the intensive Care Unit
Adapt treatment to reach a preductal saturation between 85 and 95% and a postductal saturation above 70%.
In individual cases, preductal saturation above 80% might be acceptable, as long as organs are well perfused.
The target PaCO2 range should be between 45 and 60 mmHg.
Pressure-controlled ventilation initial settings are a peak inspiratory pressure of 20-25 cm H2O and a positive 
end expiratory pressure of 2-5 cm H2O; ventilator rate of 40- 60/min.
High-frequency oscillation: initial setting are a mean airway pressure 13-17 cm H2O, frequency 10 Hz, ΔP 30-50 
cm H2O depending on chest wall vibration.
After stabilization, the FiO2 should be decreased if preductal saturation is above 95%.
further management in the intensive Care Unit
If symptoms of poor perfusion and/or blood pressure below the normal level for gestational age occur and are 
associated with preductal saturation below 80%, echocardiographic assessment should be performed.
In case of hypovolemia, isotonic fluid therapy 10-20 ml/kg NaCl 0.9% up to 3 times during the first 2 hours may 
be given and inotropics should be considered.
Pulmonary hypertension management
Perform echocardiography within the first 24 hours after birth.
Blood pressure support should be given to maintain arterial blood pressure levels at normal levels for 
gestational age.
Inhaled nitric oxide should be considered if there is evidence of extrapulmonary right-to-left shunting and the 
oxygenation index is above 20 and/or the saturation difference is more than 10%.
In case of suprasystemic pulmonary artery pressure and right-to-left shunting through the foramen ovale, 
intravenous prostaglandin E1 has to be considered.
Introduction • 25
Ch
ap
te
r 1
Extracorporeal membrane oxygenation (ECmo)
Criteria for ECMO :
–  Inability to maintain preductal saturations >85% or postductal saturations >70%.
–  Increased PaCO2 and respiratory acidosis with pH <7.15 despite optimization of ventilatory management.
–  Peak inspiratory pressure >28 cm H2O or mean airway pressure >17 cm H2O is required to achieve saturation 
>85%.
–  Inadequate oxygen delivery with metabolic acidosis as measured by elevated lactate ≥5 mmol/l and pH 
<7.15.
–  Systemic hypotension, resistant to fluid and inotropic therapy, resulting in urine output <0.5 ml/kg/h for at 
least 12- 24 hours.
–  Oxygenation index ≥40 consistently present.
timing of surgical repair and postoperative management
Surgical repair of the defect in the diaphragm should be performed after physiological stabilization, defined as 
follows:
–  Mean arterial blood pressure normal for gestational age;
–  Preductal saturation levels of 85- 95% SaO2 on fractional inspired oxygen below 50%;
–  Lactate below 3 mmol/ l;
–  Urine output more than 2 ml/kg/h.
No routine chest tube placement.
Repair on ECMO may also be considered.
Sedation and analgesia
Infants should remain sedated and be monitored using validated analgesia and sedation scoring systems.
Neuromuscular blocking agents should be avoided if possible.
Enteral feeding and gastroesophageal reflux
Enteral feeding should be started postoperatively combined with antireflux medication.
fluid management and parenteral feeding
40 ml/kg/day including medication for the first 24 hours, intake increases thereafter.
Diuretics should be considered in case of a positive fluid balance, aim for diuresis of 1- 2 ml/kg/hour.

Part ii
Prediction

Chapter 2
The validity of the observed-to-
expected lung-to-head ratio in 
congenital diaphragmatic hernia 
in an era of standardized neonatal 
treatment; a multicenter study
Kitty G. Snoek, Nina C. Peters, Joost van Rosmalen, Arno van Heijst, 
Alex J. Eggink, Esther Sikkel, René M. Wijnen, Hanneke IJsselstijn, 
Titia E. Cohen-Overbeek, Dick Tibboel
Submitted for publication
30 • Chapter 2
ABStrACt
objective: To assess the predictive value of observed-to-expected lung-to-head ratio 
(O/E LHR) for survival and chronic lung disease (CLD) in survivors of left-sided congenital 
diaphragmatic hernia (CDH) in an era of standardized neonatal treatment. Furthermore, 
we evaluated the predictive value for survival of changes of O/E LHR values during 
gestation.
methods: This study was performed in two high-volume CDH centers in the Nether-
lands. Observed-to-expected lung-to-head ratio (O/E LHR) and liver position was deter-
mined using 2D ultrasonography at 19+0-24+0 weeks gestational age (GA), between 
24+1-29+6 weeks GA, and ≥30 weeks GA in prenatally detected, isolated left-sided CDH 
patients prenatally detected born between 2008 and 2014. Ultrasound measurements 
were performed by one single experienced operator. All patients were treated according 
to a standardized neonatal treatment protocol.
results: Of the 126 included isolated left-sided CDH cases, 97 patients (77.0%) survived, 
of which 38 (39.2%) developed CLD. Multivariable logistic regression analysis including 
the first measured O/E LHR per patient and prenatal liver position showed that the O/E 
LHR was significantly associated with survival (OR 1.11; 95% CI 1.056- 1.176, p<0.001), 
and development of CLD in survivors (OR 0.96; 95% CI 0.917- 0.995, p=0.03). Prenatal 
liver position was not significantly associated with survival or development of CLD in 
survivors. Longitudinal analyses of the O/E LHR measurements during gestation showed 
no significant association of the trajectory of O/E LHR with survival.
Conclusion: In an era of standardized neonatal treatment, the first measured O/E LHR 
per patient significantly predicts survival and development of CLD in survivors in iso-
lated left-sided CDH infants.
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introDUCtion
Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 2200 live births1. 
Although the survival rate has significantly increased in the last decade to about 70-
80%2, CDH is still a life-threatening congenital anomaly3. Various prenatal parameters 
are related to a worse prognosis, such as a right-sided diaphragmatic hernia, (prenatal) 
herniation of the liver into the thorax, and associated congenital and/or chromosomal 
malformations4,5.
Metkus et al. were the first in 1996 who described the predictive value of lung-to-head 
ratio (LHR) in CDH patients6. Since the LHR increases exponentially with gestation in 
normal fetuses7, the observed-to-expected LHR (O/E LHR) was introduced in 2007 by 
Jani et al. in a multicenter study in 354 isolated CDH fetuses8. Thereafter, several studies 
have demonstrated that O/E LHR is a useful predictor of outcome9-11.
In fetuses with severe CDH (O/E LHR <25%) (NCT01240057) and fetuses with moder-
ate CDH (O/E LHR 25-34.9% or O/E LHR 35-44.9% with intrathoracic liver herniation) 
(NCT00763737) the benefit of fetoscopic endotracheal occlusion (FETO) is currently 
being investigated in randomized controlled studies. Groups were based on survival 
rates in the study from Jani et al8, which is the largest study to date. However, in that 
period there was still a lack of postnatal standardization of treatment, which has proven 
in the meantime to have influenced postnatal outcome, reaching survival rates up to 
over 80%12. Secondly, in their study each of the participating centers provided the data. 
Information concerning inter-observer reproducibility was not available and variability 
in prenatal ultrasound measurements may have influenced the results.
From 2008 onwards, all patients born in one of the centers from the CDH EURO Consor-
tium have been treated according to a standardized neonatal treatment protocol13. Sub-
sequent high survival rates might influence the “original” cut-off points and their validity 
at present for counseling future couples. Therefore, we evaluated the predictive value of 
O/E LHR established in the two Dutch prenatal CDH centers on survival and development 
of chronic lung disease (CLD) when neonates are subjected to an optimal standardization 
of treatment with ECMO availability. Moreover we evaluated the significance of the used 
cutt-off values for prediction of outcomes.
mEtHoDS
This is an observational retrospective cohort study. All patients with a prenatal diagnosis 
of CDH, born between January 2008 and December 2014, and treated in the Erasmus MC 
University Medical Center, Rotterdam, The Netherlands or Radboud University Medical 
Center, Nijmegen, The Netherlands were included. Since all infants from the Netherlands 
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with a CDH are referred to one of the two CDH centers, this represents a nationwide 
cohort. Exclusion criteria were defined as: right-sided CDH, termination of pregnancy, 
gestational age at birth < 30 weeks, and associated major structural or chromosomal 
anomalies. Since subjects are not being submitted to any handling, nor are there rules of 
human behavior being imposed, Institutional Review Board approval was waived by the 
ethical committee of the Erasmus Medical Center, Rotterdam, The Netherlands.
The original ultrasound image of a transverse plane of the fetal chest at the level of the 
four-chamber view of the heart was retrieved from patient records and used for measure-
ment of the contralateral (right) lung. The lung area was measured by manual tracing of 
the limits of the lung (mm2) Also the head circumference (mm) was determined. The 
O/E LHR was then calculated as described by Jani et al14. Prenatal ultrasound measure-
ments were performed using the GE Voluson E8 or E10 system (GE Medical Systems, 
Zipf, Austria) at the Department of Obstetrics and Gynecology, Division of Obstetrics 
and Prenatal Medicine at the Erasmus University Medical Center. The measurements 
were performed by one single experienced operator (NP) who was unaware of postnatal 
outcome. Ultrasound measurements were categorized as follows; ultrasound 1: 19+0-
24+0 weeks gestational age (GA), ultrasound 2: 24+1-29+6 weeks GA, and ultrasound 3: 
≥30+0 weeks GA. Postnatal patient characteristics were retrieved from medical records. 
Patient demographics included: gestational age at birth, birth weight, gender, associ-
ated major structural or chromosomal anomalies, FETO, side of diaphragmatic hernia, 
liver position (intrathoracic/ intra-abdominal) determined during prenatal ultrasound 
and surgical repair, diaphragmatic defect size (A/B/C/D), need for ECMO, survival and 
presence of CLD in survivors. Survival was defined as survival after the first year of life. 
CLD was defined as oxygen dependency (>0.21) at day 28 of life15. Since 2008 all patients 
have been treated according to a standardized neonatal treatment protocol13. ECMO 
therapy was available for patients born after >34 weeks gestation and birth weight 
above 2000 grams during the complete study period. Severity of CDH was divided in the 
same groups as proposed by Deprest et al16: Extreme CDH (O/E LHR <15), severe CDH 
(O/E LHR ≤25%), moderate CDH (O/E LHR 26- 35% or O/E LHR 36- 45% with intrathoracic 
liver position), and mild CDH (O/E LHR 36-45% and liver down or O/E LHR ≥46).
Statistical analysis
Patient characteristics were described as numbers (%) for categorical data, or median 
(interquartile range; IQR) for non-normally distributed data. The first measured O/E LHR 
per patient was selected and used for all analyses, excluding the longitudinal analyses. 
O/E LHR was compared between survivors and non-survivors, and survivors with and 
without development of CLD, using Mann-Whitney tests. O/E LHR was compared be-
tween centers using the Mann-Whitney test. Independent associations between O/E 
LHR and mortality, and CLD in survivors were evaluated using univariable logistic re-
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gression modelling. Multivariable logistic regression analysis with prenatal liver position 
and O/E LHR as independent variableswas then used to evaluate their predictive value 
on survival and development of CLD in survivors. The calibration of the multivariable 
logistic regression models were assessed using the Hosmer-Lemeshow goodness-of-fit 
test.
Receiver operating characteristic (ROC) curves were used to evaluate the prognostic 
value of O/E LHR for mortality, and development of CLD in survivors. Data were presented 
as areas under the ROC curves (AUC); [95% CI]. Optimal cut-off values were determined 
for significant AUC by maximizing the Youden index (sensitivity plus specificity minus 1). 
Univariable logistic regression analysis was repeated in a selection of patients in whom 
the CDH was detected before 24 weeks GA. Results from this group were compared with 
the results of the complete study group to assess whether the O/E LHR observations are 
missing at random. Then, for the evaluation of the predictive value of the trajectory of 
O/E LHR over time on survival in patients not treated with FETO, missing data of O/E LHR 
19+0-24+0 weeks GA (n=64 patients), O/E LHR between 24+1-29+6 weeks GA (n=70), 
and O/E LHR ≥30+0 weeks GA (n=11 patients), were imputed using multiple imputation 
by chained equations in SPSS with 100 imputations. Using the multiple imputation da-
taset, a linear regression of the O/E LHR at the three time points was performed for each 
patient separately, with GA (coded as a continuous variable) as the only independent 
variable. The purpose of this analysis was to summarize the longitudinal data of O/E 
LHR using an estimated level (intercept in the linear regression) and time trend (slope 
in the linear regression). The resulting estimates of the intercept and slope in the linear 
regressions were then used as independent variables in logistic regressions for survival 
and CLD in survivors. The linear regressions were performed using Microsoft Excel 2010, 
and all other analyses were performed using SPSS version 21.0 for Windows. A two-sided 
p-value of <0.05 was considered statistically significant.
rESUltS
During the study period, 238 CDH patients were born alive with a CDH in the Nether-
lands. In176 patients, the CDH was prenatally detected. Reasons for exclusions for the 
study are summarized in Figure 1. In total, 126 patients with a prenatal diagnosis of an 
isolated left CDH were included. In the study group, 97 (77.0%) patients survived, and 38 
(39.2%) of the survivors developed CLD (Table 1). Four patients were treated with FETO 
and two of them died postnatally, and of them the first O/E LHR was measured before 
plugging and ranged from 30.2- 40.9%.
O/E LHR and survival rate of patients with CDH were not significantly different between 
the two centers (data not shown). The relationship between O/E LHR and survival, strati-
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figure 1 – Flowchart of inclusion
CDH patients born between January 2008 
and December 2014
n=238
Prenatally diagnosed CDH patients
n=176
Prenatally diagnosed leftsided CDH 
patients
n=143
No prenatal diagnosis
n=62 (26.1%)
Right sided CDH
n=33 (%)
Delivery <30 weeks gestational age 
(GA)
n= 2 (%)
Prenatally diagnosed left-sided CDH patients, 
born ≥30 weeks GA
n= 141
Included patients
n= 126
Associated major malformations
n=9
- Congenital cystic adenomatoid 
malformation 
of the lung (n=3)
- Hypoplastic left heart syndrome (n=1)
- Cornelia de Lange syndrome (n=1)
- Otocephaly- dysgnatia complex (n=1)
- Multiple dysmorphic features, suspect 
for Goldenhar syndrome (n=1)
- Intracardial tumours, suspect for 
tuberous sclerosis   complex (n=1)
- Hypoplastic aortic arch (n=1)
Prenatally diagnosed isolated leftsided CDH 
patients, born ≥30 weeks GA
n= 132
No prenatal images available
n=6
Abbreviations; CDH: congenital diaphragmatic hernia.
figure 2 – O/E LHR per category for survival
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Survival rate according to the fetal observed-to-expected lung area to head circumference ratio (O/E LHR) 
in fetuses with isolated left-sided diaphragmatic hernia. The filled bars represent fetuses with intrathoracic 
herniation of the liver and the open bars represent those without herniation.
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fied by prenatal liver position in each group is shown in Figure 2. None of our patients 
fell in the extreme CDH group (O/E LHR <15%). Only one of four patients (25%) with 
severe CDH (O/E LHR ≤25%) survived. In the moderate group (O/E LHR 26- 35% or O/E 
LHR 36- 45% with intrathoracic liver position) of 47 patients, 31 patients (66.0%) survived. 
In the mild group (O/E LHR 36-45% and liver down or O/E LHR ≥46%), 65 (86.7%) of the 
75 patients survived. In figure 2, 46 patients seem to fall in the moderate group and 
73 patients in the mild group. Those differences are explained by the fact that in the 
moderate group for one patient prenatal liver position was unknown and in the mild 
group for two patients the prenatal liver position was unknown.
table 1 – Background characteristics
Variables CDH patients (n=126)
fEto 4 (3.2%)
Gestational age at delivery (weeks) 38.2 (37.7- 38.7)
Birth before 34 weeks GA 5 (4.0%)
Birth before 37 weeks GA 20 (15.9%)
Birth weight (grams) 3000 (2700- 3200)
Gender: male 65 (51.6%)
Prenatal liver position
 Intra-abdominal 69 (54.8%)
 Intrathoracic 54 (42.9%)
 Unknown/ missing 3 (2.4%)
liver position (during surgery)
 Intra-abdominal 66 (52.4%)
 Intrathoracic 53 (42.1%)
 No repair 5 (4.0%)
 Unknown/ missing 2 (1.6%)
Defect size
 A 10 (7.9%)
 B 28 (22.2%)
 C 59 (46.8%)
 D 10 (7.9%)
 No repair 5 (4.0%)
 Unknown/ missing 14 (11.1%)
ECmo 41 (32.5%)
Survival in first year of life 97 (77.0%)
ClD (in survivors) 38 (39.2%)
Data were presented as numbers (%) or median (interquartile range). Defect size was classified (Pediatrics. 
2007 Sep;120(3):e651-7).Abbreviations: FETO: fetoscopic tracheal occlusion; GA: gestational age; ECMO: ex-
tracorporeal membrane oxygenation; CLD: chronic lung disease.
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In non-survivors the median O/E LHR was 35.9 (IQR 29.7- 42.8) and 45.0 (IQR 39.9- 55.9) 
in survivors (p<0.001). The median of the O/E LHR was 43.8 (IQR 35.7- 48.9) in survivors 
with CLD and 48.0 (IQR 41.6- 57.5) in survivors without CLD (p=0.02). Figure 3 shows for 
each patient the relationship of the O/E LHR with gestational age, stratifi ed by survivors 
and non-survivors.
Univariable logistic regression analysis showed that lower O/E LHR was signifi cantly 
associated with mortality and with the development of CLD in survivors (Table 2). Mul-
tivariable logistic regression analysis with correction for prenatal liver position resulted 
in the same conclusions and showed that liver position was not signifi cantly associated 
with the outcome (Table 2). P-values of the Hosmer-Lemeshow test were larger than 
0.05, indicating an adequate model calibration. Based on ROC analysis, mortality was 
figure 3 – Relationship between O/E LHR and gestational age.
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The closed circles represent the babies who died and the solid line is the regression line is their regression 
line; the open circles represent the survivors and dashed line is their regression line.
table 2 – Logistic regression analyses with outcomes survival and chronic lung disease in survivors
Variable
Univariable analyses multivariable analyses
or 95% Ci p-value or 95% Ci p-value
Survival Survival
O/E LHR 1.11 1.055- 1.171 <0.001 1.11 1.056- 1.176 <0.001
ClD in survivors ClD in survivors
O/E LHR 0.96 0.918- 0.995 0.03 0.96 0.917- 0.995 0.03
For the multivariable analyses prenatal liver position (intrathoracic versus intra-abdominal) was also in-
cluded.
Abbreviations: O/E LHR; observed-to-expected lung-to-head ratio. GA: gestational age; OR: odds ratio; CI: 
confi dence interval.
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predicted correctly by the O/E LHR with an optimal cut-off value of 40.2 (sensitivity 0.75 
and specificity 0.72, AUC 0.77; [0.673- 0.865], p<0.01) (Figure 4). Development of CLD 
in survivors was predicted by the O/E LHR (AUC 0.64; [0.528- 0.754], p=0.02) with an 
optimal cut-off value of 49.9 (sensitivity 0.48 and specificity 0.18).
In non-FETO treated patients, the category of CDH severity based on O/E LHR measure-
ments and prenatal liver position per patient remained stable for 58 patients (79.5%) 
of the 73 patients with at least two ultrasound measurements during gestation. In the 
univariable logistic regression analysis, no differences were found in predictive value 
of the O/E LHR on survival between the selected group of patients in whom the CDH 
was detected before 24 weeks gestational age and total patient population. Therefore, 
multiple imputation was performed in the selection of patients who were not treated 
with FETO. Longitudinal analyses of the trajectory of O/E LHR measurements during 
gestation showed no significant association with survival (data not shown).
DiSCUSSion
In this nationwide study performed for the first time in an era of standardized neonatal 
treatment, we demonstrated that the first measured O/E LHR can predict survival in 
isolated left-sided CDH infants. Survival within the different O/E LHR categories was 
comparable with data from Jani et al., the largest multicenter study concerning the 
figure 4 – ROC curves for mortality and development of CLD in survivors
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Receiver operating characteristics curves for the prediction of survival in fetuses with isolated left-sided 
congenital diaphragmatic hernia according to cut-off values of observed-to-expected lung area to head 
circumference ratio (continuous line). The dashed lines are the reference lines. Figure 4a: mortality; 4b: 
chronic lung disease (CLD).
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predictive value of the O/E LHR8. A lower O/E LHR was significantly associated with 
development of CLD in survivors. The O/E LHR remained stable during gestation.
The rationale for the use of O/E LHR is that it provides an indirect assessment of 
contralateral lung volume, and therefore the likelihood of pulmonary hypoplasia17. 
Adequate prenatal counseling considering the indication for prenatal treatment (FETO) 
and expected postnatal prognosis, requires accurate prediction tools. Jani et al. ret-
rospectively evaluated the predictive value of O/E LHR in a multicenter study of 354 
isolated CDH patients (of whom 329 left-sided), who were treated without a standard-
ized protocol in a large number of centers with both high-volume and low-volume case 
load on a yearly base. The present survival rates in the different categories of O/E LHR 
are comparable with their study. Since inclusion criteria in the TOTAL trial (moderate 
CDH (NCT01240057) and severe CDH (NCT00763737)) were based on that study, it is 
important that we can conclude that those criteria are still valid in an era of standardized 
neonatal treatment protocol. A difference between the two studies is, next to different 
patient numbers and standardized treatment, a different inclusion period (2008 -2014 in 
our study versus 1996-2005 in theirs).  Improvements of neonatal therapy are a moving 
target thus this may explain the different survival rates between the two study periods 
(76% in our study versus 65% in their study). In the past a change in postnatal survival 
has resulted in a negative outcome of the original plug study and even in the US to a 
temporary moratorium about antenatal plugging of the trachea18.
We found an AUC for survival of 0.77, which is comparable to previous studies (AUC 
0.76 in the study by Jani et al.8, AUC 0.78 in the study by Ruano et al19, and AUC 0.84 
in the study by Kehl et al20). The relevance of the cut-offs of the ROC curves for clini-
cal practice is debatable. Deprest et al.16 proposed a division of patients in categories 
(extreme/severe/moderate/mild). Since our data show that 80% of the patients remain 
in the same O/E LHR category during gestation, those categories seem more suitable for 
prenatal counseling.
We found that a lower O/E LHR was significantly associated with development of CLD 
in survivors. The only study that has also evaluated CLD was the multicenter study by 
Jani et al.8, who found the same result. Therefore, it is likely that prenatally assessed 
size of the contralateral lung is not only a predictor of mortality, but also for pulmonary 
morbidity.
Interestingly, when prenatal liver position and O/E LHR were evaluated in the mul-
tivariable logistic regression analysis, only the O/E LHR was significantly associated 
with survival and development of CLD in survivors, whereas prenatal liver position was 
neither significantly associated with survival nor with development of CLD in survivors. 
This is in contrast with previous studies11,18,21 but is consistent with the study of Jani et 
al.8 The volume of intrathoracic liver could be of more value than just the fact that a part 
of the liver is herniated22,23.
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Since the first O/E LHR measurement for each patient was performed before the FETO 
procedure in the five FETO-treated patients, we decided to include the FETO-treated 
patients in all analyses, except for the longitudinal analysis. Because of the small number 
of patients, it seems not useful to perform separate analyses for this subgroup.
Strengths of our study are that we included a large cohort of isolated left CDH pa-
tients in a relatively short inclusion period who were all treated according to the same 
standardized treatment protocol including the same ECMO protocols, next to standard-
ized prenatal measurements. Since one single experienced operator has performed all 
measurements, interobserver variability has not influenced our results.Cruz-Martinez et 
al. have shown that there is a learning curve for performing O/E LHR, which emphasized 
the importance of an experienced operator24. Moreover, we have used the tracing 
method to calculate the O/E LHR which was shown to be superior to the anteroposterior 
diameter method in predicting postpartum survival in isolated left-sided CDH19.
A limitation of our study may be that, although O/E LHR was measured by one ob-
server, measurements were performed from stored ultrasound images which may not 
have been the perfect section of the cross-sectional view of the fetal thorax at the level 
of the four-chamber view of the heart. However, if there was no suitable image available 
a measurement was regarded as missing. In addition, we made sure that all measure-
ments, including outliers, were up to standard for daily clinical practice.
In conclusion, in isolated left-sided CDH patients, O/E LHR still predicts survival and 
development of CLD in survivors in an era of a standardized neonatal treatment proto-
col, and the previously established categories of severe, moderate and mild CDH remain 
valid.
ACKnoWlEDGEmEntS
We thank Dagmar de Bruijn from the Radboud University Medical Center, Nijmegen, The 
Netherlands for her help with data collection.
40 • Chapter 2
rEfErEnCES
 1. Badillo A, Gingalewski C. Congenital diaphragmatic hernia: treatment and outcomes. Semin 
Perinatol 2014; 38: 92-6.
 2. Lally KP, Lasky RE, Lally PA, et al. Standardized reporting for congenital diaphragmatic hernia--an 
international consensus. J Pediatr Surg 2013; 48: 2408-15.
 3. van den Hout L, Sluiter I, Gischler S, et al. Can we improve outcome of congenital diaphragmatic 
hernia? Pediatr Surg Int 2009; 25: 733-43.
 4. Hedrick HL, Danzer E, Merchant A, et al. Liver position and lung-to-head ratio for prediction of 
extracorporeal membrane oxygenation and survival in isolated left congenital diaphragmatic 
hernia. Am J Obstet Gynecol 2007; 197: 422 e1-4.
 5. Mullassery D, Ba’ath ME, Jesudason EC, Losty PD. Value of liver herniation in prediction of outcome 
in fetal congenital diaphragmatic hernia: a systematic review and meta-analysis. Ultrasound 
Obstet Gynecol 2010; 35: 609-14.
 6. Metkus AP, Filly RA, Stringer MD, Harrison MR, Adzick NS. Sonographic predictors of survival in 
fetal diaphragmatic hernia. J Pediatr Surg 1996; 31: 148-51; discussion 51-2.
 7. Peralta CF, Cavoretto P, Csapo B, Vandecruys H, Nicolaides KH. Assessment of lung area in normal 
fetuses at 12-32 weeks. Ultrasound Obstet Gynecol 2005; 26: 718-24.
 8. Jani J, Nicolaides KH, Keller RL, et al. Observed to expected lung area to head circumference ratio 
in the prediction of survival in fetuses with isolated diaphragmatic hernia. Ultrasound Obstet 
Gynecol 2007; 30: 67-71.
 9. Bebbington M, Victoria T, Danzer E, et al. Comparison of ultrasound and magnetic resonance 
imaging parameters in predicting survival in isolated left-sided congenital diaphragmatic hernia. 
Ultrasound Obstet Gynecol 2014; 43: 670-4.
 10. Alfaraj MA, Shah PS, Bohn D, et al. Congenital diaphragmatic hernia: lung-to-head ratio and lung 
volume for prediction of outcome. Am J Obstet Gynecol 2011; 205: 43 e1-8.
 11. Jani JC, Benachi A, Nicolaides KH, et al. Prenatal prediction of neonatal morbidity in survivors with 
congenital diaphragmatic hernia: a multicenter study. Ultrasound Obstet Gynecol 2009; 33: 64-9.
 12. van den Hout L, Schaible T, Cohen-Overbeek TE, et al. Actual outcome in infants with congenital 
diaphragmatic hernia: the role of a standardized postnatal treatment protocol. Fetal diagnosis 
and therapy 2011; 29: 55-63.
 13. Reiss I, Schaible T, van den Hout L, et al. Standardized postnatal management of infants with 
congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus. Neonatology 
2010; 98: 354-64.
 14. TOTAL TRIAL, 2016. (Accessed 11th of February, 2016, at http://totaltrial.eu/?id=6.)
 15. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-9.
 16. Deprest JA, Flemmer AW, Gratacos E, Nicolaides K. Antenatal prediction of lung volume and 
in-utero treatment by fetal endoscopic tracheal occlusion in severe isolated congenital diaphrag-
matic hernia. Seminars in fetal & neonatal medicine 2009; 14: 8-13.
 17. Benachi A, Cordier AG, Cannie M, Jani J. Advances in prenatal diagnosis of congenital diaphrag-
matic hernia. Seminars in fetal & neonatal medicine 2014; 19: 331-7.
 18. Harrison MR, Keller RL, Hawgood SB, Kitterman JA, Sandberg PL, Farmer DL, Lee H, Filly RA, Far-
rell JA, Albanese CT. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal 
congenital diaphragmatic hernia. N Engl J Med 2003 Nov 13;349(20):1916-24.
Validity of the O/E LHR in CDH in an era of standardized treatment  • 41
Ch
ap
te
r 2
 19. Ruano R, Takashi E, da Silva MM, Campos JA, Tannuri U, Zugaib M. Prediction and probability of 
neonatal outcome in isolated congenital diaphragmatic hernia using multiple ultrasound param-
eters. Ultrasound Obstet Gynecol 2012; 39: 42-9.
 20. Kehl S, Siemer J, Brunnemer S, et al. Prediction of postnatal outcomes in fetuses with isolated 
congenital diaphragmatic hernias using different lung-to-head ratio measurements. J Ultrasound 
Med 2014; 33: 759-67.
 21. Werner NL, Coughlin M, Kunisaki SM, et al. Prenatal and postnatal markers of severity in congeni-
tal diaphragmatic hernia have similar prognostic ability. Prenat Diagn 2016; 36: 107-11.
 22. Cannie M, Jani J, Chaffiotte C, et al. Quantification of intrathoracic liver herniation by magnetic 
resonance imaging and prediction of postnatal survival in fetuses with congenital diaphragmatic 
hernia. Ultrasound Obstet Gynecol 2008; 32: 627-32.
 23. Werneck Britto IS, Olutoye OO, Cass DL, et al. Quantification of liver herniation in fetuses with 
isolated congenital diaphragmatic hernia using two-dimensional ultrasonography. Ultrasound 
Obstet Gynecol 2015; 46: 150-4.
 24. Cruz-Martinez R, Figueras F, Moreno-Alvarez O, et al. Learning curve for lung area to head circum-
ference ratio measurement in fetuses with congenital diaphragmatic hernia. Ultrasound Obstet 
Gynecol 2010; 36: 32-6.

Chapter 3
Score for Neonatal Acute Physiology-
II predicts outcome in congenital 
diaphragmatic hernia patients
Kitty G. Snoek, Irma Capolupo, Francesco Morini, Joost van Rosmalen, 
Anne Greenough, Arno van Heijst, Irwin K.M. Reiss, Hanneke IJsselstijn, 
Dick Tibboel, CDH EURO Consortium
Accepted for publication – Pediatr Crit Care Med 2016, February
44 • Chapter 3
ABStrACt
objective: Accurate and validated predictors of outcome for infants with congenital 
diaphragmatic hernia are needed. Score for Neonatal Acute Physiology-II has been 
validated to predict mortality in newborns. We investigated whether Score for Neonatal 
Acute Physiology-II in congenital diaphragmatic hernia could predict mortality, need for 
extracorporeal membrane oxygenation (ECMO) (in patients born in a center with extra-
corporeal membrane oxygenation availability), and development of bronchopulmonary 
dysplasia (oxygen dependency beyond 28 days after birth) in survivors.
Design, setting: Data were obtained from a prospective, multicenter RCT of initial ven-
tilation strategy carried out by the Congenital Diaphragmatic Hernia EURO Consortium 
(NTR 1310).
Patients, interventions: Congenital diaphragmatic hernia infants without severe 
chromosomal anomalies or severe cardiac anomalies born between November 2008 
and December 2013 were randomized for initial ventilation strategy (high-frequency 
oscillation/ conventional mechanical ventilation).
measurements and main results: Logistic regression analyses were used to evaluate 
associations between Score for Neonatal Acute Physiology-II and outcome parameters. 
Of the 171 included patients, 46 died (26.9%), 40 of 108 (37.0%) underwent extracorpo-
real membrane oxygenation, and 39 of 125 survivors (31.2%) developed bronchopulmo-
nary dysplasia. In nonsurvivors, the median Score for Neonatal Acute Physiology-II was 
42.5 (interquartile range 33.5-53.8) and 16.5 (interquartile range 9.0-27.5) in survivors 
(p<0.001). Score for Neonatal Acute Physiology-II also significantly differed between 
extracorporeal membrane oxygenation and non-extracorporeal membrane oxygen-
ation-treated patients (p<0.001), and survivors with and without bronchopulmonary 
dysplasia (p<0.001). Multivariable logistic regression analyses adjusted for hernia side, 
liver position, ventilation mode, gestational age, center and observed-to-expected 
lung-to-head-ratio, showed that Score for Neonatal Acute Physiology-II was associated 
with mortality (OR 1.16 [1.09-1.23], p<0.001), and need for ECMO support (odds ratio 
1.07 [1.02-1.13], p=0.01), but not for the development of bronchopulmonary dysplasia 
(odds ratio 1.04 [0.99-1.09], p=0.14).
Conclusions: The Score for Neonatal Acute Physiology-II predicts not only mortality 
but also need for extracorporeal membrane oxygenation in congenital diaphragmatic 
hernia patients. We, therefore, recommend to implement this simple and rapid scoring 
system in the evaluation of severity of illness in patients with congenital diaphragmatic 
hernia and thereby have insight into the prognosis within 1 day after birth.
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introDUCtion
Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 2,200 live births1. 
The defect in the diaphragm allows abdominal organs to “herniate” into the thoracic 
cavity, which leads to underdevelopment of both lungs although more pronounced on 
the ipsilateral side. Lung hypoplasia and pulmonary hypertension are the main causes of 
respiratory failure and death. The aim of postnatal treatment is to prevent further lung 
damage by a gentle ventilation strategy and to stabilize the cardiopulmonary status, 
followed by surgical repair of the defect. If conventional management fails, infants may 
require extracorporeal membrane oxygenation (ECMO) with a resulting survival of 51%2.
Although the mortality rate has significantly decreased in the past decade to about 
30%3, CDH is still a life-threatening congenital anomaly4. Various prenatal parameters 
are related to a worse prognosis, such as a low observed-to-expected lung to head ratio 
(O/E LHR), a right-sided hernia, herniation of the liver or stomach into the chest, and 
associated congenital malformations5. Nevertheless, some neonates with prenatally 
expected poor outcome survive, whereas neonates with prenatally expected good out-
come die; those contradictions may be due to the inability to predict the pulmonary 
vascular response after birth. Reliable postnatal prediction models of survival and need 
of different treatment modalities in CDH infants are scarce. Recently, Brindle et al pub-
lished a prediction model based on postnatal baseline indicators and showed that this 
model could discriminate between high, intermediate and low risk of death6.
The Score for Neonatal Acute Physiology, version II (SNAP-II score) is a prediction 
model used in newborns admitted to neonatal ICUs and is based on six physiological 
parameters. SNAP-II score is a simplification of the original 28-items SNAP score7. Some 
studies have shown that the SNAP-II is related to worse outcome in prematurely born 
neonates and infants with persistent pulmonary hypertension of the newborn8,9. In CDH 
patients, retrospective studies have shown that SNAP-II were higher in patients with a 
worse outcome10,11. The studies, however, included relatively low numbers of patients 
(47 and 88 patients) and one was performed before the introduction of a gentle ventila-
tion strategy10.
We have evaluated data collected in a multicenter, prospective randomized study 
comparing initial ventilation strategy12. Our aim was to evaluate whether the SNAP-II 
predicted mortality, need for ECMO, and development of bronchopulmonary dysplasia 
(BPD) in CDH infants. We hypothesized that higher SNAP-II would have been assigned to 
nonsurvivors, patients with need for ECMO, and survivors who developed BPD.
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mAtEriAlS AnD mEtHoDS
Study design and population
Data collected in a randomized clinical multicenter trial were analysed12. From Novem-
ber 2008 to December 2013, inborn neonates with prenatally detected CDH could be 
included in the trial. All parents gave prenatally written informed consent prior to inclu-
sion in the study. The study was initially approved by the Erasmus MC Ethical Review 
Board (NTR1310), and the local institutional review boards provided institution-specific 
approval.
The study was conducted in nine tertiary, perinatal centers that all participated in 
the CDH EURO Consortium. High-volume centers were defined as more than 10 CDH 
patients treated in 1 year. Exclusion criteria were gestational age below 34 weeks, severe 
chromosomal anomalies likely to result in death in the neonatal period, severe cardiac 
anomalies with expected need of corrective surgery in the first 60 days after birth, renal 
anomalies associated with oligohydramnios, severe orthopaedic and skeletal deformities 
likely to influence lung development, severe anomalies of the central nervous system. 
We excluded patients with a gestational age below 34 weeks, so that the results could 
not be influenced by severe lung prematurity. Besides, a gestational age below 34 weeks 
is internationally considered a contraindication for neonatal ECMO treatment due to the 
high risk of bleeding complications, in particular, intracranial hemorrhage. After birth, 
children were randomized to either initial conventional mechanical ventilation (CMV) or 
high-frequency oscillation (HFO). All children were treated according to a standardized 
neonatal treatment protocol13.
The SNAP-II score was collected within the first 12 hours after birth, and comprises 
six physiologic parameters; mean blood pressure, temperature, (PaO2 (mmHg): FiO2 
(%)), serum pH, presence of multiple seizures, and urine output (Supplemental Digital 
Content 1)7. For each parameter, the worst score within the first 12 hours of life was used 
to calculate the SNAP-II, independent of possible treatment interventions.
BPD was defined as oxygen dependency at day 28 according to the definition of Jobe 
and Bancalari14. ECMO support (in centers with availability of ECMO only) could be initi-
ated if one or more of the following predetermined failure criteria were met for at least 
3 hours at two consecutive measurements: inability to maintain preductal saturations 
above 85% (± 7 kPa or 52 mmHg) or postductal saturations above 70% (± 5.3 kPa or 40 
mmHg); increase in CO2 greater than 65 torr or mmHg (8.5 kPa) despite optimization of 
ventilatory management; peak inspiratory pressure greater than 28 cm H2O or mean 
arterial pressure greater than 17 cm H2O; inadequate oxygen delivery with metabolic 
acidosis defined as lactate greater than or equal to 5 mmol/L and pH less than 7.20 and/ 
or hypotension resistant to fluid therapy and adequate inotropic support, resulting in a 
urine output less than 0.5 mL/kg/hour; and oxygenation index consistently greater than 
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or equal to 4012. None of the patients was transferred from a non-ECMO to an ECMO 
center.
Data analysis
Patient characteristics are described as number (%), mean± SD or median (interquartile 
range; IQR). Survival rates of patients born in a center with ECMO facilities and patients 
born in a center without ECMO facilities were compared using the chi-square test. 
SNAP-II were compared between survivors and nonsurvivors, patients with and without 
need of ECMO treatment (in patients born in a center with availability of ECMO only), 
and the presence of BPD (in survivors only) using the Mann-Whitney U test. SNAP-II 
were compared between centers using the Kruskal-Wallis test. Independent associa-
tions between SNAP-II and mortality, ECMO support (in patients born in a center with 
availability of ECMO only), and BPD (in survivors only) were evaluated using univariable 
logistic regression modeling and were presented as odds ratio (OR) [95% CI], p value. 
In multivariable logistic regression analyses, SNAP-II, gestational age, initial ventilation 
type, side of defect, center, O/E LHR, and position of the liver were included as indepen-
dent variables. For BPD, ECMO support was also included as independent variable in 
the multivariable logistic regression analysis. The calibration of the multivariable logistic 
regression models were assessed using the Hosmer-Lemeshow goodness-of-fit test. Re-
ceiver operating characteristic (ROC) curves were used to evaluate the prognostic value 
of SNAP-II for mortality, need of ECMO support (in patients with availability of ECMO 
only), and development of BPD (in survivors only). Those data were presented as areas 
under the ROC curves (AUC); [95% CI]. All analyses were performed using SPSS version 
21.0 for Windows. A two-sided p value of <0.05 was considered statistically significant.
rESUltS
One hundred and seventy-one patients were included in the analysis of whom 108 (63.2%) 
were born in a hospital with ECMO facilities. Forty-six patients (26.9%) died, 40 of the 108 
infants born in a center with ECMO facilities received ECMO (37.0%), and 39 of the 125 
survivors (31.2%) developed BPD (Figure 1) (Table 1). In six centers, ECMO was available; 
two centers had no ECMO availability; and in one center ECMO was available from January 
1, 2013, onward. Twenty-seven patients (25.0%) born in a center with ECMO facilities died 
versus 19 patients (30.2%) born in a center without ECMO facilities, p=0.46.
The SNAP-II scores were not significantly different between centers (data not shown). 
The SNAP-II scores were not significantly different between the two ventilation groups 
(CMV (median 21.0 (IQR 10.0 to 40.0)) and HFO (median 25.0 (IQR 14.0 to 40.0)), p=0.44. 
Of the nine centers, five were high-volume centers and four were low-volume centers. 
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The median SNAP-II scores were comparable in high-volume centers (median 23.0 (IQR 
10.0 to 37.0)) and low-volume centers (median 25.0 (IQR 16.0 to 41.0)), p=0.21.
In nonsurvivors the median SNAP-II score was 42.5 (IQR 33.5 to 53.8) and 16.5 (IQR 9.0 
to 27.5) in survivors (p<0.001). In the selection of the 108 patients born in a center with 
ECMO facilities, the median SNAP-II score was 35.0 (IQR 30.0 to 46.0) in patients treated 
with ECMO and 16.0 (IQR 10.0 to 26.0) in patients without ECMO treatment (p<0.001). 
Survivors with BPD had a median SNAP-II score of 25.0 (IQR 21.0 to 35.0) versus 14.0 
(IQR 7.0 to 21.0) in those without BPD (p<0.001). In a subgroup of patients who were 
treated with ECMO (n=40), 19 survived and 21 died. Of the 19 survivors, the median 
SNAP-II score was 32 (IQR 23 to 44), and the median SNAP-II score was 40 (IQR 32 to 51) 
for nonsurvivors, p=0.04.
Univariable logistic regression analyses showed that SNAP-II score was significantly 
associated with mortality (OR 1.11 [1.08- 1.15], p<0.001), need of ECMO support (OR 
1.08 [1.05- 1.12], p<0.001) (in patients born in a center with ECMO facilities), and BPD in 
survivors (OR 1.07 [1.04- 1.11], p<0.001) (Table 2).
Multivariable logistic regression analyses correcting for O/E LHR, defect side, liver po-
sition, type of ventilation, center, and gestational age, demonstrated that SNAP-II score 
was significantly associated with mortality (OR 1.16 [1.09- 1.23], p<0.001), and need for 
ECMO support in patients born in a center with ECMO facilities (OR 1.07 [1.02- 1.13], 
figure 1 – Flowchart of included patients
All patients
n=171
Centre with ECMO facilities
n=108 (63.2%)
Centre without ECMO facilities
n=63 (36.8%)
ECMO +
n=40 (37.0%)
ECMO -
n=68 (63.0%)
Survived
n=19 (47.5%)
Died
n=21 (52.5%)
Survived
n=62 (91.2%)
Died
n=6 (8.8%)
BPD +
n=15 (78.9%)
BPD -
n=4 (21.1%)
BPD +
n=15 (24.2%)
BPD -
n=47 (75.8%)
ECMO -
n=63   (100%)
Survived
n=44 (69.8%)
Died
n=19 (30.2%)
BPD +
n=9 (20.5%)
BPD -
n=35 (79.5%)
aaa
b b b
Abbrevations: ECMO: extracorporeal membrane oxygenation. BPD: bronchopulmonary dysplasia. a: total 
of patients that died: n=46/ 171 (26.9%) b: total of survivors with BPD: n=39/ 125 (31.2%).
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table 1 – Patient characteristics
Variable n=171
Gestational age (weeks) 38.0± 1.3
Birth weight (grams) 2923± 460
Fetoscopic endotracheal occlusion 19 (11.1%)
Male gender 84 (49.1%)
Left sided defect 148 (86.5%)
Liver position: intrathoracic 101 (59.1%)
Type of repair
 Patch correction 92 (53.8%)
 Primary closure 53 (31.0%)
 No repair 26 (15.2%)
Defect size
 A 11 (6.4%)
 B 49 (28.7%)
 C 68 (39.8%)
 D 12 (7.0%)
 No repair 26 (15.2%)
 Missing 5 (2.9%)
Treatment with nitric oxide 84 (49.1%)
Treatment with inotropics 146 (85.4%)
Initial ventilation mode: HFO 80 (46.8%)
Age at repair (days) 4.0 (3.0- 6.5)
Ventilation time (days) 11.5 (7.0- 20.5)
ICU admission (days) 22.0 (13.0- 40.0)
Results are presented as n (%), mean± SD or median (IQR).
Abbreviations: HFO: high-frequency oscillation. ICU: intensive care unit.
table 2 – Associations of SNAP-II score with death, need for ECMO, BPD
outcome or p-value 95% Ci
mortality (n=171) 1.11 <0.001 1.08- 1.15
need for ECmo (n=108) 1.08 <0.001 1.05- 1.12
BPD (n= 125) 1.07 <0.001 1.04- 1.11
Abbreviations: ECMO: extracorporeal membrane oxygenation; BPD: bronchopulmonary dysplasia; OR: 
odds ratio; CI: confidence interval.
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p=0.01). In the multivariable logistic regression analysis with correction for O/E LHR, 
defect side, liver position, type of ventilation, center, gestational age, and adding the 
variable ECMO support, we found that the SNAP-II score did not predict the develop-
ment of BPD in survivors (OR 1.02 [0.97- 1.08], p=0.46) (Table 3). The p-values of the 
Hosmer-Lemeshow tests were larger than 0.05, indicating an adequate model calibra-
tion.
Based on ROC analysis, SNAP-II scores predicted mortality (AUC 0.88; [0.82-0.94], 
p<0.001), need for ECMO support (in patients born in a center with ECMO facilities) (AUC 
0.81; [0.72-0.90], p<0.001) and BPD development in survivors (AUC 0.77; [0.68-0.86], 
p<0.001) (Figure 2).
DiSCUSSion
We have demonstrated in this prospective study on a large cohort of prenatally detected 
CDH patients that the SNAP-II score calculated within the first 12 hours of life predicted 
the outcome of survival, and need for ECMO support in inborn patients with CDH.
Skarsgard et al have assessed the ability of admission SNAP-II score to predict mortal-
ity in 88 infants with CDH born between January 1996 and October 1997 in the Canadian 
Neonatal Network database10. This was a retrospective, multicenter study with patients 
selected based on the International Classification of Diseases, 9th Edition code (756.6) 
for diaphragmatic anomalies and included patients ventilated before the introduction 
of the gentle ventilation strategy. They found that SNAP-II predicted mortality with an 
OR of 1.06 and AUC of 0.76. In our study, we found a comparable OR (1.11) and AUC 
(0.88). It is possible that the higher predictive value we found may be due to the greater 
homogeneity of our study population when compared with that of Skarsgard’s report 
that derived from centers with different treatment protocols.
In 2001, The Congenital Diaphragmatic Hernia Study Group estimated disease sever-
ity in the first 5 minutes after birth in more than one thousand neonates with CDH15. In 
that retrospective study, a prediction model based on variables obtained at the time 
of birth such as birth weight and 5-minute Apgar score was designed to estimate risks 
for populations and they found that those variables were most useful in a predictive 
equation. It is not, however, clear whether those variables were obtained before or after 
intubation. More recently, Schultz et al retrospectively investigated the Wilhord Hall/
Santa Rosa prediction formula (pO2[max]– pCO2[max]) and showed that mortality in 
CDH patients could be predicted with that formula16. They, however, included a relatively 
small number of patients, and the infants were not treated according to a standardized 
treatment protocol. Subsequently, Baird et al compared 3 different prediction models 
in the same cohort of 94 infants17. They showed that the prediction model of the Con-
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genital Diaphragmatic Hernia Study Group predicted mortality best with an AUC of 0.85, 
followed by SNAP-II score (AUC 0.79). In addition, they concluded that gestational age 
did not improve the prediction model, which is consistent with our results. A limitation 
of their study is that not all the components of the SNAP-II score, for example, lowest 
temperature, were not collected, and the SNAP-II score was not routinely calculated and 
recorded.
In the study from Brindle et al6, postnatal variables were collected, including birth 
weight, 5-minute Apgar score, presence of chromosomal or major cardiac anomaly, and 
suprasystemic pulmonary hypertension. Their model identified infants at low, intermedi-
ate, and high risk of death. The data from the CDH registry, however, were obtained from 
voluntary participation, which had potential selection bias. In future studies, a combina-
tion of the SNAP-II score and the prediction model published by Brindle et al may further 
improve risk stratification of CDH infants. Chiu et al recently showed in 52 outborn CDH 
patients that Score for Neonatal Acute Physiology with Perinatal Extension-II (SNAPPE) 
predicted survival and need for ECMO well18. In the SNAPPE score, however, Apgar 
figure 2 – ROC curves
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score, birth weight and small for gestational age are also included, which makes this 
score more time consuming to calculate. Furthermore, in their study, only outborn CDH 
patients were included, whereas we only included inborn CDH patients.
We investigated the role of the SNAP-II score in the prediction of the need of ECMO. 
This was recently researched by Coleman et al11. In their retrospective study, they found 
that in outborn CDH patients, the SNAP-II score calculated within the first 24 hours 
after admission predicted the use of ECMO support with an AUC of 0.76. We calculated 
SNAP-II score prospectively in the first 12 hours after birth, hence our study population 
was more homogenous than that of the previous study11 and found an AUC of 0.81. A 
table 3 – Associations of SNAP-II score with death, need for ECMO, BPD
outcome or p-value 95% Ci
mortality
SNAP-II score 1.16 <0.001 1.09- 1.23
O/E LHR 0.96 0.04 0.92- 1.00
Side: left 0.26 0.18 0.04- 1.83
Liver: intrathoracic 1.37 0.66 0.34- 5.50
Initial ventilation: HFO 2.48 0.16 0.69- 8.86
Gestational age 0.74 0.24 0.44- 1.22
Center 0.85 0.21 0.65- 1.10
need for ECmo
SNAP-II score 1.07 0.01 1.02- 1.13
O/E LHR 0.95 0.04 0.91- 1.00
Side: left 0.44 0.41 0.06- 3.10
Liver: intrathoracic 4.38 0.04 1.08- 17.83
Ventilation: HFO 1.78 0.35 0.53- 6.00
Gestational age 0.94 0.83 0.56- 1.60
Center 1.29 0.04 1.01- 1.64
BPD
SNAP-II score 1.02 0.46 0.97- 1.08
O/E LHR 0.99 0.67 0.97- 1.02
Side: left 1.10 0.92 0.15- 8.18
Liver: intrathoracic 6.71 0.003 1.94- 23.22
Initial ventilation: HFO 1.13 0.83 0.38- 3.38
Gestational age 0.81 0.37 0.51- 1.28
Center 1.04 0.79 0.81- 1.33
Need for ECMO 6.00 0.03 1.15- 31.20
Abbreviations: ECMO: extracorporeal membrane oxygenation; BPD: bronchopulmonary dysplasia; OR: 
odds ratio; CI: confidence interval; O/E LHR: observed-to-expected lung-to-head ratio; HFO: high-frequency 
oscillation.
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prediction study based on blood gas analyses showed that infants with a PaCO2 greater 
than 60mmHg on the first arterial blood gas had a higher 90-day mortality rate and 
were more likely to receive ECMO19. They, however, did not report the site of obtaining 
the blood samples (pre- or postductal) and they did not perform ROC curves so our 
results cannot be compared with theirs. Survival rates following ECMO found in the 
current study are comparable with those reported by Stevens et al20. On the other hand, 
Downard et al reported that 12 of the 14 patients treated with ECMO survived, which 
means a high survival rate of 86%21. In the study of Downard et al, however, 28% of the 
patients were outborn, which is associated with a favorable prognosis22. Furthermore, 
our study population may have been more severely ill. Downard et al regrettably did not 
report parameters associated with survival such as gestational age, lung-to-head ratio 
and liver position (intrathoracic or intra-abdominal).
We also investigated whether the SNAP-II score predicted BPD in surviving CDH 
patients. To the best of our knowledge, this has not been done in previous studies. A 
large number of patients who were treated with ECMO subsequently died, and many 
survivors who were treated with ECMO developed BPD (Figure 1). This could explain why 
SNAP-II score predicted the development of BPD in survivors in the univariable logistic 
regression analysis, but not in the multivariable logistic regression analysis in which 
ECMO was added as independent variable.
In various reports of patients with CDH, other nonpatient-related factors were ana-
lyzed for association with the outcome. For example, Nasr and Langer showed that in 
140 infants location of delivery influenced the outcome22. In our study, all patients were 
inborn so a bias of severity of illness due to location of birth did not influence our results. 
Grushka et al evaluated the effect of hospital case volume on the outcome in 121 CDH 
patients23. They found that SNAP-II score was not significantly different for high- com-
pared with low-volume centers; this was confirmed in our study.
Our data were collected in a randomized clinical trial, and the difference in initial 
ventilation strategy could be seen as a study limitation. SNAP-II score, however, was 
not significantly different between the 2 ventilation groups, and the type of ventilation 
was not significantly associated with outcome in the multivariable logistic regression 
modeling. The optimal initial ventilation strategy was recently investigated12. We have 
shown that independent of ventilation strategy, SNAP-II score reliably predicts out-
come. Therefore we do not think that this has influenced our results. A limitation of the 
SNAP-II score itself is that one of the items concerns the presence of multiple seizures. 
It is known, however, that neonatal seizures can be very subtle so possibly some of the 
studied patients may have experienced unrecognized seizures in the first 12 hours after 
life24. The strengths of the current study are that, besides initial ventilation strategy, all 
children were treated according to the same study protocol. Furthermore, all children 
were inborn, which means that information from birth onward was available. A strength 
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of the SNAP-II score is that data collection of the six scoring items takes only 2-4 min-
utes7. Future studies should address whether the use of a combination of the SNAP-II 
score and other predictive (biochemical) markers such as lactate25, troponin T26, and 
endothelin-127, could further improve prediction of prognosis in CDH patients.
ConClUSionS
Determining SNAP-II score in the first 12 hours after birth is a reliable, not time-con-
suming scoring system to predict outcome in antenatally diagnosed CDH patients with 
a gestational age of more than 34 weeks. We, therefore, recommend to implement this 
simple and rapid scoring system in the evaluation of severity of illness in patients with 
CDH, to thereby obtain insight into the prognosis within 1 day after birth. For research 
purposes, it can also be used to compare severity of illness to evaluate differences in 
outcomes between centers.
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Supplemental digital content 1 - Score for Neonatal Acute Physiology-II
Variables Values Points 
Mean blood pressure ≥  30 mmHg 
20 – 29 mmHg 
< 20 mmHg 
 0 points 
 9 points 
 19 points 
Lowest temperature >35.6 °C = > 96°F 
35° - 35.6°C = 95° - 96°F 
< 35.0°C = < 95°F 
 0 points 
 8 points 
 15 points 
pO2 (mmHg) : FiO2 (%) > 2,49 
1,0 – 2,49 
0,3 – 0,99 
< 0,3 
 0 points 
 5 points 
 16 points 
 28 points 
Lowest serum pH ≥ 7,2               
7,10 – 7,19 
< 7,10 
 0 points 
 7 points 
 16 points 
Multiple seizures 
 
No 
Yes 
 0 points 
 19 points 
Urine output (ml./kg./hr.) 
 
≥ 1               
0,1 – 0,9   
< 0,1 
 0 points 
 5 points 
 18 points 
Total score  …... points 
 
Please fill in the worst score within the first 12 hours of life
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ABStrACt
Background: Congenital diaphragmatic hernia is a severe congenital anomaly with sig-
nificant mortality and morbidity, for instance chronic lung disease. Sphingolipids have 
shown to be involved in lung injury, but their role in the pathophysiology of chronic lung 
disease has not been explored. We hypothesized that sphingolipid profiles in tracheal 
aspirates could play a role in predicting the mortality/ development of chronic lung 
disease in congenital diaphragmatic hernia patients. Furthermore, we hypothesized 
that sphingolipid profiles differ between ventilation modes; conventional mechanical 
ventilation versus high-frequency oscillation.
methods: Sphingolipid levels in tracheal aspirates were determined at days 1, 3, 7 and 
14 in 72 neonates with congenital diaphragmatic hernia, born after > 34 weeks gesta-
tion at four high-volume congenital diaphragmatic hernia centers. Data were collected 
within a multicenter trial of initial ventilation strategy (NTR 1310).
results: 36 patients (50.0%) died or developed chronic lung disease, 34 patients (47.2%) 
by stratification were initially ventilated by conventional mechanical ventilation and 38 
patients (52.8%) by high-frequency oscillation. Multivariable logistic regression analysis 
with correction for side of the defect, liver position and observed-to-expected lung-to-
head ratio, showed that none of the changes in sphingolipid levels were significantly 
associated with mortality/development of chronic lung disease. At day 14, long-chain 
ceramides 18:1 and 24:0 were significantly elevated in patients initially ventilated by 
conventional mechanical ventilation compared to high-frequency oscillation.
Conclusions: There is no predictive role of tracheal aspirates sphingolipid levels for mor-
tality/development of chronic lung disease in congenital diaphragmatic hernia infants. 
Elevated levels of ceramides 18:1 and 24:0 in the conventional mechanical ventilation 
group when compared to high-frequency oscillation could probably be explained by 
high peak inspiratory pressures and remodelling of the alveolar membrane.
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introDUCtion
In patients with congenital diaphragmatic hernia (CDH), lung related problems such as 
chronic lung disease (CLD) and pulmonary vascular disease including pulmonary hyper-
tension are the primary causes of mortality1 with ventilator-induced lung injury (VILI) 
and high concentrations of oxygen predisposing newborns to develop CLD as prime 
morbidity2.
Since 2008, CDH neonates are treated according to the same neonatal treatment 
protocol, developed during a consensus meeting of the CDH EURO Consortium3. Pre-
natally diagnosed CDH infants are intubated after birth and mechanically ventilated. 
Conventional mechanical ventilation (CMV) and high-frequency oscillation (HFO) are 
two ventilation modalities that are associated with VILI and thus predispose to develop-
ing CLD. In a randomized clinical trial (the VICI-trial) looking at initial ventilation strategy 
(CMV vs HFO) of prenatally diagnosed CDH infants, 41 of the 91 patients (45.1%) initially 
ventilated with CMV died or had CLD by day 28 compared to 43 of the 80 patients (53.8%) 
using HFO4. This difference, however, did not reach statistical significance.
The exact mechanism for the development of CLD in CDH remains unknown. In 
postmortem lung biopsies non-specific features as persistent inflammation, edema, 
vascular changes and parenchymal fibrosis were observed after mechanical ventilation5. 
Due to changes in treatment modalities over the years in premature born neonates, the 
so-called ‘new BPD’ developed, characterized by interrupted septation and abnormal 
vascularization, leading to fewer and enlarged alveoli6. In contrast to premature born 
neonates, lungs of fetuses with CDH are not surfactant deficient7, and surfactant re-
placement therapy has no beneficial effect in term neonates with CDH8.
Sphingolipids are classically thought to be purely structural elements of the cell 
membrane, but have been revealed as key bioactive mediators in a variety of patho-
physiological processes9. They have an important role as messenger molecule in the 
regulation of proliferation and apoptosis10. Sphingolipids are involved in lung develop-
ment, injury and repair as suggested by elevated sphingolipid levels in brochoalveolar 
lavage of newborn rats exposed to hyperoxia (injury model of CLD) which declined 
during subsequent ambient air exposure (repair)11.
Given the lack of knowledge on the pathogenesis of CLD in CDH, we have analyzed 
the bronchoalveolar lavage for sphingolipids in tracheal aspirates at specific time-points 
during the first month of a prospective ventilation study (VICI-trial)4. We hypothesized 
that sphingolipid profiles could have a predictive role for mortality/development of 
CLD. Secondly, we aimed to determine whether CMV versus HFO leads to different 
sphingolipid levels in CDH patients. These aims were achieved.
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mAtEriAlS AnD mEtHoDS
Patient Population
Inborn neonates born between November 2008 and December 2013, after a gestation 
of more than 34 weeks with a prenatal diagnosis of CDH, were included in a multicenter 
RCT of initial ventilation strategy (NTR 1310)4. Ethical approval was given by the medical 
ethics review board of Erasmus MC, Rotterdam, the Netherlands (NTR 1310). Thereafter, 
all local medical ethical committees gave their approval (Bambino Gesu Children’s 
Hospital, Universitätsklinikum Mannheim, Radboud University Medical Centre). Parents 
gave written informed consent. The procedures, including obtaining informed consent, 
were conducted in accord with the ethical standards of the Committee on Human 
Experimentation of the institution in which the experiments were done. Exclusion 
criteria were: severe chromosomal anomaly such as trisomy 13 or 18, which may imply 
a decision to stop or not to start medical treatment; severe cardiac anomalies expected 
to need corrective surgery in the first 60 days after birth; renal anomalies associated 
with oligohydramnios; severe orthopedic and skeletal deformities which were likely to 
influence thoracic or lung development; and severe anomalies of the central nervous 
system. Patients with a gestational age of less than 34 weeks were excluded so that the 
results could not be influenced by severe lung prematurity. Written parental informed 
consent was obtained before birth. All children were treated according to the same 
standardized protocol3. Patients were randomized for initial ventilation strategy (CMV 
or HFO) within two hours after birth. CLD was defined as oxygen dependency (>21%) 
at day 28 as described by Jobe and Bancalari12. Diaphragmatic defect size was classified 
according to the definition of the CDH study group and assessed during surgical repair13.
tracheal Aspirates
Tracheal aspirates were obtained during routine tracheal suctioning within the first 24 
hours of life and at day 3, 7, and 14. Tracheal aspirates were only collected during the pe-
riod of mechanical ventilation. During tracheal suctioning, flushing with 0.5-1.0 ml saline 
was performed according to standard practice. Tracheal aspirates were immediately cen-
trifuged at 1500g for 6 minutes at 20 °C and samples were stored at −80°C until analysis.
Sphingolipid measurements
Sphingolipids were measured as previously described11. Briefly, lipids were extracted 
from tracheal aspirate samples and sphingolipids were separated and analyzed using 
high performance liquid chromatography and tandem mass spectrometry (LC-MS/MS). 
The analyses were performed at the Analytical Facility for Bioactive Molecules of the 
Hospital for Sick Children, Toronto, ON, Canada. Sphingolipid levels were presented as 
ng/mL.
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Statistical analysis
Patient characteristics were described as number (%) for categorical variables, mean 
± SD for normally distributed variables or median (interquartile range; IQR) for con-
tinuous variables that were not normally distributed. Patient characteristics between 
participants and non-participants were analyzed using independent samples t-test 
for continuous data or chi square tests for categorized data. Sphingolipid levels were 
compared between patients who died/developed CLD and patients who survived/did 
not develop CLD, and between patients who were initially ventilated by CMV and HFO 
by using the Mann-Whitney U test. All analyses were performed for each of the four 
time-points separately. Independent associations between sphingolipids levels and 
mortality/ development of CLD were determined using multivariable logistic regression 
modelling and were presented as odds ratio (OR) [95% confidence interval], p-value. 
Observed-to-expected lung-to-head ratio (O/E LHR), side of the defect, liver position, 
centre and ventilation mode were included as independent variables in these models. 
Sphingolipid levels were logarithmically transformed due to skewed distribution, and 
non-detectable values were set to the lower detection threshold 0.03 ng/mL. The cali-
bration of the multivariable logistic regression models was assessed using the Hosmer-
Lemeshow goodness-of-fit test. All statistical tests, except for the analyses to determine 
difference in patients characteristics between participants and non-participants, were 
two-sided and used a Bonferroni-adjusted significance level of 0.0125 to correct for 
multiple testing at the four time points. All analyses were performed using SPSS version 
21.0 for Windows statistical software.
rESUltS
Tracheal aspirates were collected in 69 of the 171 infants who were included in the RCT 
at the four participating centers. Additionally, in three patients from one center there 
was only written consent for sample collection, and not for randomization of initial 
ventilation mode. Thus, tracheal aspirates from 72 patients were collected at various 
time-points. 179 tracheal aspirates were obtained, of which 49 were collected at day 1, 
56 samples at day 3, 46 samples at day 7, and 21 samples at day 14. Patients who had 
tracheal aspirates collected showed an increased prevalence of left-sided diaphragm 
defect compared to the patients who had no aspirates collected (Table 1). Of the 72 
included patients, 16 patients (22.2%) died in the first year of life, and 20 of the 56 survi-
vors (35.7%) developed CLD; thus, 36 patients (50.0%) died/developed CLD. Thirty-eight 
patients (52.8%) were initially ventilated by HFO and 34 patients (47.2%) by CMV.
No significant differences in sphingolipid profiles were found at day 1, 3, 7 and 14 
between patients who died/developed CLD and patients who survived/did not develop 
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CLD (Table 2). Median sphingolipid levels over time for each sphingolipid are presented 
in Figure 1. Multivariable logistic regression analyses with correction for O/E LHR, side 
of the defect, liver position, center and ventilation mode showed that none of the 
sphingolipid levels were associated with mortality/development of CLD (Table 3). The 
p-values of the Hosmer-Lemeshow test were larger than 0.05, indicating an adequate 
model calibration.
No significant differences in sphingolipid profiles were found at day 1, 3, and 7 be-
tween patients who were initially ventilated by CMV versus HFO (Table 4). At day 14, 
ceramide-C18:1 and ceramide-C24:0 were increased for patients initially ventilated 
by CMV (median 1.4 (IQR 1.1- 4.3)) and (median 81.0 (IQR 33.6- 205.2)) respectively 
compared to HFO (median 0.5 (0.0- 1.1)) (p=0.005) and (median 25.3 (IQR 2.9- 53.0)) 
table 1 – Patient characteristics
Included patients
n=72
Non-included patients
n=102
p-value
Gestational age (weeks) 38.0± 1.2 37.9± 1.4 0.66
Birth weight (grams) 2957± 443 2901± 467 0.43
Fetoscopic endotracheal occlusion 5 (6.9%) 14 (13.7%) 0.16
Male gender 33 (45.8%) 51 (50.0%) 0.59
Left sided defect 68 (94.4%) 83 (81.4%) 0.01
Liver position: intrathoracic 37 (51.4%) 66 (64.7%) 0.08
Type of repair 0.06
Patch correction 48 (66.7%) 46 (45.1%)
Primary closure 19 (26.4%) 35 (34.3%)
No repair 5 (6.9%) 21 (20.6%)
Diaphragmatic defect size 0.05
A 5 (6.9%) 7 (6.9%)
B 5 (6.9%) 28 (27.4%)
C 21 (29.2%) 34 (33.3%)
D 35 (48.7%) 10 (9.8%)
No repair 5 (6.9%) 21 (20.6%)
Missing 1 (1.4%) 2 (2.0%)
Treatment with nitric oxide 33 (45.8%) 53 (52.0%) 0.43
ECMO (if ECMO was available) 22/ 56 (39.3%) 20/ 55 (36.4%) 0.76
Treatment with inotropics 60 (83.3%) 89 (87.2%) 0.47
Age at repair (days) 5.0 (3.0- 9.0) 4.0 (3.0- 6.0) 0.28
Ventilation time (days) 15.0 (7.8- 23.0) 10.0 (7.0- 17.5) 0.29
ICU admission (days) 22.5 (15.3- 39.8) 20.5 (13.0- 40.5) 0.99
Data are presented as n (%), mean± SD or median (IQR).
Abbreviations: ECMO: extracorporeal membrane oxygenation. HFO: high-frequency oscillation; ICU: inten-
sive care unit.
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respectively (p=0.008). In a selection of patients who died/developed CLD, at day 14 
ceramide-C18:1 was increased for patients initially ventilated by CMV (median 1.4 (IQR 
1.2- 5.6)) compared to HFO (median 0.5 (0.1- 1.1)) (p= 0.009), but ceramide-C24:0 was 
significantly increased in patients initially ventilated by CMV (median 102.5 (IQR 31.3- 
225.9)) compared to HFO (median 23.3 (IQR 6.4- 33.7)) (p=0.011).
figure 1 – Median values of sphingolipids over time
Black: CLD or died. Grey: No CLD or alive.
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DiSCUSSion
In this prospective international multicentre study, we determined sphingolipid levels 
in tracheal aspirates of antenatally diagnosed CDH patients in the neonatal period. We 
found no significant differences in temporal sphingolipid profiles between patients 
who died/developed CLD compared to patients who survived/did not develop CLD. 
Furthermore, no significant sphingolipid differences were found between patients 
initially ventilated by CMV compared to patients initially ventilated by HFO except for 
ceramide-C18:1 and ceramide-C24:0 at day 14.
Bioactive sphingolipids have been investigated regarding their role in respiratory 
diseases such as asthma14 and COPD15. Moreover, sphingolipids are important factors 
in lung development and disease9, and recently have been shown to play a role in the 
pathogenesis of CLD in mice16.
In lungs of preterm infants who were ventilated or received oxygen treatment, 
epithelial cell apoptosis and proliferation of epithelial, endothelial and smooth muscle 
cells were observed17. Since we did not find any significant difference in sphingolipid 
levels in tracheal aspirates of CDH patients, it seems that the role of sphingolipids in 
the pathophysiology of CLD is different in CDH patients when compared to for instance 
premature born neonates. The finding that lungs of fetuses with CDH are not surfactant 
deficient7 supports this idea. No beneficial effect of surfactant replacement therapy 
has been shown in term neonates with CDH8, nor in CDH neonates on ECMO18. Even in 
prematurely born neonates with CDH, surfactant replacement therapy did not improve 
survival rates19. The predisposing risk factors for CLD also vary between neonates with 
CDH and preterm born neonates; for example, chorioamnionitis being associated with 
premature birth and an increased risk of developing BPD20 is absent in CDH. Chorioam-
nionitis is an inflammatory process and sphingolipids being involved in the regulation 
of inflammation21, underscore a role for sphingolipids in the pathophysiology of CLD in 
premature infants.
Another possibility is that the lung hypoplasia seen in CDH leads to less production 
of ceramides essential for lung development. To solve this problem other causes of pul-
monary hypoplasia should be investigated such as obstructive uropathy, but these data 
are neither available in our biobank nor in the literature. Fetal lung development occurs 
in a relative hypoxic environment that stimulates vascular development via Hypoxia 
Inducible Factors (HIFs)22. HIFs upregulate genes necessary for proper lung vascular and 
alveolar development23. Most deaths among CDH patients are due to severe pulmonary 
hypertension. It was recently shown that ceramide upregulation was associated with 
decreased Vascular Endothelial Growth Factor (VEGF) expression via suppression of 
HIF-1α, suggesting a role for sphingolipids in VEGF regulation24. Since VEGF has an 
important role in pulmonary vascular development, and it was shown that increased 
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plasma VEGF-A correlates with clinical severity of pulmonary vascular disease in CDH 
infants25, this mechanism could be involved in CDH patients. Our study design, however, 
did not provide for measuring VEGF plasma levels to test this hypothesis.
When we compared tracheal aspirate sphingolipids levels for the initial ventilation 
strategy, HFO versus CMV, we found no differences between the two ventilation modali-
ties at day 1, 3 and 7. However, at day 14, two long chain ceramides (ceramide-C18:1 
and ceramide-C24:0) were significantly elevated in patients initially ventilated by CMV 
when compared to HFO. It is remarkable that only at day 14 significant differences 
were observed. One explanation may be that in CMV the use of high peak inspiratory 
pressures and shear stress over time lead to sphingomyelinase activation and sphingo-
myelin degradation to ceramides. Alternatively, it is plausible that CMV increases over 
time de novo ceramide synthesis. Unfortunately, the study design did not allow inclusion 
of a non-ventilated control group and, therefore, we do not know whether ceramide 
levels were increased by either ventilation modality. Ceramides enhance apoptosis and 
decrease vascular barrier integrity26. Of note, increased apoptosis has been found in 
epithelial cells of CLD patients, but whether this was triggered by ceramides was not 
investigated27. In the current study, the increase in very long-chain (C24:0) ceramides, 
known to stimulate cell proliferation and not apoptosis28, fits with the favorable clinical 
outcomes in the CMV group when compared to the HFO group4.
To our knowledge this is the first study investigating lung sphingolipid metabolism in 
CDH patients. Unique is the prospective multicentre design in a relatively large cohort 
of patients. Secondly, apart from the initial ventilation strategy, all children were treated 
according to the same study protocol3. A few limitations should be considered. Firstly, 
patient characteristics between patients of whom samples were collected and patients 
of whom no samples were collected, were different with respect to the side of the defect, 
although a recent multicentre study found that morbidity following repair of right-sided 
CDH was not significantly different from that in left-sided CDH survivors29. Therefore 
we believe that there was no bias in patient inclusion. Secondly, we have corrected for 
multiple testing for multiple time-points, but no formal testing for multiple testing of 
different sphingolipids was performed, which could be seen as a possible limitation. 
The number of TA samples decreases over time which may lead to a selection bias. This 
decrease is explained by the fact that some CDH infants have died and other infants 
were not invasively ventilated anymore. However, due to the study design TA sampling 
was only performed in ventilated infants. Our data were collected in a randomized 
clinical trial and the difference in ventilation strategy could be seen as a study limitation. 
However, in the multivariate analyses we adjusted for the possible effect of ventilation 
strategy. In conclusion, sphingolipids are likely not involved in the pathogenesis of CLD 
or mortality in antenatally diagnosed CDH infants.
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ABStrACt
Biomarkers may be helpful in prediction of outcomes of infants with congenital dia-
phragmatic hernia. The predictive value of high-sensitivity Troponin T and N-terminal 
pro-brain natriuretic peptide was investigated in 128 infants with congenital diaphrag-
matic hernia. After correction for multiple testing, those biomarkers did not predict 
severe pulmonary hypertension, death, need of extracorporeal membrane oxygenation, 
or bronchopulmonary dysplasia.
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introDUCtion
Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly characterized by 
pulmonary hypoplasia and pulmonary vascular abnormalities1. The severity of illness is 
determined mainly by the extent of the pulmonary hypertension (PH)1. Some severely ill 
children may benefit from extracorporeal membrane oxygenation (ECMO), but even in 
these children, the rate of mortality remains relatively high2. Alternatively, a right-sided 
defect, a lower observed-to-expected lung-to-head ratio (O/E LHR), and the intratho-
racic liver position are associated with worse prognosis. A reliable method to predict 
postnatal outcome is still lacking. Echocardiography is used to estimate the degree of 
PH, but its application is often not standardized and associated with great interobserver 
variability. A biomarker that is investigator independent and not reliant on the availabil-
ity of specialized physicians could improve risk stratification, identify high-risk patients, 
and guide decision making on the initiation of specific treatment modalities such as 
ECMO. Two biomarkers that have proven predictive value in cardiovascular diseases are 
high-sensitivity Troponin T (hsTnT) and N-terminal pro-brain natriuretic peptide (NT-
proBNP)3,4. HsTnT is released in response to myocardial damage5. Increased hsTnT levels 
were shown to be a marker of poor prognosis in patients with PH5; thus, they also may 
have a prognostic role in CDH. NT-proBNP is a natriuretic peptide that is secreted from 
the ventricles in response to increased ventricular pressure and volume loads. Four stud-
ies that investigated the predictive value of natriuretic peptides in infants with CDH6-9 
found that these markers could predict the severity of PH. The studies, however, were 
from single centers with relatively small samples (maximum of 28 patients)6,7,9 or had a 
retrospective study design8.
We hypothesized that in infants with antenatally diagnosed CDH, hsTnT and NT-proBNP 
levels are greater in those with severe PH, nonsurvivors, those requiring ECMO, survivors 
with bronchopulmonary dysplasia (BPD) and nonsurviving ECMO-treated patients.
mEtHoDS
Inborn patients with a prenatal diagnosis of CDH and gestation >34 weeks were eligible 
to participate in an international, multicenter prospective randomized controlled trial, 
named the VICI-trial (supplemental figure 1)10. Ethical approval was given by the medi-
cal ethics review board of Erasmus MC, Rotterdam, The Netherlands. Thereafter, all local 
medical ethical committees provided their approval. Written parental informed consent 
was obtained before birth. One of the exclusion criteria was expected corrective heart 
surgery within the first 60 days of life10. Immediately after birth, infants were randomized 
to conventional mechanical ventilation or high-frequency oscillation ventilation. Apart 
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from the initial ventilation strategy, all infants were treated according to the standard-
ized neonatal treatment protocol11. Veno-arterial ECMO therapy could be initiated if one 
or more predetermined failure criteria applied10. The severity of PH was dichotomized 
into two levels12 (<2/3 systemic pressure versus (mild) vs >2/3 systemic-to-systemic 
pressure (severe)), measured by echocardiography within the first 24 hours of life. BPD 
was defined as oxygen dependency (>0.21) at day 2813. Defect size was classified accord-
ing to the definition of the CDH study group14.
In five centers, 1-mL blood samples were collected within the first 24 hours of life and 
at days 3, 7 and 14 when a central or peripheral line was present (also in ECMO-treated 
patients). Samples were immediately centrifuged at 3000 rpm for 6 minutes at 20 °Cel-
sius. Thereafter, plasma was removed and serum from the samples was stored at −20 °C 
or less. Levels of hsTnT and NT-proBNP levels were measured in the central chemistry 
laboratory of Erasmus MC (Good Laboratory Practice certified) with the Elecsys elec-
trochemiluminescence immunoassay (Cobas, a division of Roche Diagnostics Limited, 
Rotkreuz, Switzerland). For hsTnT, for quality control, Elecsys PreciControl Troponin 1 and 
2 were used as suggested by the company. HsTnT levels are expressed as pg/mL and 
the measuring range was from 3 to 10.000 pg/mL. For NT-proBNP, for quality control, 
Liquichek Cardiac Markers Plus Control LT 1 and 2 were used as suggested by the com-
pany, Cobas. NT-proBNP levels are expressed as pmol/L, and the measuring range was 
from 5 to 35000 pg/mL or 0.6 to 4130 pmol/L. The upper reference limit was defined 
as the 97.5th percentile15. The analyzer automatically calculated the analytic concentra-
tion of each sample with a conversion factor of pmol/L x 8.457= pg/mL and pg/mLx 
0.118=pmol/L.
Data analysis
Descriptive statistics are shown as number (%), mean± SD or median (interquartile range 
(IQR)) as appropriate. HsTnT and NT-proBNP values were compared between groups by 
the use of the Mann-Whitney U tests. Groups were defined based on the severity of PH 
at day 1, death, need for ECMO (in ECMO centers only), BPD in survivors, and mortality in 
ECMO-treated patients. Multivariable logistic regression analyses with the independent 
variables diaphragmatic defect side, liver position (thoracic or abdominal), and O/E LHR 
as covariates were performed to determine the additional predictive value of hsTnT and 
NT-proBNP on the predefined outcome parameters. To facilitate the interpretation of 
the results of the logistic regression, ORs for NT-proBNP are presented with the use of 
nmol/L as unit of measurement. The logistic regression analyses were repeated by the 
use of biomarker values at different days (1, 3, 7, or 14 days) for all outcomes except 
mortality in ECMO-treated patients. For mortality in ECMO-treated patients, the differ-
ence between the first biomarker value during ECMO and last biomarker value before 
ECMO was used as predictor. We considered a correction for multiple testing at different 
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days of life by using a significance level of 5% divided by the number of time points per 
outcome.
rESUltS
The inclusion period was from November 2008 until December 2013. Blood samples 
were collected from 121 of 171 randomized patients. For seven patients, their parents 
had provided written consent for only sample collection and no randomization. Of the 
99 surviving infants (77.3%), 31 (31.3%) developed BPD. Eighty-one infants (63.3%) were 
born in an ECMO-center; 27 of them (33.3%) were treated with ECMO, and 15 of those 
(55.6%) died (Table 1). For five infants, the classification of PH was missing; 51 (39.8%) 
had <2/3 systemic PH (mild) and 72 (56.3%) had >2/3 systemic PH (severe). Sampled 
infants had significantly greater birth weights, more often a left-sided defect, more 
often an intra-abdominal liver position, more often diaphragmatic defect size B or C, 
died later, and had a shorter duration of stay in the intensive care unit than non-sampled 
infants (Table 2).
At day 1, hsTnT levels were analyzed in 86 patients and NT-proBNP levels in 116 pa-
tients. The median age of blood sampling at day 1 was 2 hours (IQR 1.3- 3.9 hours). For 
the following days, samples were collected less frequently (Figures 2 and 3). Median 
(IQR) storage time was 3.78 years (IQR 2.59- 4.75 years). HsTnT levels on day 1 were 
significantly greater in patients with ECMO treatment compared with patients without 
ECMO treatment (p=0.01), and in survivors with BPD compared with survivors without 
BPD (p=0.02) (Table 3). Multivariable logistic regression analysis with correction for 
defect side, liver position, and O/E LHR, but without correction for multiple testing, 
showed that levels of hsTnT on day 1 were associated with need for ECMO (p=0.03), 
and BPD in survivors (p=0.03) (Table 4). The estimated OR for ECMO of 1.018 (95% CI 
1.002- 1.033, p=0.03) expresses the increase in the probability for the need for ECMO 
because of a change in hsTnT on day 1 of 1 unit pg/mL. For example, the estimated OR 
associated with an increase of hsTnT on day 1 from the 25th percentile (58.5 pg/mL) to 
the 75th percentile (269.8 pg/mL) was an OR=1.018(269.8-58.5)= 43.36. After correction for 
multiple testing, no significant associations for levels of hsTnT on day one were found. 
There were no significant differences in the levels tested at the other time points. Levels 
of NT-proBNP were significantly greater in survivors with BPD compared with survivors 
without BPD on day 1 (p=0.01) and on day 3 (p=0.04) (Table 3). In multivariable logistic 
regression analysis with correction for defect side, liver position, and O/E LHR, however, 
NT-proBNP was not significantly associated with any of the outcomes (Table 4). There 
were no significant differences in levels tested at the other time points.
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DiSCUSSion
In this prospective, multicenter study, the predictive values of hsTnT and NT-proBNP were 
investigated in patients antenatally diagnosed with CDH. In the univariable analysis, 
levels of hsTnT on day 1 were significantly different between patients with and without 
the need for ECMO and between survivors with and without BPD, and NT-proBNP levels 
on day 1 and 3 were significantly different between survivors with and without BPD. 
After correction for multiple testing in the multivariable analyses, neither hsTnT nor NT-
proBNP levels were significantly related with any of the outcomes.
table 1 – Patient characteristics
included patients
n=128
Gestational age (weeks) 38.1± 1.3
Birth weight (grams) 2981± 467
Fetoscopic endotracheal occlusion 12 (9.4%)
Male sex 60 (46.9%)
Left sided defect 120 (93.8%)
Liver position: intrathoracic 68 (53.1%)
Type of repair
 Patch correction 72 (56.2%)
 Primary closure 43 (33.6%)
 No repair 13 (10.2%)
Diaphragmatic defect size*
 A 7 (5.5%)
 B 43 (33.6%)
 C 55 (43.0%)
 D 5 (3.9%)
 No repair 13 (10.2%)
 Missing 5 (3.9%)
Treatment with nitric oxide 60 (46.9%)
Treatment with inotropics 111 (86.7%)
Initial ventilation mode: HFO 64 (50.0%)
Age at repair (days) 4.0 (3.0- 8.0)
Age at death (days) 13.0 (4.8- 25.5)
Ventilation time (days) (in survivors) 10.0 (7.0- 17.5)
ICU admission (days) (in survivors) 19.0 (13.0- 35.5)
Data are presented as n (%), mean± SD or median (IQR).
Abbreviations: HFO: high-frequency oscillation; ICU: intensive care unit.
*Reference: Lally KP, Lasky RE, Lally PA, Bagolan P, Davis CF, Frenckner BP, et al. Standardized reporting for 
congenital diaphragmatic hernia--an international consensus. J Pediatr Surg. 2013;48:2408-15.
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Several studies have investigated the prognostic value of Troponin T16-20 in infants; 
however, it has never been investigated solely in infants with CDH. Astoria et al. ana-
lyzed peak troponin levels from daily samples in 48 neonates (18 of whom had CDH) 
while they received ECMO as a predictor of death19, whereas we analyzed the difference 
between the first hsTnT level during ECMO and the last hsTnT level before ECMO was 
used. They found that cardiac troponin was an independent marker for nonsurvival. In 
our study, hsTnT levels did not predict mortality in patients with the need for ECMO. We 
did find that hsTnT levels on day 1 were significantly different for patients who required 
ECMO compared with patients without need for ECMO. For the 18 infants with CDH in 
table 2 – Patient characteristics of included and non-included patients
included patients
n=128
non-included patients
n=50
p-value
Gestational age (weeks) 38.1± 1.3 37.8± 1.4 0.18
Birth weight (grams) 2981± 467 2804± 415 0.02
Fetoscopic endotracheal occlusion 12 (9.4%) 7 (14.0%) 0.37
Male gender 60 (46.9%) 26 (52.0%) 0.54
Left sided defect 120 (93.8%) 35 (70.0%) <0.001
Liver position: intrathoracic 68 (53.1%) 37 (74.0%) 0.01
Type of repair 0.02
 Patch correction 72 (56.2%) 26 (52.0%)
 Primary closure 43 (33.6%) 11 (22.0%)
 No repair 13 (10.2%) 13 (26.0%)
Diaphragmatic defect size* <0.001
 A 7 (5.5%) 4 (8.0%)
 B 43 (33.6%) 8 (16.0%)
 C 55 (43.0%) 17 (34.0%)
 D 5 (3.9%) 8 (16.0%)
 No repair 13 (10.2%) 13 (26.0%)
 Missing 5 (3.9%) 0 (0%)
Treatment with nitric oxide 60 (46.9%) 29 (58.0%) 0.18
Treatment with inotropics 111 (86.7%) 41 (82.0%) 0.42
Initial ventilation mode: HFO 64 (50.0%) 22 (44.0%) 0.47
Age at repair (days) 4.0 (3.0- 8.0) 4.0 (3.0- 9.0) 0.90
Age at death (days) 13.0 (4.8- 25.5) 1.5 (0.8- 15.3) 0.02
Ventilation time (days) (in survivors) 10.0 (7.0- 17.5) 13.0 (7.0- 26.8) 0.58
ICU admission (days) (in survivors) 19.0 (13.0- 35.5) 26.5 (19.3- 51.5) 0.03
Data are presented as n (%), mean± SD or median (IQR).
Abbreviations: HFO: high-frequency oscillation; ICU: intensive care unit.
*Reference: Lally KP, Lasky RE, Lally PA, Bagolan P, Davis CF, Frenckner BP, et al. Standardized reporting for 
congenital diaphragmatic hernia--an international consensus. J Pediatr Surg. 2013;48:2408-15.
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the study of Astoria et al., levels of troponin are consistent with the CDH neonates who 
required ECMO in our study. El-Khuffash et al. investigated Troponin T in prematurely 
born infants in three studies16-18. In the first study, greater levels of cardiac troponin were 
found in nonsurvivors/ patients with severe impaired neurodevelopment18. In another 
study, troponin T levels were greater in premature infants with persistent ductus arte-
riosus than controls17. In the third study, significantly greater levels of troponin T were 
found in premature infants with lower Apgar scores at 5 minutes of life with significant 
correlations of troponin T levels and echocardiographic markers for left ventricular func-
tion16. Because those patient populations differed from those investigated in our study, 
results could not be compared. An interesting finding however, was that troponin T was 
correlated positively with echo measurements of myocardial dysfunction. Ventricular 
function is impaired in patients with CDH7,9. Patel and Moenkemeyer have shown that in 
response to therapy for PH, echo functional measurements changed9. Moreover, Baptista 
et al. showed that levels of NT-proBNP were correlated with myocardial dysfunction7. The 
right ventricular pressure overload in CDH may lead to a decrease in coronary perfusion 
gradient and thus impaired right coronary artery flow21, resulting in troponin T release 
and immediate troponin T leakage of the right and left ventricle22. That speculation may 
figure 2 – Mean values of NT-proBNP over time
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a) Black: survivors. Grey: non-survivors. b) Black: patients without need for ECMO. Grey: patients with need 
for ECMO. c) Black: survivors without bronchopulmonary dysplasia. Grey: survivors with bronchopulmo-
nary dysplasia. Abbreviations: ECMO: extracorporeal membrane oxygenation. 
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be supported by the study of Möller et al., who found significantly greater levels of tro-
ponin T in a cohort of 47 asphyxiated infants compared with controls20. Troponin T may 
be excreted in periods of asphyxia that cause myocardial damage. Hence, those data 
support why we found greater levels of troponin T in infants with CDH who required 
ECMO. This might also explain the substantial elevation of troponin levels in our study 
as compared to with prematurely born neonates16-18.
To our knowledge, few studies have investigated the usefulness of NT-proBNP in 
infants with CDH6-9. In contrast to our study, Baptista et al. found in a prospective study 
that levels of NT-proBNP at 24 hours of life were significantly greater in nonsurvivors than 
survivors7 and that NT-proBNP levels correlated with estimated pulmonary artery pres-
sure. We found no significant difference in levels of NT-proBNP between nonsurvivors 
and survivors. The differences in the results between the two studies may be explained 
by the different sample sizes and Baptista et al. had estimated the mean pulmonary 
artery pressure, whereas we distinguished two levels (mild PH vs severe PH) based on 
the estimated pulmonary artery pressure. Steurer et al. found in 27 infants with CDH that 
levels of BNP were greater on day 1 in poor-outcome patients (nonsurvivors/ ongoing 
respiratory support at 56 days of age), but on day 7 there was no longer an association 
figure 3 – Mean values of hsTnT over time
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a) Black: survivors. Grey: non-survivors. b) Black: patients without need for ECMO. Grey: patients with need 
for ECMO. c) Black: survivors without bronchopulmonary dysplasia. Grey: survivors with bronchopulmo-
nary dysplasia. Abbreviations: ECMO: extracorporeal membrane oxygenation.
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table 3 – Mann Whitney U tests results
Day nt-proBnP hstnt
Day 1 Pulmonary hypertension p=0.81 p=0.06
 <2/3 systemic (mild) 181.1 (80.1- 429.7) 56.5 (43.6- 109.6) 
 >2/3 systemic (severe) 141.2 (87.5- 461.1) 82.0 (49.4- 195.2) 
Death p=0.11 p=0.07
 Survivors 95.2 (57.4- 303.6) 65.4 (41.3- 106.4)
 Nonsurvivors 192.1 (118.1- 676.8) 98.0 (47.2- 260.7)
ECmo need p=0.09 p=0.01
 No need of ECMO 134.5 (62.9- 451.5) 67.3 (44.3- 111.9)
 Need of ECMO 237.5 (137.8- 422.1) 130.7 (58.5- 269.8)
BPD in survivors p=0.01 p=0.02
 No presence of BPD 81.0 (40.4- 232.3) 56.5 (35.0- 77.5)
 Presence of BPD 127.9 (77.3- 1170.8) 80.6 (57.7- 240.5)
Day 3 Death p=0.10 p=0.71
 Survivors 174.9 (122.8- 1235.0) 118.6 (59.4- 164.3)
 Nonsurvivors 654.2 (397.3- 4328.8) 216.8 (149.3- 613.8)
ECmo need p=0.23 p=0.22
 No need of ECMO 754.1 (255.9- 1306.0) 80.5 (56.0- 157.8)
 Need of ECMO 654.5 (257.8- 3409.3) 174.4 (81.4- 566.0)
BPD in survivors p=0.04 p=0.13
 No presence of BPD 148.0 (129.7- 866.0) 136.4 (61.1- 173.5)
 Presence of BPD 1021.0 (72.6- 1441.8) 91.8 (47.0- 147.2)
Day 7 Death p=0.62 p=0.22
 Survivors 240.9 (145.3- 592.7) 56.7 (28.3- 99.1)
 Nonsurvivors 829.6 (326.4- 3040.3) 102.7 (47.5- 396.8)
BPD in survivors p=0.41 p=0.05
 No presence of BPD 297.9 (165.7- 546.6) 56.7 (24.8- 98.1)
 Presence of BPD 208.7 (65.5- 780.9) 50.5 (29.0- 145.4)
Day 14 Death p=0.09 p=0.52
 Survivors 281.9 (154.9- 873.0) 58.2 (37.3- 85.6)
 Nonsurvivors 1709.5 (915.5- 3483.5) 59.5 (34.2- 110.4)
BPD in survivors p=0.35 p=0.69
 No presence of BPD 271.5 (152.6- 692.9) 58.2 (42.7- 73.2)
 Presence of BPD 562.4 (151.5- 1390.3) 67.3 (30.1- 152.2)
mortality in patients with ECmo need* p=0.89 p=0.85
Survivors 115.5 (−168.5- 2706.0) 24.6 (−134.4- 99.3)
Nonsurvivors 471.7 (−1134.4- 525.1) −46.4 (−77.5- 157.6)
Data are presented as median (IQR). NT-proBNP was presented in pmol/L and hsTnT in pg/ mL. * The dif-
ference of the value of the biomarkers before and after start of ECMO was analyzed. Abbreviations: ECMO: 
extracorporeal membrane oxygenation; BPD: bronchopulmonary dysplasia.
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table 4 – Multivariable logistic regression analyses
Associations of biomarkers with severity of PH, death, ECMO need, BPD in survivors and death in patients 
who were placed on ECMO
independent variable or p-value 95% Ci Sign. Correction*
PH <2/3 systemic vs >2/3 systemic
NT-proBNP day 1 0.858 0.76 0.325- 2.263 O/E LHR
HsTnT day 1 1.010 0.07 0.999- 1.020 O/E LHR
Death
NT-proBNP day 1 1.120 0.82 0.423- 2.963 Liver, O/E LHR
NT-proBNP day 3 0.993 0.97 0.700- 1.407 O/E LHR
NT-proBNP day 7 1.140 0.54 0.749- 1.737 –
NT-proBNP day 14 2.100 0.11 0.843- 5.232 –
HsTnT day 1 1.002 0.58 0.995- 1.009 Liver, O/E LHR
HsTnT day 3 0.999 0.23 0.996- 1.001 O/E LHR
HsTnT day 7 1.004 0.34 0.996- 1.012 –
HsTnT day 14 1.002 0.85 0.982- 1.023 –
ECmo need
NT-proBNP day 1 0.457 0.39 0.077- 2.719 Liver, O/E LHR
NT-proBNP day 3 1.015 0.95 0.651- 1.581 O/E LHR
HsTnT day 1 1.018 0.03 1.002- 1.033 Liver, O/E LHR
HsTnT day 3 1.004 0.23 0.997- 1.011 O/E LHR
BPD in survivors
NT-proBNP day 1 0.995 0.98 0.662- 1.496 Liver
NT-proBNP day 3 1.145 0.43 0.820- 1.600 Liver
NT-proBNP day 7 0.576 0.10 0.298- 1.113 Liver
NT-proBNP day 14 0.992 0.99 0.257- 3.830 Liver
HsTnT day 1 1.014 0.03 1.002- 1.026 Liver
HsTnT day 3 1.005 0.25 0.996- 1.014 Liver
HsTnT day 7 1.015 0.05 1.000- 1.031 Liver
HsTnT day 14 1.020 0.17 0.992- 1.049 Liver
Death in patients who were treated with ECmo**
NT-proBNP 0.626 0.22 0.296- 1.322 –
HsTnT 0.988 0.32 0.964- 1.012 –
*Observed-to-expected lung-to-head ratio, side and liver position were included as covariates. Covariates 
with significant effects (p-value <0.05) are shown in this column.
**The difference between the first biomarker value during ECMO and last biomarker value before ECMO 
was used as predictor.
NT-proBNP was presented in nmol/L and hsTnT in pg/mL.
Abbreviations: OR: odds ratio; CI: confidence interval. PH: pulmonary hypertension; ECMO: extracorporeal 
membrane oxygenation; BPD: bronchopulmonary dysplasia.
Significance levels: PH <2/3 systemic vs >2/3 systemic: 0.025; death 0.0125; ECMO need 0.025; BPD in survi-
vors 0.0125; death in patients who were treated with ECMO 0.05.
90 • Chapter 5
with worse outcome6. This finding is consistent with our study. In contrast to the study 
from Steurer et al., however, we did not find greater levels of NT-proBNP on day 1 in 
nonsurvivors. There are a number of differences in the two studies, including the sample 
sizes. Second, they defined poor outcome as the composite outcome of prolonged re-
spiratory support at 56 days or death, whereas we performed separate tests for survival 
and second, BPD (defined as oxygen dependency at day 28) in the selection of survivors. 
Third, they used another method for measuring the BNP levels, which is a different 
molecule. Because NT-proBNP has a longer half-life than BNP (118 vs 18 minutes) and it 
is easier to measure23, we believe that NT-proBNP should be used in future studies, such 
as studies that focus on biomarker level differences in response to therapy.
Partridge et al. performed a single-center study in a relatively large cohort of infants 
with CDH8. In contrast to our results, they found that BNP measured prerepair was 
significantly lower in patients without PH compared with patients with PH. Differences 
may be explained that in the first place a different molecule was measured. Second, 
in their paper, the timing of the prerepair BNP measurement was not specified, and it 
may be the peak troponin level during this time period. This may account for differ-
ences from our study, next to the fact that they performed a retrospective study without 
pre-specified time points. Third, to define PH, echocardiographies in their study were 
performed as clinically indicated, whereas we performed one echocardiography in the 
first 24 hours. Moreover, they measured the right ventricular systolic pressure estimate 
to determine the presence of PH, and we categorized patients based on the ratio be-
tween the pulmonary and systemic pressure. We believe that a standardized protocol 
that includes the assessment of ventricular function, and with a correlation of data to 
biomarkers levels, would be the next step in future studies. Partridge et al. did not find 
differences in BNP levels in patients who required ECMO or phosphodiesterase type 5 
inhibitors (sildenafil) compared with patients managed with inhaled nitric oxide alone. 
Similarly, we also did not find that levels of NT-proBNP were different between patients 
with and without need for ECMO.
The strengths of this study are, first, that samples were drawn routinely at predeter-
mined times starting very early after birth and, second, that the outcomes were not 
dependent on a participating center because all patients were treated according to 
the same standardized neonatal treatment protocol. The outcome ‘need for ECMO’ was 
analyzed in a selection of patients born in an ECMO center. To exclude laboratory differ-
ences, samples were analyzed in one laboratory.
A limitation of our study is that included patients had a shorter duration of stay in 
the intensive care unit, so our results may not be generalizable to all patients with CDH. 
Another limitation is that effects of therapies might have influenced biomarkers levels. 
Thus, in the interpretation of biomarker levels, the current treatment and clinical setting 
should always be taken into account. Moreover, the severity of PH was estimated on 
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the basis of echocardiographic measurements instead of right heart catheterization, 
which is seen as the golden standard but unrealistic in these patients. PH was only as-
sessed within the first 24 hours of life. In future studies, it would be better to assess the 
persistence of PH into the first weeks of life, based on a standardized protocol including 
assessment of ventricular function, and correlate the data to biomarkers levels.
In conclusion, in inborn patients with CDH, the biomarkers hsTnT and NT-proBNP had 
no significant predictive value when measured at predetermined specific time points for 
the specific outcomes tested. Since routine based measurements of biomarkers do not 
seem useful, future research should study whether biomarker levels determined before 
and after the start of clinical interventions (such as start of iNO or initiation of an ECMO 
procedure) could better predict outcomes.
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ABStrACt
objectives: To determine the optimal initial ventilation mode in congenital diaphrag-
matic hernia.
Summary background data: Congenital diaphragmatic hernia is a life-threatening 
anomaly with significant mortality and morbidity. The maldeveloped lungs have a high 
susceptibility for oxygen and ventilation damage resulting in a high incidence of bron-
chopulmonary dysplasia (BPD) and chronic respiratory morbidity.
methods: An international, multicenter study (NTR 1310), the VICI-trial was performed 
in prenatally diagnosed congenital diaphragmatic hernia infants (n=171) born between 
November 2008 and December 2013, who were randomized for initial ventilation strat-
egy.
results: Ninety-one (53.2%) patients initially received conventional mechanical ventila-
tion and 80 (46.8%) high-frequency oscillation. Forty-one patients (45.1%) randomized to 
conventional mechanical ventilation died/ had BPD compared with 43 patients (53.8%) 
in the high-frequency oscillation group. An odds ratio of 0.62 [95% confidence interval 
(95% CI) 0.25-1.55] (P=0.31) for death/ BPD for conventional mechanical ventilation vs 
high-frequency oscillation was demonstrated, after adjustment for center, head-lung 
ratio, side of the defect, and liver position. Patients initially ventilated by conventional 
mechanical ventilation were ventilated for fewer days (P=0.03), less often needed ex-
tracorporeal membrane oxygenation support (P=0.007), inhaled nitric oxide (P=0.045), 
sildenafil (P=0.004), had a shorter duration of vasoactive drugs (P=0.02), and less often 
failed treatment (P=0.01) as compared with infants initially ventilated by high-frequency 
oscillation.
Conclusions: Our results show no statistically significant difference in the combined 
outcome of mortality or BPD between the 2 ventilation groups in prenatally diagnosed 
congenital diaphragmatic hernia infants. Other outcomes, including shorter ventilation 
time and lesser need of extracorporeal membrane oxygenation, favored conventional 
ventilation.
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introDUCtion
Congenital diaphragmatic hernia (CDH) is a developmental defect of the diaphragm 
that occurs in approximately 1 in 3000 live births1. It is characterized by maldevelop-
ment of both the ipsilateral and contralateral lung and abnormal prenatal pulmonary 
vascular growth. Although pulmonary hypoplasia and pulmonary hypertension are the 
main causes of mortality, ventilator-induced lung injury and oxygen toxicity may result 
in prolonged oxygen dependency, or bronchopulmonary dysplasia (BPD)2. Logan et al3 
have suggested that 25% of the mortality is due to potentially treatable aspects of the 
underlying pathophysiology and that ventilator-induced lung injury could be one of 
these aspects.
Since 2008, all CDH patients born in European countries represented in the CDH 
EURO consortium have been treated according to a standardized neonatal treatment 
protocol that was developed at a consensus meeting4. After implementation of this 
protocol, mortality decreased from 33% to 12%5. This decrease in mortality rate should 
be interpreted against of the year upon year variability in mortality rates. Nevertheless, 
standardization of care is an ideal backcloth to undertake multicenter randomized 
controlled trials (RCTs).
The optimal initial invasive ventilation strategy in antenatal diagnosed CDH patients, 
however, is still unknown. Certain studies with retrospective or observational study 
designs have shown improved survival and lower incidence of BPD with the use of high-
frequency oscillation (HFO) ventilation6-11. They reported that HFO may result in favor-
able outcome in CDH because of better oxygenation and higher mean airway pressure 
without increasing the incidence of barotrauma. In another study, however, based on 
the CDH EURO consortium registry, HFO as initial ventilation mode was associated with 
increased rates of mortality and BPD2. We, therefore, performed the first prospective 
multicenter study (VICI-trial) of conventional mechanical ventilation (CMV) or HFO as 
the initial ventilation strategy12. The primary outcome measure was death or BPD13.
mEtHoDS
A prospective, randomized clinical trial was performed. All participating centers were 
members of the CDH EURO consortium4. Prenatally diagnosed CDH infants, born at a 
gestational age of more than 34 weeks between November 2008 and December 2013 in 
1 of the 9 centers were eligible for inclusion. Exclusion criteria were severe chromosomal 
anomaly such as trisomy 13 or 18, which may imply a decision to stop or not to start 
medical treatment; severe cardiac anomalies expected to need corrective surgery in 
the first 60 days after birth; renal anomalies associated with oligohydramnios; severe 
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orthopedic and skeletal deformities that were likely to influence thoracic or lung devel-
opment; and severe anomalies of the central nervous system. We excluded patients with 
a gestational age of less than 34 weeks so that the results could not be influenced by 
lung prematurity. Besides, neonates with a gestational age below 34 weeks cannot be 
placed on extracorporeal membrane oxygenation (ECMO). Ethical approval was given 
by the medical ethics review board of Erasmus MC, Rotterdam, the Netherlands (NTR 
1310). Thereafter, all local medical ethical committees gave their approval. Parents gave 
written informed consent. The procedures, including obtaining informed consent, were 
conducted in accord with the ethical standards of the Committee on Human Experimen-
tation of the institution in which the experiments were done. The centers’ duration of 
experience with HFO before initiation of the VICI-trial ranged from 8 years to 19 years.
To achieve equal distribution of the 2 ventilation modes among the participants, 
block randomization stratified per center was carried out using a computer-generated 
randomization schedule for each centre by a 24-hour interactive web response system. 
After birth, infants were centrally randomized to either CMV or HFO. The allocated venti-
lation mode was started within 2 hours after birth. Patients were monitored up to 1 year 
of life or until discharge whichever came first. CMV was provided by a neonatal ventila-
tor capable of positive pressure ventilation or triggered modes. Initial settings were a 
positive inspiratory pressure (PIP) of 20 to 25 cmH2O and a positive end-expiratory pres-
sure (PEEP) of 3 to 5 cmH2O, with a ventilator rate of 40 to 60/min. According to clinical 
practice, PIP was increased in the case of ventilation problems and the PEEP or FiO2 were 
adjusted if oxygenation problems occurred. Weaning from ventilation was preferentially 
by means of decreasing PIP or frequency to achieve PaCO2 levels above 45mm Hg. HFO 
was provided by a high-frequency oscillatory ventilator. Initial settings were mean air-
way pressure 13 to 17 cmH2O, frequency 10 to 12 Hz, delta P 30 to 50 cmH2O depending 
on chest wall vibration. According to clinical practice, the frequency was reduced and/
or delta P was increased in the case of ventilation problems and the MAP and/or FiO2 
were adjusted if oxygenation problems occurred. All patients were treated according 
to the same standardized CDH EURO Consortium neonatal treatment protocol.4 The 
initially allocated ventilation mode could be switched if one or more of the following 
predetermined failure criteria were met at 2 consecutive time points for at least 3 hours: 
inability to maintain preductal saturations above 85% (±52mm Hg or 7 kPa) or post-
ductal saturations above 70% (±5.3 kPa or 40 mm Hg); increase in CO2 >65 mm Hg or 
8.5 kPa despite optimization of ventilatory management; PIP > 28 cmH2O; mean airway 
pressure > 17 cmH2O; inadequate oxygen delivery with metabolic acidosis defined as 
lactate ≥ 5 mmol/ L and pH < 7.20; hypotension resistant to fluid therapy and inotropic 
support resulting in a urine output < 0.5 ml/kg/hour; oxygenation index of longitudinal 
evaluation ≥ 40. Patients could experience one or more criteria for treatment failures. If a 
patient born in an ECMO center should meet one of these failure criteria, either an ECMO 
CMV versus HFO for CDH; the VICI-trial • 103
Ch
ap
te
r 6
procedure was considered to be initiated or the initially allocated ventilation mode was 
considered to be switched. If subsequently there was no improvement, the infant was 
placed on ECMO. If a patient born in a center without ECMO availability should meet one 
of these failure criteria, only the ventilation mode was considered to be switched. None 
of the patients was transferred from a non-ECMO center to an ECMO-center. Arterial 
blood pressure was to be maintained at a normal level for gestational age. In case of 
hypotension and/or poor perfusion, 10 to 20 ml/kg NaCl 0.9% was to be administered 
1 to 2 times and inotropic agents were considered according to the local practice. If 
there was suprasystemic pulmonary artery pressure and right-to-left shunting through 
the foramen ovale, administration of intravenous phosphodiesterase type-5 inhibitor 
E5 (PDE-5) (Sildenafil) was to be considered. According to the protocol, paralysis in the 
delivery room was to be avoided if possible. Antenatal data, neonatal characteristics as 
well as data on the clinical course, and treatment were collected. Defect size was classi-
fied intraoperatively according to the CDH study group14. Liver position was determined 
during surgery or if there was no surgical repair from prenatal echographic data. Pul-
monary hypertension was categorized as none, <2/3 systemic, 2/3 systemic to systemic, 
or suprasystemic. The latter 3 categories are according to the definition of Keller et al15.
Sample size calculation
In each ventilation category, 187 infants were to be randomized to give 80% power us-
ing a 5% significance level to detect a 15% difference in the combined primary outcome 
of death or BPD. BPD was defined as oxygen dependency beyond 28 days after birth13. 
To allow for some nonevaluable patients and dropouts, inclusion of 200 patients per 
group was planned.
Statistical analysis
To determine whether differences in the demographics of the 2 treatment arms were 
statistically significant, independent samples t tests for continuous variables that were 
normally distributed, χ2 tests for categorical variables, and Mann-Whitney U tests for 
continuous variables that were not normally distributed, were used. Multiple logistic 
regression analysis using treatment arm, center, lung-to-head ratio, position of the 
liver, and side of the defect as independent variables served to evaluate the primary 
outcome. A subgroup analysis was performed for infants who underwent surgical repair, 
with defect size added to the independent variables to evaluate the primary outcome. 
The subgroup analysis and the independent variables for the logistic regression model 
were selected a priori. However, the 4 centers that each treated fewer than 10 patients in 
total, were evaluated as a single center in all analyses. Missing data of lung-to-head ratio 
(n=23 patients) and diaphragmatic defect size (n=5) were imputed by automatic mul-
tiple imputation in SPSS with 100 imputations. The predictors in the imputation models 
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consisted of BPD or death, as well as all independent variables (except initial ventilation 
mode) in the logistic regression models. The goodness-of-fit of the logistic regression 
models was assessed using the Hosmer-Lemeshow test. Patients were analyzed in the 
group of randomization, even after switching of ventilator mode. Overall mortality with-
in first 60 days of life was calculated using Kaplan-Meier curves and compared between 
treatment arms using a log-rank test stratified by center. The Mantel-Haenszel test with 
stratification by center was used to compare overall mortality in the first year of life, 
presence of pulmonary hypertension, iNO, vasoactive medication, phosphodiesterase 
inhibitor 5 (Sildenafil, Pfizer, Basel, Switzerland), and requirement of ECMO (in ECMO 
centers only) between treatment arms. The Van Elteren test with stratification by center 
was used to compare the difference of severity of BPD, number of days of ventilation, the 
number of treatment failures, severity of pulmonary hypertension, and number of days 
treated with vasoactive medication between the 2 treatment arms. Treatment failures 
were only recorded (ie, those infants whose initial ventilation mode was switched or 
who were placed on ECMO) for patients whose ventilator mode was switched and those 
figure 1 – Flowchart of patient inclusion
VICI-trial
Total n=171
HFO
n=80 (46.8%)
CMV
n=91 (53.2%)
Survived
n=55 (68.8%)
Died
n=25 (31.3%)
Survived
n=70 (76.9%)
Died
n=21 (23.1%)
BPD
n=18 (32.7%)
No BPD
n=37 (67.3%)
BPD
n=21 (30.0%)
No BPD
n=49 (70.0%)
CDH patients 
Nov 2008- Dec 2013
n=619
Reason no inclusion (n=448):
Parents not approached for consent n=237
Not inborn                                      n=61
Antenatally unknown                                        n=41
No consent                                                            n=41
Gestational age <34 weeks                              n=37
Logistical problem                                              n=7
Unknown                                                               n=5
Associated severe anomalies                          n=5
Antenatally expected renal problems          n=4
Mother in labour before consent                  n=4
Severe cardiac anomaly                                     n=3
Severe language problem                                 n=1
Died before ventilation started                      n=1
Immediate need of ECMO                                 n=1
BPD indicates bronchopulmonary dysplasia; CDH, congenital diaphragmatic hernia; CMV, conventional 
mechanical ventilation; ECMO, extracorporeal membrane oxygenation; HFO, high-frequency oscillation.
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who were placed on ECMO. All statistical tests were 2-sided, and a P value of <0.05 was 
considered statistically significant. The analyses were conducted using IBM SPSS 21.0 for 
Windows (IBM Corp., Amonk, NY) for the primary outcome and STATA 13.0 for Windows 
(StataCorp LP, College Station, TX) for secondary outcomes.
rESUltS
Between November 2008 and December 2013, 171 antenatally diagnosed CDH patients 
from 9 European centers were included (Figure 1). The predicted severity of illness 
(SNAP-II score and O/E LHR) did not significantly differ between the 2 groups (Table 
1). The characteristics of the 448 nonincluded patients were not significantly different 
for the prevalence of death as compared with the included patients (Table 2). None 
of the included patients was withdrawn from the study and the primary outcome was 
observed for all included patients. ECMO was available in 6 of the 9 centers (involving 
table 1 – Baseline Characteristics by Randomized Ventilation Mode
Variable Hfo (n= 80) CmV (n= 91) P-value
FETO 12 (15.0%) 7 (7.7%) 0.15
LHR 1.51 (1.07- 1.92) 1.53 (1.13-2.00) 0.67
O/ E LHR 47% (15%-141%) 48% (21%- 100%) 0.46
Gestational age 38 (37.3- 39.0) 38.1 (37.4- 38.9) 0.39
Birth weight (kg) 2.89 (0.47) 2.95 (0.46) 0.38
Male sex 36 (45.0%) 48 (52.7%) 0.36
SNAP-II score 25.0 (14.0- 40.0) 21.0 (10.0- 40.0) 0.44
Left side CDH 73 (91.3%) 75 (82.4%) 0.12
Liver 0.76
Intrathoracic 46 (57.5%) 55 (60.4%)
Abdominal 34 (42.5%) 36 (39.6%)
Type of repair 0.73
Primary closure 26 (32.5%) 27 (29.7%)
Patch repair 42 (52.5%) 50 (54.9%)
No repair 12 (15.0%) 14 (15.4%)
Diaphragmatic defect size 0.10
A 6 (7.5%) 5 (5.5%)
B 21 (26.3%) 28 (30.8%)
C 28 (35.0%) 40 (44.0%)
D 10 (12.5%) 2 (2.2%)
No repair 12 (15.0%) 14 (15.4%)
Unknown 3 (3.8%) 2 (2.2%)
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table 1 – (continued)
Variable Hfo (n= 80) CmV (n= 91) P-value
Major cardiac anomaly 0.42
Aortic hypoplasia 2 (2.6%) 0 (0%)
ASD and VSD 1 (1.3%) 0 (0%)
HLHS variant 0 (0%) 1 (1.1%)
Aortic stenosis 0 (0%) 1 (1.1%)
No cardiac anomaly 77 (96.3%) 89 (97.8%)
Age at repair (days) 5.0 (3.0- 9.0) 4.0 (3.0- 5.0) 0.005
Centers 0.43
1: (ECMO) 19 (46.3%) 22 (53.7%)
2: (ECMO) 7 (41.2%) 10 (53.8%)
3: (no ECMO) 7 (43.8%) 9 (56.2%)
4: (ECMO since 01-01-2013) 30 (55.6%) 24 (44.4%)
5: (ECMO) 12 (48.0%) 13 (52.0%)
6: (ECMO) 3 (37.5%) 5 (62.5%)
7: (ECMO) 1 (12.5%) 7 (87.5%)
8: (no ECMO) 1 (100%) 0 (0%)
9: (ECMO) 0 (0%) 1 (100%)
Results presented as n (%), mean (SD) or median (IQR). ASD, atrial septal defect; FETO, fetoscopic endo-
tracheal occlusion; HLHS, hypoplastic left heart syndrome; LHR, lung-to-head ratio; O/E LHR, observed to 
expected lung-to-head ratio; PH, pulmonary hypertension; SNAP-II score, score for neonatal acute physiol-
ogy-II; VSD, ventricular septal defect.
table 2 – Background characteristics nonparticipants
Variable n =448
Sex: female 167/ 411 (40.6%)
Unknown 37 (8.3%)
Gestational age (weeks) 36.8 (3.0)
Birth weight (kg) 2.76 (0.68)
Side
Left 345/ 421 (81.9%)
Right 73/421 (17.3%)
Bilateral 3/421 (0.7%)
Unknown 27 (6.0%)
Inborn 320/425 (75.3%)
Unknown 23 (5.1%)
Death 105/ 420 (25.0%)
Unknown 28 (6.3%)
Results are presented as n (%) or mean (SD).
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100 patients), in 2 centers it was not (17 patients), and in 1 center ECMO was introduced 
in 2013 (46 patients before ECMO and 8 patients after ECMO). Forty of the 108 (37%) 
patients born in a center with ECMO availability were subsequently supported by ECMO 
(Figure 2). Although the protocol dictated that the allocated ventilator mode should 
be started within 2 hours after birth, in all children, it was started within 1 hour after 
delivery.
Forty-one of the 91 patients (45.1%) initially ventilated with CMV died or had BPD 
by day 28 compared with 43 of the 80 patients (53.8%) in HFO. That difference was not 
statistically significant after taking into account of center, lung-to-head ratio, side of 
the defect, and position of the liver, with an odds ratio (OR) of 0.62 [95% confidence 
interval (95% CI) 0.25- 1.55] (P=0.31) comparing CMV with HFO (Table 3). LHR (OR 0.164, 
P <0.001, 95% CI 0.064- 0.420) and liver position (OR 9.47, P <0.001, 95% CI 3.402- 26.359) 
were significantly associated with a worse outcome. The primary outcome results with-
out pooling of the centers are shown in Supplemental Digital Content 1. A subgroup 
analysis of the 145 operated infants taking into account center, lung-to-head ratio, side 
of the defect, position of the liver, and defect size, demonstrated that 27 of 77 patients 
figure 2 – Flowchart treatment failures
Included  patients
n=171
Born in centre with 
ECMO facilities
n=108 (63.2%)
Born in centre without 
ECMO facilities
n=63 (36.8%)
Treatment failures
Preductal saturation: n= 4 
Increase CO2:                           n= 7
Increase PIP:                             n= 2
Inadequate oxygen:              n= 7
Hypotension:                           n= 1
Oxygenation index >40:      n= 2
Treatment failures
Preductal saturation: n=4 
Increase CO2:                      n=2
Increase PIP:                         n=0
Inadequate oxygen:          n=0
Hypotension:                       n=1
Oxygenation index >40:  n=0
Only CMV: n= 41  (67.2%)
Switch:                 n= 4    (6.6%)
ECMO:                  n= 16 (26.2%)
CMV
n=61 (56.5%)
HFO
n=47 (43.5%)
CMV
n=30 (47.6%)
HFO
n=33 (52.4%)
Only CMV: n=20 (66.7%)
Switch:                  n=10 (33.3%)
Only HFO: n=20 (60.6%)
Switch:          n=13 (39.4%)
Treatment failures
Preductal saturation: n= 8
Increase CO2:                          n= 7
Increase PIP:                            n= 6
Inadequate oxygen:             n= 2
Hypotension:                          n= 0
Oxygenation index >40:     n= 2
Only HFO: n=12 (25.5%)
Switch:                   n=11 (23.4%)
ECMO:                    n=24 (51.1%)
Treatment failures
Preductal saturation: n=12
Increase CO2:                           n=14
Increase PIP:                              n=8
Inadequate oxygen:               n=9
Hypotension:                            n=1
Oxygenation index >40:       n=4
CMV indicates conventional mechanical ventilation; ECMO, extracorporeal membrane oxygenation; HFO, 
high-frequency oscillation; PIP, peak inspiratory pressure. Preductal saturation: inability to maintain pre-
ductal saturations above 85% (±52 mmHg or 7kPa) or postductal saturations above 70 % (±5.3 kPa or 40 
mmHg). Increase CO2: increase in CO2 >65 mmHg or 8.5 kPa despite optimization of ventilatory manage-
ment. Increase PIP: peak inspiratory pressure >28 cm H2O; mean airway pressure >17 cm H2O. Inadequate 
oxygen: inadequate oxygen delivery with metabolic acidosis defined as lactate ≥5 mmol/ L and pH <7.20. 
Hypotension: hypotension resistant to fluid therapy and inotropic support resulting in a urine output <0.5 
ml/kg/hour. Oxygenation index >40: oxygenation index of longitudinal evaluation ≥40.
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table 3 – Primary outcome: All patients (n=171)
Variable or 95% Ci P
Ventilation
HFO Ref
CMV 0.620 0.249- 1.548 0.306
LHR 0.166 0.067- 0.413 0.000
Liver
Down Ref
Up 10.574 4.006-27.911 0.000
Side
Left Ref
Right 0.986 0.235- 4.139 0.985
Centers
Center(1) Ref
Center(2) 0.221 0.034- 1.453 0.116
Center(3) 0.114 0.019- 0.683 0.017
Center(4) 0.210 0.038- 1.152 0.072
Center(5) 0.440 0.133- 1.455 0.179
Center(6) 2.310 0.461- 11.585 0.309
95% CI indicates 95% confi dence interval; CMV, conventional mechanical ventilation; HFO, high-frequency 
oscillation; OR, odds ratio; Ref: reference category.
figure 3 – Kaplan-Meier curve of all included patients comparing CMV and HFO
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(35.1%) in CMV and 31 of 68 patients (45.6%) in HFO died or had BPD by day 28; OR of 
0.76 (95% CI 0.24- 2.41) (P =0.64) (Table 4). Median (interquartile range, IQR) values in 
the Hosmer Lemeshow test in the primary outcome of all patients were 0.306 (0.178 to 
0.481) and in the subgroup analyses 0.653 (0.547to 0.779).
The duration of survival within first 60 days after birth did not differ between the 2 
groups (P=0.19). (Figure 3). The overall mortality in the first year after birth was 21 pa-
tients (23.1%) in the CMV group and 25 patients (31.3%) in the HFO group (P=0.26). The 
median duration of ventilation was 10.0 days (IQR 6.0 to 18.0 days) in the CMV group and 
13.0 days (IQR 8.0 to 23.0 days) in the HFO group (P=0.03) (Table 5). A subgroup analysis 
of the 108 patients born in a center with ECMO availability showed that 16 patients 
(26.2%) initially ventilated by CMV received ECMO vs 24 patients (51.1%) ventilated by 
HFO (P=0.007). The number of treatment failures was significantly different between 
the 2 treatment groups, 27 patients (33.8%) in the HFO group vs 20 patients (22.0%) 
table 4 – Subgroup analyses in operated patients (n=145)
Variable or 95% Ci P
Ventilation
HFO Ref
CMV 0.755 0.237- 2.412 0.636
LHR 0.157 0.043- 0.578 0.005
Liver
Down Ref
Up 8.234 2.230- 30.400 0.002
Side
Left Ref
Right 0.764 0.096- 6.065 0.799
Defect size
Defect size A Ref
Defect size B 6.087 0.145- 255.322 0.343
Defect size C 9.915 0.260- 378.726 0.217
Defect size D 49.831 0.588- 4222.363 0.084
Centers
Center(1) Ref Ref Ref
Center(2) 0.110 0.010- 1.213 0.071
Center(3) 0.087 0.008- 0.896 0.040
Center(4) 0.048 0.005- 0.480 0.010
Center(5) 0.155 0.032- 0.750 0.020
Center(6) 2.386 0.424- 13.426 0.324
95% CI indicates 95% confidence interval; CMV, conventional mechanical ventilation; HFO, high-frequency 
oscillation; OR, odds ratio; Ref: reference category.
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in the CMV group (P=0.01). Of the 22 infants who were initially ventilated by CMV and 
due to treatment failures that switched to HFO, 14 (63.6%) died, 18 (81.8%) died or 
had BPD by day 28, and 8 (36.4%) also received ECMO treatment. In the CMV group, 
39 patients (42.9%) received iNO vs 45 patients of the 80 patients (56.2%) in the HFO 
group (P=0.045). Eleven patients (12.1%) initially ventilated by CMV received a phos-
phodiesterase 5 inhibitor vs 25 patients (31.2%) initially ventilated by HFO (P=0.004). 
The median duration of vasoactive medication was 6.0 days (IQR 3.3 to 11.8 days) in 
the CMV group and 8.0 days (IQR 4.3 to 19.0 days) in HFO (P=0.02). The median age at 
repair was 5.0 days (IQR 3.0 to 9.0 days) in the CMV group and 4.0 days (IQR 3.0- 5.0 days) 
in the HFO group (P=0.005). The median length of ICU stay of the survivors in the CMV 
group was 23.0 days (IQR 23.8 to 35.3 days) and that of the survivors in the HFO group 
20.0 days (IQR 13.0 to 54.0 days), P=0.99. Patients born in a center with ECMO facilities as 
table 5 – Secondary Outcomes by Ventilation Group Corrected for Center
Variable Hfo (n= 80) CmV (n= 91) P
Overall mortality in first year of life 25 (31.3%) 21 (23.1%) 0.26
Length of ventilation (days) 13.0 (8.0- 23.0) 10.0 (6.0- 18.0) 0.03
Severity BPD 0.13
No BPD 37 (46.3%) 50 (54.9%)
Mild BPD 7 (8.8%) 13 (14.3%)
Moderate BPD 2 (2.5%) 1 (1.1%)
Severe BPD 9 (11.3%) 6 (6.6%)
Died 25 (31.3%) 21 (23.1%)
ECMO (in ECMO centers only) 24/ 47 (51.1%) 16/ 61 (26.2%) 0.007
Inhaled nitric oxide 45 (56.2%) 39 (42.9%) 0.045
Phosphodiesterase inhibitor 5 (Sildenafil) 25 (31.2%) 11 (12.1%) 0.004
Vasoactive medication 73 (91.2%) 73 (80.2%) 0.08
Duration vasoactive medication (days)
(in survivors only)
8.0 (4.3- 19.0) 6.0 (3.3- 11.8) 0.02
Number of treatment failures 27 (33.8%) 20 (22.0%) 0.01
Presence pulmonary hypertension 57 (71.3%) 59 (64.8%) 0.16
Missing: n=3 Missing: n=4
Severity pulmonary hypertension 0.59
None 20 (25.0%) 29 (31.9%)
<2/3 systemic 9 (11.3%) 10 (11.0%)
2/3 systemic- systemic 26 (32.5%) 26 (28.6%)
> systemic 22 (27.5%) 21 (23.1%)
Missing 3 (3.8%) 5 (4.4%)
Results presented as n (%) or median (IQR). BPD indicates bronchopulmonary dysplasia; ECMO, extracorpo-
real membrane oxygenation.
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compared with patients born in a center without ECMO facilities were not significantly 
different for the primary outcome (died or BPD), overall mortality in the first year of life, 
length of ventilation, severity of BPD, frequency of iNO, vasoactive medication, number 
of treatment failures, and switching of ventilation mode (Supplemental Digital Content 
2). In Supplemental Digital Content 3a and 3b, secondary outcomes per ventilation 
group and differences between ECMO centers and non-ECMO centers are shown. In the 
sensitivity analysis, there was no significant interaction between ECMO availability and 
type of initial ventilation (OR 2.05, P= 0.44).
The trial was stopped early after enrolment of 171 participants in an inclusion period 
of 5 years because of lower than anticipated recruitment rates and due to a lack of finan-
cial resources and a lack of research infrastructure in 1 high-volume center.
DiSCUSSion
In this first RCT comparing HFO and CMV in infants prenatally diagnosed with CDH, 
we have demonstrated no statistically significant difference in the combined outcome 
of mortality or BPD between the 2 ventilation groups. The infants initially supported 
by CMV required a significantly shorter duration of ventilation and inotrope support, 
however, and were less likely to receive vasoactive medication or phosphodiesterase 
type 5 inhibitors or be placed on ECMO.
Previous animal studies as well as observational and retrospective human studies 
about the optimal mechanical ventilation strategy in CDH have shown contradictory 
results2, 8, 9. On the one hand, animal studies have suggested that HFO could improve 
pulmonary gas exchange, minimize barotrauma, and decrease the presence of inflam-
matory mediators16, 17. The models used in those studies are not comparable, however, 
to the clinical situation, as in the animal models, the CDH was induced by interfering 
with development of the lungs in a normally programmed lung antenatally, which is 
quite different from the pathophysiology of the abnormal lung development in CDH. 
On the other hand, Wilson et al18 showed in infants that there was no difference in out-
come between HFO and CMV ventilation. That study, however, was performed before 
the introduction of a gentle ventilation strategy with permissive hypercapnia. We found 
that infants initially ventilated by HFO needed mechanical ventilation for a longer time 
despite no significant difference in markers of severity such as SNAP-II score and O/E 
LHR between the 2 ventilation groups. A possible explanation is the process by which 
HFO causes overinflation of the terminal lung units, and especially of the ipsilateral 
lung, which leads to disruption of the epithelium and thereby to retained secretions and 
debris. Due to that process, the alveoli could possibly be more vulnerable to inflamma-
tion19.
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Moreover, the intubation and endotracheal suctioning procedures in mechanical 
ventilation can lead to injury of the tracheobronchial tree and – possibly even more 
important – to damage to the ciliated cells of the tracheal epithelium and mucociliary 
transport system19. We did not document the frequency of endotracheal suctioning and 
it is debatable whether this is more often needed in HFO than CMV, but the longer dura-
tion of HFO may have been associated with more endotracheal suctioning procedures. 
Although in HFO tidal volumes are very low, high levels of PEEP with constant tidal 
volumes may also exacerbate VILI20. Schultz et al21 found that prolonged mechanical 
ventilation induced pulmonary inflammation in preterm infants by increasing pulmo-
nary edema. As infants with HFO were ventilated longer, this could have contributed to 
more pulmonary inflammation21. In future studies, tracheal aspirates of CDH patients 
examining sphingolipids levels may possibly give further insight in the exact mecha-
nism of VILI22.
Infants in the HFO group received vasoactive medication for a longer period and were 
significantly more likely to receive iNO and a phosphodiesterase type 5 inhibitor. Those 
treatment modalities are used in the treatment of pulmonary hypertension15. We also 
found that infants initially ventilated by CMV were significantly less likely to receive 
ECMO treatment. The above results suggest that in the CMV group, the occurrence of 
pulmonary hypertension was less frequent and that it was less severe. The protocol 
dictated echocardiography only in the first 24 hours after birth, in which period we 
documented no significant difference in the occurrence and severity of pulmonary hy-
pertension. However, subsequent echocardiographies were undertaken that influenced 
management of the patients.
Some limitations of this study should be considered. Firstly, we did not achieve the 
calculated sample size. Secondly, we excluded patients born before 34 weeks of ges-
tation, as these infants could additionally have respiratory distress syndrome and the 
results of surfactant administration in this group are poor23. Moreover, very poor survival 
has been reported in CDH infants born before 33 weeks of gestation treated by FETO24. 
Almost 10% of the parents refused to participate in the study. Due to limited financial 
resources and a lack of research infrastructure in 1 high-volume center, inclusion was 
stopped after 1 year and 8 months. We had extended the inclusion period from 3 to 5 
years and we calculated that the study would need to continue for a total period of 10 
years to achieve the sample size. At that time, we had no expectation of an improving 
inclusion rate and saw no reason to further extend the inclusion period and therefore 
stopped the study. The data were not analyzed until after this decision and thus the 
decision was not influenced by preliminary results.
Using the assumptions of the original power calculation, the attained sample size 
(n=80 for the HFO group and n=91 for the CMV group) yields a power of at least 44% to 
detect a difference of 15% in primary outcome between the 2 ventilation groups. After a 
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child’s condition had stabilized situation in the delivery room, the child was transferred 
to the ICU and received the allocated ventilation strategy. In all children, the allocated 
ventilator support was started within 1 hour after birth, but it cannot be excluded that 
receiving the other type of ventilation in the delivery room before that has influenced 
our results.
The major strengths of the current study was the fact that it was carried out in as many 
as 9 European centers in which all CDH patients are treated according to a standardized 
neonatal treatment protocol4. All centers had at least a period of more than 10 years of 
experience with HFO so we do not think that the factor “experience” has influenced our 
results. Secondly, central randomization stratified per center was carried out. We have 
reported size of the defect, major cardiac anomalies, and the outcome of patients who 
did not receive surgical therapy.
A meta-analysis of HFOV and prevention of BPD in prematurely born infants has 
shown a significant, although modest reduction in BPD25, but a subsequent more de-
tailed analysis did not confirm that effect26. A recently reported follow-up study of one of 
the RCTs included in that meta-analysis showed superior lung function at 11 to 14 years, 
despite no reduction in BPD27. It would thus be important to re-assess our patients at 
school age. It is acknowledged that the lung morphology of very prematurely born in-
fants is very different from the dysplastic lungs of CDH infants, so we cannot extrapolate 
those results to our study.
In conclusion, although secondary analyses seem to suggest some benefit to CMV, 
based on the primary outcome of interest, we must conclude that there is no difference 
in effect between CMV and HFO as a primary mode of ventilation in infants with antena-
tally diagnosed CDH. Infants with CDH initially ventilated by CMV compared with those 
who received HFO required a shorter duration of ventilation and vasoactive medication 
and were less likely to require other medication to treat pulmonary hypertension or 
ECMO.
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Supplemental digital content 1 – Primary outcome without pooling of the centers
Variable or 95% Ci p-value
Ventilation(1) 0.615 0.245- 1.545 0.301
LHR 0.164 0.064- 0.420 0.000
Liver(1) 9.989 3.757- 26.564 0.000
Side(1) 0.999 0.220- 4.545 0.999
Center(1) 0.362 0.033- 3.948 0.404
Center(2) 0.110 0.018- 0.659 0.016
Center(3) 0.213 0.007- 6.532 0.375
Center(4) 0.208 0.038- 1.142 0.071
Center(5) 0.436 0.133- 1.428 0.170
Center(6) 2.258 0.455- 11.210 0.319
Center(7) 0.000 0.000- 0.000 1.000
Center(8) 0.000 0.000- 0.000 1.000
Constant 10.469 1.342- 81.651 0.025
Supplemental digital content 2 – Primary and secondary outcomes by ECMO availability
Variable no ECmo available
(n=63)
ECmo available
(n=108)
p-value
BPD or died 28 (44.4%) 56 (51.9%) 0.35
Overall mortality in first year of life 19 (30.2%) 27 (25.0%) 0.46
Length of ventilation (days) 9.0 (7.0- 16.0) 12.0 (7.0- 21.0) 0.25
Severity BPD 0.42
No BPD 35 (55.6%) 52 (48.1%)
Mild BPD 5 (7.9%) 15 (13.9%)
Moderate BPD 1 (1.6%) 2 (1.9%)
Severe BPD 3 (4.8%) 12 (11.1%)
Died 19 (30.2%) 27 (25.0%)
Inhaled nitric oxide 27 (42.9%) 57 (52.8%) 0.21
Phosphodiesterase inhibitor 5 (Sildenafil®) 11 (17.5%) 25 (23.1%) 0.38
Vasoactive medication 54 (85.7%) 92 (85.2%) 0.93
Duration vasoactive medication (days)
(in survivors only)
6.0 (4.0- 8.0) 8.0 (4.5- 13.0) <0.001
Number of treatment failures 1.0 (1.0-2.0) 1.0 (0.0- 2.0) 0.39
Presence pulmonary hypertension 32 (53.3%) 83 (79.8%) <0.001
Severity pulmonary hypertension 0.004
None 28 (44.4%) 21 (19.4%)
<2/3 systemic 7 (11.1%) 12 (11.1%)
2/3 systemic- systemic 11 (17.5%) 41 (38.0%)
> systemic 14 (22.2%) 29 (26.9%)
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Supplemental digital content 2 – (continued)
Variable no ECmo available
(n=63)
ECmo available
(n=108)
p-value
Missing 3 (4.8%) 5 (4.6%)
Switching ventilation mode 23 (36.5%) 38 (35.2%) 0.86
Results presented as n (%) or median (IQR). Abbreviations: BPD: bronchopulmonary dysplasia; ECMO: extra-
corporeal membrane oxygenation.
Supplemental digital content 3a – CMV group: Outcomes by ECMO availability
Variable no ECmo available
(n=30)
ECmo available
(n=61)
p-value
BPD or died 12 (40.0%) 29 (47.5%) 0.50
Overall mortality in first year of life 9 (30.0%) 12 (19.7%) 0.27
Length of ventilation (days) 9.0 (7.0- 13.0) 11.0 (6.0- 19.5) 0.25
Severity BPD 0.38
No BPD 18 (60.0%) 32 (52.5%)
Mild BPD 2 (6.7%) 11 (18.0%)
Moderate BPD 0 (0.0%) 1 (1.6%)
Severe BPD 1 (3.3%) 5 (8.2%)
Died 9 (30.0%) 12 (19.7%)
Inhaled nitric oxide 11 (36.7%) 28 (45.9%) 0.40
Phosphodiesterase inhibitor 5 (Sildenafil®) 2 (6.7%) 9 (14.8%) 0.27
Vasoactive medication 23 (76.7%) 50 (82.0%) 0.55
Duration vasoactive medication (days)
(in survivors only)
6.0 (4.0- 8.0) 8.0 (4.0- 12.3) 0.005
Number of treatment failures 2.5 (1.8- 3.0) 1.5 (1.0- 3.0) 0.22
Presence pulmonary hypertension 13 (44.8%) 45 (77.6%) 0.002
Severity pulmonary hypertension 0.03
None 16 (53.3%) 13 (21.3%)
<2/3 systemic 3 (10.0%) 7 (11.5%)
2/3 systemic- systemic 4 (13.3%) 22 (36.1%)
> systemic 6 (20.0%) 15 (24.6%)
Missing 1 (3.3%) 4 (6.5%)
Switching ventilation mode 10 (33.3%) 12 (19.7%) 0.15
Results presented as n (%) or median (IQR). Abbreviations: BPD: bronchopulmonary dysplasia; ECMO: extra-
corporeal membrane oxygenation.
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Supplemental digital content 3b – HFO group: Outcomes by ECMO availability
Variable no ECmo available
(n=33)
ECmo available
(n=47)
p-value
BPD or died 16 (48.5%) 27 (57.4%) 0.43
Overall mortality in first year of life 10 (30.3%) 15 (31.9%) 0.88
Length of ventilation (days) 12.0 (7.0- 21.0) 13.5 (8.0- 23.0) 0.43
Severity BPD 0.78
No BPD 17 (51.5%) 20 (42.6%)
Mild BPD 3 (9.1%) 4 (8.5%)
Moderate BPD 1 (3.0%) 1 (2.1%)
Severe BPD 2 (6.1%) 7 (14.9%)
Died 10 (30.3%) 15 (31.9%)
Inhaled nitric oxide 16 (48.5%) 29 (61.7%) 0.24
Phosphodiesterase inhibitor 5 (Sildenafil®) 9 (27.3%) 16 (34.0%) 0.52
Vasoactive medication 31 (93.9%) 42 (89.4%) 0.48
Duration vasoactive medication (days) 
(in survivors only)
7.0 (4.0- 13.5) 8.0 (6.0- 14.0) 0.005
Number of treatment failures 1.0 (0.5- 1.0) 1.0 (0.0- 2.0) 0.58
Presence pulmonary hypertension 19 (61.3%) 38 (82.6%) 0.04
Severity pulmonary hypertension 0.15
None 12 (36.4%) 8 (17.0%)
<2/3 systemic 4 (12.1%) 5 (10.7%)
2/3 systemic- systemic 7 (21.2%) 19 (40.4%)
> systemic 8 (24.2%) 14 (29.8%)
Missing 2 (6.1%) 1 (2.1%)
Switching ventilation mode 13 (39.4%) 26 (55.3%) 0.16
Results presented as n (%) or median (IQR). Abbreviations: BPD: bronchopulmonary dysplasia; ECMO: extra-
corporeal membrane oxygenation.
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In congenital diaphragmatic hernia (CDH), lung hypoplasia and pulmonary hyperten-
sion are the main causes of neonatal mortality1. Mortality significantly decreased dur-
ing the past 10 years, after the introduction of the gentle ventilation strategy and the 
development of international standards for postnatal therapy2. Still, ventilator-induced 
lung injury is largely responsible for the development of chronic lung disease in children 
with CDH3.
In this issue of Pediatric Critical Care Medicine, Herber-Jonat et al present the results of 
a well- performed laboratory study in rabbits with induced CDH4. CDH was induced by 
fetal surgery and 5 days later perfluorooctylbromide, a perfluorocarbon, was instilled 
into the lungs of randomly selected fetal rabbits; other fetal rabbits received saline. 
A third group were non-operated fetuses who served as controls. Fetal instillation of 
perfluorooctylbromide was associated with improvement of lung-to-body weight ratio, 
total lung capacity, and lung compliance when compared with fetal instillation of saline. 
Secondly, at messenger RNA (mRNA) level only, expression of genes involved in extracel-
lular matrix formation and remodeling in the hypoplastic lung was increased. However, 
surfactant protein expression, distal airway size, mean linear intercept, and airspace 
and tissue fractions were similar between the two groups and also similar to fetuses 
who were not operated upon. The authors concluded that fetal perfluorooctylbromide 
treatment resulted in improved lung growth, lung mechanics and extracellular matrix 
remodeling. Extrapulmonary effects of perfluorooctylbromide, such as effects on neuro-
nal cell alteration and effects in the brain, should be determined in future studies before 
this therapy can be studied in human prenatal studies.
A ventilation technique known as liquid ventilation stems from the year 1929, when 
Von Neergard incidentally found that filling the lungs with saline solution dramatically 
improved the static pulmonary compliance in cats5. After further investigation of dif-
ferent types of liquids, Clark and Gollan received fame for their experiments of liquid 
ventilation using perfluorocarbon in mice for the first time6. In 1989, liquid ventilation 
showed its potential in a first trial in prematurely born neonates7. In CDH, Hirschl et al 
conducted a randomized trial in sheep8 and concluded that partial liquid ventilation 
(PLV) during extracorporeal membrane oxygenation may have beneficial effects on 
pulmonary function and gas exchange. Pranikoff et al applied PLV with the use of per-
flubron in four CDH patients who required extracorporeal life support postnatally9. They 
concluded that this therapy was possibly associated with improvement in gas exchange 
and lung compliance. Later on Hirschl et al conducted a randomized trial in 13 CDH 
infants who were randomized to either PLV perfluorocarbon-induced lung growth or 
conventional mechanical ventilation10. They found that perfluorocarbon-induced lung 
growth can be performed safely. However, when this trial was still ongoing, in 2001 the 
Food and Drug Administration decided that all clinical trials with perflubron had to be 
discontinued until safety data were available. That decision was based on findings that 
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adults with acute respiratory distress syndrome randomized to PLV had no improved 
outcome and experienced more adverse events such as more pneumothoraces, hy-
poxic episodes, and hypotensive episodes11. Nevertheless in China, adults with acute 
respiratory distress syndrome are currently recruited in a randomized controlled trial of 
perfluorocarbon instillation (NCT01391481).
In normal fetal lung development, the lungs are liquid-filled, and fluid secretion and 
fetal breathing movements are necessary for lung maturation12. In abnormal situations 
such as in prematurely born neonates in which transition from liquid-breathing to an 
air-breathing situation takes place prematurely, and in fetuses with an amniotic fluid-de-
ficient environment, lung development is likely to be immature resulting in lung-related 
problems postnatally. Instillation of perfluorooctylbromide in the trachea approximately 
to functional residual capacity can simulate the antenatal situation of liquid-filled airway 
branches. Thereafter, gas tidal volumes are delivered using a mechanical conventional 
ventilator. This is called PLV. In total liquid ventilation the lungs are completely filled 
with a liquid, whereas in PLV the lungs are filled until functional residual capacity. Per-
fluorocarbons have a high solubility for respiratory gases6. By eliminating the air-liquid 
interface, lung compliance can be improved13. Because of their dense characteristics, 
perfluorooctylbromide gravitate to dependent part of the lungs, and collapsed regions 
can be re-opened and ventilation/perfusion ratio may improve13. Next to these advan-
tages, pulmonary inflammation and injury may be reduced as a result of decreased 
cytokine production. Moreover, in pigs receiving PLV, a redistribution of pulmonary 
blood flow away from the dependent region of the lung was found, as well as increased 
vascular resistance and pulmonary artery pressure14.
In line with the experiments of the article from Herber-Jonat et al, we know that a 
complete obstruction of the fetal airways results in massive lung distension and 
a poly-alveolar lung the so-called congenital high airway obstruction syndrome 
(CHAOS)15. Taking this concept, the Tracheal Occlusion To Accelerate Lung Growth trial 
(NCT01240057) is an ongoing trial of tracheal occlusion to accelerate lung growth in 
prenatally diagnosed high-risk CDH infants stratified according to observed to expected 
lung-to-head ratio. Another study is planning to include patients for early tracheal 
occlusion (NCT01731509). Moreover, a trial known as the HFO versus conventional Ven-
tilation in Infants with Congenital Diaphragmatic hernia: an International randomized 
clinical trial (NTR 1310) was performed in nine European centers to identify the optimal 
ventilation strategy in antenatally diagnosed CDH infants. These studies might solve 
some of the challenges that stand in the way of further improvement in the treatment 
of CDH infants. Herber-Jonat et al conducted a randomized laboratory study in animals 
with a unique study design. Instead of only obstructing the fetal airway, they antenatally 
filled the lungs with perfluorooctylbromide, thus simulating the situation in normal 
lung development. However, the authors focused on mRNA expression and protein 
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analyses were not performed, which should be a serious limitation for the interpretation 
of the results. Second, in this study diaphragmatic hernia was induced by fetal surgery 
of normal programmed lungs, which makes the pathophysiology of developing CDH 
potentially different when compared to humans. Moreover, in rabbits, term birth occurs 
in the early saccular stage of lung development, whereas in humans the alveolariza-
tion process has taken place already during gestation. Therefore a different respons on 
perfluorooctylbromide may be found in humans.
Although the prognosis of CDH has improved during the past years, it is still a life-
threatening disease and ventilator-induced lung injury remains a significant problem. 
Conclusive findings from randomized clinical trials may enable us to improve the out-
come of CDH further. Once adverse long-term effects of PLV have been excluded, setting 
up a randomized clinical trial of antenatal or postnatal instillation of perfluorooctylbro-
mide in carefully selected patients might be a promising tool to investigate alternative 
ways of supporting the vulnerable lungs in high-risk newborns with CDH further.
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ABStrACt
Due to the high risk of respiratory insufficiency in congenital diaphragmatic hernia 
(CDH), international guidelines suggest that neonates are routinely intubated after birth. 
We encountered five prenatally diagnosed CDH cases, in which we considered to forgo 
routine intubation after birth. Three patients were ventilated during surgical repair only 
as they did not experience respiratory insufficiency. One patient received continuous 
positive airway pressure for several minutes after birth followed by oxygen through a 
nasal cannula, and received mechanical ventilation only during surgical repair. The fifth 
patient developed a bradycardia directly after birth and was therefore intubated several 
minutes after birth. Extubation was feasible after 30 minutes, and oxygen was provided 
by a nasal cannula until the surgical repair. Our experience indicate that dispensing with 
routine intubation dependent of the transitional phase of the neonate in a selected 
subgroup of CDH infants (LHR >2.5 or O/E LHR >50%, liver down) was found feasible.
Routine intubation in CDH; resetting our minds • 131
Ch
ap
te
r 8
introDUCtion
Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly with still a high 
mortality rate of about 25%. In the 1980s a shift in treatment occurred after the introduc-
tion of delayed surgical repair1, i.e. waiting until the infant’s condition has stabilized, and 
a new ‘gentle’ ventilation strategy was introduced2. The consensus guidelines published 
by the CDH EURO Consortium dictate routine intubation and mechanical ventilation 
after birth3. However, ventilator-induced lung injury is a risk factor of chronic lung dis-
ease, which is seen in about 56% of infants with CDH4. We describe five cases in which 
we considered to forgo routine intubation after birth. For each patient, this decision was 
prenatally discussed with the parents and discussed during regular multidisciplinary 
perinatal meetings between all involved clinicians.
CASE rEPort
In these five cases, CDH was antenatally detected between 25 weeks and 38.5 weeks of 
gestation, with the following characteristics: lung-to-head ratio (LHR) from 2.5 to 4.2, 
observed-to-expected LHR (O/E LHR) between 50 to 80%, liver position intra-abdominal, 
and gastric position in all but one case intra-abdominal. Prenatal ultrasound was per-
formed using the GE Voluson E8/E10 system (GE Medical Systems, Zipf, Austria) at the 
Department of Obstetrics and Gynecology, Division of Obstetrics and Prenatal Medicine 
by experienced investigators.
Between the gestational ages of 36+1 and 38+6 weeks, four patients were delivered 
by vaginal delivery, and one patient was delivered by caesarean section. The Apgar 
score at 5 minutes was 8 or higher, lowest umbilical arterial cord blood pH was 7.27, 
and birth weight was between 2470 and 3580 grams. After birth, a nasogastric tube was 
inserted and continuous suctioning was started to prevent dilatation of bowel loops in 
the ipsilateral thoracic cavity compromising lung expansion. In all patients, preductal 
saturations in the transitional phase were in the normal range5.
Three patients were ventilated during the surgical repair only and postoperatively 
received oxygen by nasal cannula for a maximum of 14 days. They did not experience re-
spiratory insufficiency after birth. A fourth patient received continuous positive air pres-
sure (CPAP) with PEEP of 5 cm H2O and 80% O2 for several minutes after birth followed 
by oxygen through a nasal cannula, and received mechanical ventilation only during 
surgical repair. Postoperatively this patient received supplemental oxygen by a nasal 
cannula for 26 days. The fifth patient developed a bradycardia directly after birth (60 
bpm) and was therefore intubated several minutes after birth. Extubation was feasible 
after 30 minutes, and oxygen was provided by a nasal cannula until the surgical repair.
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In all but one cases a thoracoscopic approach and a primary closure could be per-
formed. In one case conversion to a laparotomy with patch repair was necessary because 
the anterior part of the diaphragm could not be attached with the weak tissue of the 
posterior part of the diaphragm. Length of stay at the intensive care unit ranged from 
four to ten days.
DiSCUSSion
In conclusion, dispensing with routine intubation dependent of the transitional phase 
of the neonate in a selected subgroup of CDH infants (LHR >2.5 or O/E LHR >50%, liver 
down) was found feasible. It is even preferable to prevent consequences of ventilation 
such as fluctuations of blood pressure, sedation and ventilator-induced lung injury. 
Larger studies should corroborate this finding and perhaps bring about a resetting of 
the dogma of endotracheal intubation in all prenatally diagnosed CDH patients.
Routine intubation in CDH; resetting our minds • 133
Ch
ap
te
r 8
rEfErEnCES
 1. Cartlidge PH, Mann NP, Kapila L. Preoperative stabilisation in congenital diaphragmatic hernia. 
Arch Dis Child 1986; 61: 1226-8.
 2. Wung JT, James LS, Kilchevsky E, James E. Management of infants with severe respiratory failure 
and persistence of the fetal circulation, without hyperventilation. Pediatrics 1985; 76: 488-94.
 3. Reiss I, Schaible T, van den Hout L, et al. Standardized postnatal management of infants with 
congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus. Neonatology 
2010; 98: 354-64.
 4. van den Hout L, Reiss I, Felix JF, et al. Risk factors for chronic lung disease and mortality in new-
borns with congenital diaphragmatic hernia. Neonatology 2010; 98: 370-80.
 5. Dawson JA, Kamlin CO, Vento M, et al. Defining the reference range for oxygen saturation for 
infants after birth. Pediatrics 2010; 125: e1340-7.

Chapter 9
Pharmacodynamic considerations 
in the treatment of pulmonary 
hypertension in infants: challenges 
and future perspectives
Ulrike S. Kraemer, Suzan Cochius-den Otter, Kitty G. Snoek, Dick Tibboel
Expert Opin Drug Metab Toxicol. 2016 Jan;12(1):1-19
136 • Chapter 9
ABStrACt
introduction: Pulmonary hypertension (PH) in infants is a life-threatening disease with 
a high mortality. It is treated with different drugs that act upon the three different path-
ways involved in its development. Studies on the drug pharmacodynamics are sparse, 
however.
Areas covered: This review reports a search on the currently available literature in Eng-
lish on drug pharmacodynamics in infants with PH. The search yielded 2499 citations 
in the EMBASE, MEDLINE, COCHRANE, Web of Science, PubMed Publisher and Google 
Scholar databases since 1961. Of these, 1691 did not meet the research question. Even-
tually, 655 articles were of interest, including 44 randomized controlled trials on PH in 
infants. These articles cover all PH medications used in infancy.
Expert opinion: Mortality of PH in infancy has dropped considerably over the past 
years. iNO is widely used, followed by sildenafil – both orally and intravenously in 
contrast to the exclusively oral use in adults. In adults, the pharmacodynamic effects 
of the different medications are tested using the 6-minute walking test, changes in the 
NYHA classification, or by invasive measurement of pulmonary pressure. Reliable data 
of pharmacodynamics tested in adequate series or in randomized controlled trials in 
children are lacking, however, for most of these medications.
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ArtiClE HiGHliGHtS:
• All medications influencing the three major pathways of PH are also used in infants. 
Only for iNO there is sufficient evidence for its positive effect in PPHN and a favorable 
effect in post- cardiac surgery patients.
• Sildenafil is used increasingly even though only a few RCTs showed a decrease in 
OI and mortality in resource limited settings. This effect needs to be validated in 
comparison to for example iNO.
• To date, Bosentan cannot be recommended due to a lack of valid data. Availability 
of an intravenous formulation might make (selective) endothelin receptor blockers 
drugs of choice in the future.
• The lack of noninvasive and continuous methods to monitor actual changes of PH 
in infants complicates pharmacodynamic research. Advanced echocardiography 
including tissue Doppler imaging, strain and strain rate imaging and new plasma 
biomarkers will hopefully solve this problem in the future.
• Only large international RCTs can include sufficient numbers of patients and yield 
valid data to further improve treatment of infants with PH.
1 introDUCtion
Pulmonary hypertension (PH) in children is a life-threatening cardio-respiratory disorder 
with considerable mortality and morbidity1. Like in adults, it is defined as the mean 
pulmonary artery pressure (mPAP) exceeding 25 mmHg with a pulmonary capillary 
wedge pressure of minimal 15 mmHg evaluated by right heart catheterization2. How-
ever, the pulmonary vascular transition of the neonate after birth takes time to achieve 
normal values of mPAP. During fetal life, the placenta delivers oxygenated blood to the 
organs. Due to the high resistance in the pulmonary circulation, most of the blood flow 
bypasses the lungs through the foramen ovale and ductus arteriosus. Immediately after 
birth when the newborn takes the first breaths, the blood flow to the lungs significantly 
increases and the pulmonary vascular resistance drops due to multiple factors. Normal 
values of mPAP are usually reached around two months after birth.
Although the etiology of PH is heterogeneous, the elevated mPAP and increased pul-
monary vascular resistance (PVR) will lead to right ventricular hypertrophy and dilation, 
which can result in right ventricular failure and eventually in death. General mechanisms 
that cause PH include increased vascular tone and reactivity, vessel wall structural 
remodeling and thrombosis, and impaired vascular growth3. Typical histopathological 
changes are adventitial thickening, medial hypertrophy, intima proliferation and fibrosis, 
and more complex lesions such as plexogenic arteriopathy4. Different molecular path-
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ways are involved in the development of abnormal pulmonary vasculature, but the roles 
of these pathways in human pulmonary vascular development are not understood in 
great detail. In vitro studies in adults and children with PH have shown increased expres-
sion of endogenous vasoconstrictors such as thromboxane and endothelin-1 (ET-1), and 
decreased expression of vasodilators5. Increased ET-1 plasma concentrations have been 
found in newborn infants with PPHN and in CDH infants but also in patients with PH 
due to congenital heart defects6,7. In vitro, ET-1 activated Rho-kinase in the lungs of fetal 
lambs with PPHN, which decreased tube formation and the number of branch points. 
The latter events were prevented by treatment with bosentan, suggesting that bosentan 
stimulates vascular growth in PPHN8. Increased ET-1 plasma concentrations have also 
been found in piglets with PH due to overcirculation. Bosentan completely prevented 
arteriolar thickening and thereby the development of PH9. Sildenafil is thought to be 
able to increase cGMP in the pulmonary artery smooth muscle cells but also seems to 
have a role in the treatment of right ventricle hypertrophy (RVH). PDE5 is not expressed 
in the normal human heart nor in the rat heart, but is markedly upregulated in the 
hypertrophied right ventricle. In a rat model with RVH, cGMP and cAMP increased after 
treatment with sildenafil but this was not the case in the normal right ventricle. More-
over, contractility increased significantly, and sildenafil therefore seems promising for 
the treatment of PH10.
The first classifications of PH were designed mainly to address the different causes of 
PH in adults, but the latest adaption also includes classic neonatal and pediatric causes 
of PH. A new pediatric classification has been developed in 2011, which differentiates 
five subcategories (Table 1). Persistent pulmonary hypertension of the newborn (PPHN) 
is listed in a separate subcategory in Group 1. Other conditions added are congenital 
and acquired left heart inflow and outflow tract obstruction (Group 2) as well as devel-
opmental lung diseases associated with PH, such as congenital diaphragmatic hernia 
and bronchopulmonary dysplasia (Group 3)11.
Epidemiological data on pediatric PH are sparse. Recently, however, a few national 
and international registries have published incidence and prevalence figures. The major-
ity of children with progressive PH suffer from idiopathic/ heritable PH or from PH due 
to a congenital heart disease, but the number of children with lung disease, including 
lung hypoplasia or bronchopulmonary dysplasia, is growing12. In the United Kingdom, 
the prevalence of idiopathic PH is 2.1 per million children13, and in France it is 2.2 per 
million14. PPHN has an incidence of 2 per 1000 live births15. In this transient form of PH 
the physiological decrease of pulmonary vascular resistance after birth does not occur.
Targeted PH therapies in infants and children have improved outcomes in general, but 
are mainly based on data from adult studies. Three main pathways are known to influ-
ence PH: the nitric oxide-cGMP pathway, the endothelin pathway, and the prostacyclin 
pathway (Figure 1)16. Targeted pharmacological therapy includes three classes of drugs 
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based on these pathways. Adults also receive combinations of these medications even 
though there is no consistent evidence that an upfront combination therapy (use of 
two or more therapies in treatment-naïve patients) might be beneficial to long-term 
outcome17. Inhaled, oral and intravenous therapies are being used. Most of these drugs, 
table 1 – Updated Classification of Pulmonary Hypertension*
1. Pulmonary arterial hypertension
1.1 Idiopathic PAH
1.2 Heritable PAH
1.2.1 BMPR2
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drug and toxin induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
1’’ Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic disorders: glycogenstorage disease, Gaucher disease, thyroiddisorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
Notes: *5th WSPH Nice 2013.
BMPR: bone morphogenic protein receptor type II; CAV1: caveolin-1; ENG: endoglin; HIV: human immuno-
deficiency virus; PAH: pulmonary arterial hypertension.
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however, not only dilate the pulmonary vasculature, but also have systemic effects such 
as hypotension.
There is a lack of knowledge of the pathophysiology of the different types of PH 
and lack of well-designed trials for this specific group of patients. Hence, an extensive 
overview of the level of evidence for the different medications used in infancy can help 
clinicians optimize their therapies.
2 mEDiCAtion inflUEnCinG tHE nitriC oxiDE-CGmP PAtHWAY
2.1 inhaled nitric oxide (ino):
2.1.1 Introduction to iNO:
In 1987, nitric oxide (NO) was recognized as a key endothelial-derived vasodilator and 
endothelial derived growth factor18. The therapeutic potential of inhaled NO (iNO) as a 
selective vasodilator in patients with PH was first described in 199119. The inhalation gas 
INOmax (Linde Gas Therapeutics GmbH, Oberschleissheim, Germany) was the first to be 
accepted as a medical product – in 1999 by the Food and Drug Administration (FDA) for 
the USA and in 2001 by the European Commission for the EU for the treatment of ARDS 
and PH in neonates.
2.1.2 Pharmacokinetics and metabolism of iNO
After inhalation, iNO diffuses rapidly across the alveolar-capillary membrane into the 
smooth muscle of pulmonary vessels and activates soluble guanylate cyclase. This 
enzyme mediates many of the biological effects of iNO and is responsible for the conver-
sion of GTP to cGMP. The increase of intracellular concentrations of cGMP relaxes smooth 
muscle via several mechanisms. iNO also has some other effects in the lung such as 
bronchodilation, as well as anti-inflammatory and antiproliferative effects20. iNO diffuses 
into the bloodstream and reacts with oxyhemoglobin to form methemoglobin and ni-
trate, and reacts with deoxyhemoglobine to form iron-nitrosyl Hb. Within 48 hours, 70% 
of the iNO is excreted as nitrate in the urine.
In a normal lung, low oxygen tension leads to constriction of the vessels in the hypoxic 
region and the blood flow is directed toward lung regions with better ventilation. iNO 
enhances this mechanism by increasing blood flow to well ventilated lung areas that, 
in some diseases, have an elevated vascular tone. This is the advantage of iNO over 
intravenous vasodilators. The latter usually lead to a general vasodilation of the pulmo-
nary vasculature, also including areas with less or no ventilation, resulting in increased 
intrapulmonary shunting and reduced PaO220.
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2.1.3 Clinical efficacy and role of iNO in current PH management
Over 20 years, iNO has been frequently used in the treatment of PH in children, espe-
cially in neonates suffering from PPHN. In a Cochrane analysis from 200621, fourteen 
randomized controlled trials (RCTs) were included. The authors concluded that with the 
present evidence it appears reasonable to use iNO in an initial concentration of 20 ppm 
for term and near term infants with hypoxic respiratory failure. Outcome appeared to be 
improved in terms of a reduced incidence of the combined endpoint of death or need 
for extracorporeal membrane oxygenation (ECMO). There was less need for ECMO, but 
the mortality stayed the same. In 50% of the infants oxygenation was improved while 
receiving iNO. Interestingly, the outcome did not seem to be affected by the presence or 
absence of echocardiographic signs of PH. iNO could not be recommended for patients 
with congenital diaphragmatic hernia (CDH) because in the one available RCT in patients 
with CDH22 outcome had not improved, and was even slightly worse.
In 2010, Golomek et al. published a retrospective pooled analysis of three pivotal clini-
cal trials comparing patients treated with iNO with control patients23. All three trials were 
part of the Cochrane analysis and included a total of 524 patients (260 iNO, 264 control). 
This combined analysis was performed to assess the effects of iNO on oxygenation and 
the efficacy across a range of disease severities, and days of ventilation. Golomek et 
al. defined disease severity in four categories depending on the baseline oxygenation 
index (OI): ≤ 15 = mild, >15 - ≤25 = moderate, >25 - ≤ 40 = severe, and > 40 = very 
severe. They studied the effect of iNO after 30 minutes. In all four categories the PaO2 
significantly improved. Furthermore, the median duration of mechanical ventilation was 
significantly shorter (11 days versus 14 days).
In contrast to what is the case in the US, iNO is standard of care in infants with CDH in 
Europe if PH is evident, even though positive pharmacodynamic effects in these infants 
seem to be weaker than in infants with PPHN24. In the US there is an increasing use 
of iNO; however, in view of its high costs and the absence of a decrease in mortality, 
iNO is used less frequently than in Europe25,26. It is not clear why iNO is less effective in 
infants with CDH than in infants with other underlying causes of PH. The actual patho-
physiological mechanism is not completely understood. Shehata et al. found reduced 
vascular expression of NO synthase in postmortem lung specimens of CDH-patients not 
treated with ECMO, which might explain the lack of effect of iNO27. Such reduction was 
found earlier in a CDH rat model as well28.
There is some evidence that premature infants with prolonged preterm rupture of the 
membranes (PPRM) might respond favorable to iNO. Part of the evidence comes from 
a non-RCT on the antenatal risk factors and inflammatory response during hypoxic re-
spiratory failure (HRF) in infants ≤ 32 weeks29. The 17 premature infants who developed 
HRF were also exposed to PPROM and responded well to iNO. They showed a transient 
suppression in nitrite and nitrate and inflammatory cytokines obtained from airway 
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specimens. The authors concluded therefore that these infants may have a transient 
deficiency in the inflammatory response, including a defect in nitric oxide generation 
in airspace. Further research is needed to support these findings. Furthermore, one 
Cochrane analysis has evaluated the effects of iNO in premature infants with respira-
tory distress on death, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage 
(IVH), and neurodevelopmental disability30. A total of 14 RCT’s were identified and 
grouped into three categories: entry in the first three days of life based on oxygenation 
criteria, routine use in preterm infants, and later enrolment based on increased risk of 
BPD. An evaluation of the absence or presence of PH was mostly not part of the study 
design. The authors of the Cochrane analysis found no positive effect of iNO used in 
the early period, but suggested that the later use of iNO might be effective to prevent 
BPD. However, this needs to be proven by further studies, especially with the focus on 
development of PH in this age group. Other factors such as maternal ethnicity have 
been discussed; but so far there is no proof for a possible beneficial response of iNO 
related to maternal ethnicity.
iNO is also often used in patients with PH due to congenital heart disease before and 
after surgery. This application was subject of a Cochrane analysis in 2005, which was 
updated in 201431,32. The first analysis included four RCTs with a total of 215 infants and 
children and found no difference in mortality, changes of pulmonary hypertensive crises 
(PHTC), changes in mPAP, heart rate or PaO2:FiO2 ratio. The updated analysis included 
another three studies and again concluded that outcomes did not differ between the 
use of iNO or not. One study, including 124 patients with a median age of three months, 
had a low risk of bias33. This was a trial investigating the effect of iNO on PHTC, time on 
study gas, and length of intensive care stay when given routinely to children with high 
pulmonary flow or pressure, or both, after corrective heart surgery33. The pharmacody-
namic effect of iNO was monitored by pulmonary artery, systemic artery, and right and 
left atrium pressure measurements. In the iNO group there were significant fewer PHTC’s 
and the time to extubation was also shorter. The PVR index was significantly lower in the 
iNO group after surgery. As expected, the time to wean a patient from the study gas was 
longer in the iNO group. Even though the Cochrane analyses stated that it is impossible 
to validate positive effects of iNO on outcome after cardiac surgery, iNO is widely used 
for this indication34.
Because iNO inhibits platelet aggregation, adhesion, and agglutination, it may lead to 
bleeding disorders. Further side effects of iNO are elevation of nitrogen dioxide levels and 
methemoglobinemia. All of these side effects seem to be insignificant, however, when 
using a low dose iNO. In all the above studies iNO doses up to 20 ppm did not cause toxic 
effects. In view of the low risk of methemoglobinemia, infants are usually not monitored 
in general practice, even though monitoring is mostly recommended. Furthermore, iNO 
can lead to rebound PH which can complicate weaning of iNO. Namachivayam et al. 
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published a RCT on the effect of a single dose of sildenafil in 30 ventilated infants and 
children with iNO and showed that sildenafil given one hour before withdrawal of iNO 
prevented rebound PH and reduced the duration of ventilation35. As mentioned above, 
iNO is expensive since it has been accepted as a medicinal product.
One RCT of 40 children investigated the effect of oral citrulline as a precursor to NO 
synthesis in congenital heart surgery. A total of 40 patients received either citrulline or 
placebo just before the start of surgery. Oral citrulline supplementation proved safe and 
patients with elevated citrulline concentration had a lower risk of postoperative PH36. So 
far, the supplementation of NO precursors has not yet been implemented in standard 
of care.
iNO has been investigated broadly and has been well established in every day practice. 
It is effective in PPHN and seems to be effective in post cardiac surgery in increasing oxy-
genation and decreasing PVR but there have been no changes in mortality documented. 
Not all studies discussed included a control group. The validity of comparing the effects 
of a “proven” therapy like iNO with those of an untested therapy such as iloprost is debat-
able. But in this review we did not specifically focus on the study designs. All referred 
trials and studies have been summarized in Table 2.
2.2 Sildenafil
2.2.1 Introduction to sildenafil
Sildenafil citrate is a selective phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is an 
enzyme that specifically degrades cGMP. With the inhibitory effect of sildenafil on PDE5, 
it increases cGMP and enhances NO-mediated vasodilatation of the smooth muscles in 
vessels, viscera, and corpus cavernosum.
Sildenafil was approved by the FDA in 1998 for the treatment of erectile dysfunction; 
in 2005, it was also approved for its use in PH in adults. In 2012, the FDA issued a warning 
against its use in children based on the STARTS-2 study, which showed an increased risk 
of death in the group of children over 20 kg receiving a high dose of sildenafil. STARTS-2, 
the extension phase of the STARTS-1 study, found increased mortality in the high-dose 
group after two years compared to the medium- and low-dose groups. There was no 
placebo group. However, when corrected for idiopathic PH etiology, high PVR index and 
high right atrial pressures at baseline, the hazard ratios were reduced in the high-dose 
group. These findings raise uncertainty about the strength of the relationship between 
sildenafil dose groups and survival53,54. Therefore, the EMA did approve the use of low 
dose sildenafil in children.
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2.2.2 Pharmacokinetics and metabolism of sildenafil
Sildenafil is available for oral and intravenous administration. Nebulized sildenafil has 
been studied in animal models, but data on human use are not available at this point in 
time55.
Sildenafil is metabolized in the liver via CYP3A4 and CYP2C9 into its active metabolite 
desmethylsildenafil (DMS). The tissue half-time is approximately 2 - 4 hours for both 
intravenous and oral preparations. In severe renal or hepatic failure, clearance can be 
significantly reduced. Pharmacokinetics of oral sildenafil in children over one year of 
age is similar to that in adults53,56. The plasma concentration for sildenafil derived from in 
vitro studies is approximately 50 - 400 ng/mL. Desmethylsildenafil concentrations can be 
measured too; however, in most studies only sildenafil concentrations are determined. 
Three studies in infants have been reported. One is an open-label dose-escalating trial 
in neonates receiving intravenous sildenafil in the first ten days of life. A correlation be-
tween postnatal age and clearance was shown, as clearance increased threefold to adult 
values within the first seven days. Volume of distribution was fourfold higher compared 
to adults, resulting in a longer tissue half-time of approximately 6.8 hours57. The second 
study showed that a loading dose was desirable to establish plasma concentrations in 
a shorter period; however, in both studies this loading infusion needed to be given in 
at least three hours to avoid hypotension. Patients receiving the loading dose in 5 or 30 
minutes often developed hypotension. Although patient numbers are small, an effect 
on oxygenation index was seen with a sildenafil plasma concentration of approximately 
58ng/ mL and higher, with the use of a loading dose of at least 0.06mg/kg in three hours 
and infusion of 0.36 mg/kg/day58. The third study investigated the administration of oral 
sildenafil in post-ECMO infants. At dosages 1.3 - 10 mg/kg/day, plasma concentrations 
were 300 and 100 ng/mL at one and six hours, respectively; but both the interpatient 
and intrapatient variability were very high, possibly due to variable gut absorption. Dos-
ing of 0.5 - 2 mg/kg six-hourly would provide an exposure comparable to the adult dose 
of 20 mg six-hourly56,59. A pharmacokinetic study evaluating the safety and dosing of 
sildenafil in preterm infants is currently underway (NCT01670136).
2.2.3 Clinical efficacy and role of sildenafil in current PH management
A Cochrane analysis from 2011 investigated the efficacy and safety of sildenafil treat-
ment in neonates with PPHN60. Three randomized single-center trials were included, in 
which NO and ECMO were initially not available. In total, 51 patients received sildenafil 
and 37 patients received placebo61-63. Baquero et al. treated a small group of patients 
with a high risk of mortality (OI ≥ 40 and PAP ≥ 40mmHg) with 1 - 2 mg/kg sildenafil or 
placebo six-hourly and showed significant improvement of SpO2 and OI after 24 hours 
in the sildenafil-treated group. Also, mortality was significantly lower, i.e. 15% versus 
85%. For this reason the study was stopped early. The study of Herrera Torres et al. was 
Pharmacodynamic considerations in pulmonary hypertension • 149
Ch
ap
te
r 9
included in the Cochrane review and evaluated the effect of sildenafil 2mg/kg six-hourly 
in 13 patients versus 11 patients treated with placebo60. All patients were moderately 
sick with an OI > 25 and oxygenation and mean airway pressure (MAP) improved from 
the first dose. Vargas-Origel et al. showed a significant increase of PaO2 after 7 hours 
of treatment with sildenafil 3mg/kg six-hourly and a decrease in MAP after 13 hours in 
a larger group with OI ≥ 20. Again, mortality was significantly lower in the sildenafil-
treated group. iNO became available for the last 11 patients in this study but this did 
not influence the results. Although the patient numbers are small and not all outcome 
measures are adequately reported, the meta-analysis showed a significant reduction in 
mortality in the treated group (20% versus 54% in the placebo group). No adverse events 
were reported63. Another RCT in PPHN, not included in this Cochrane review, compared 
sildenafil with MgSO4 in patients with OI ≥ 30 and PAP ≥ 40mmHg. Thirty-one patients 
were treated with 0.5 – 2 mg/kg sildenafil six-hourly and 34 with IV MgSO4 (loading dose 
200 mg/kg, maintenance 20 mg/kg/hr, max 100mg/kg/hr). Clinical response in the silde-
nafil group was significantly sooner, 36 versus 60 hours. This was defined as OI < 15 and 
PAP < 20mmHg. The mean blood pressure in the MgSO4 group was significantly lower 
and these children needed more inotropic support64. A RCT comparing sildenafil and 
placebo in PPHN patients already on iNO is currently recruiting patients (NCT01720524). 
Another RCT in which iNO-naive PPHN patients were treated with sildenafil was termi-
nated early due to insufficient recruitment (NCT01409031).
Sildenafil is also being used in cardiac surgery and this setting has been studied in four 
RCTs. Vassalos et al. administered oral sildenafil (0.5 mg/kg six-hourly) or placebo the day 
before cardiac surgery in 24 infants with either ventricular (VSD) or atrioventricular sep-
tal defects (AVSD) but without PH. All received invasive pressure monitoring in the main 
pulmonary artery and left atrium. Post-operative PAP, pulmonary vascular resistance 
index (PVRI), and MAP did not differ between the groups. However, pre- and postopera-
tive left and right ventricular and septal systolic functions were significantly lower in 
the sildenafil group compared to placebo, persisting through day one. Also, the mean 
Doppler-derived cardiac index was significantly lower in the sildenafil group. Neither 
ventilation time nor length of ICU stay differed between groups. No adverse events were 
reported65. El Midany et al. enrolled 101 infants with large VSDs with moderate-to-severe 
PH (>40 mmHg and systolic PAP >50% of systemic pressure, PVR >3WU but <8WU) in a 
randomized open-label study. The sildenafil group started treatment 2 weeks before the 
surgery; a control group received sildenafil only postoperatively. There was no control 
group receiving only placebo66. The starting dose of 0.5 mg/kg six-hourly was increased 
to 2 mg/kg in both groups. In both groups, mean PAP decreased significantly at all time 
points of the study (which were all postoperatively) although starting sildenafil before 
surgery did not further decrease mPAP. Pretreatment of infants is not accepted in daily 
practice worldwide and these two studies confirm this. In a postoperative setting, a small 
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group of patients who underwent surgery for a VSD or AVSD were randomly assigned to 
intravenous sildenafil with the addition of iNO 20 ppm after 20 minutes or to iNO with 
the addition of sildenafil after 20 minutes. iNO reduced the PVRI and sildenafil further 
reduced the PVRI, and this double effect was also seen in patients receiving sildenafil 
first. However, sildenafil significantly lowered systemic blood pressure and systemic 
vascular resistance and increased the OI and alveolar-arterial gradient. The latter two 
findings were reasons to stop the study early41. A second RCT for postoperative PH in 
infants over 60 days was done in a multicenter setting67. Patients were assigned to one of 
three continuous doses of IV sildenafil or placebo. Unfortunately, the study was heavily 
underpowered with a total of 17 patients due to slow patient recruitment. Patients in the 
treatment groups required less additional therapy for PH, but this was not significant. 
Median time to extubation was significantly shorter for patients on sildenafil. In the first 
four hours, the reduction in systolic PAP was significantly greater in the sildenafil group, 
and only a minor reduction in systemic blood pressure was seen67.
Besides the results from STARTS-2 mentioned above, several other safety issues de-
serve attention. Concerns have been raised about the effect of sildenafil on the systemic 
blood pressure. However, in the trials performed in PPHN, this was not seen60,64. In the 
pharmacokinetic studies on intravenous sildenafil, hypotension without severe hemo-
dynamic instability was seen when using a short loading dose57,58. One study found a 
negative impact on cardiac function, but this was not reported in other studies65. The 
use of sildenafil in extreme premature infants has been associated with retinopathy of 
prematurity (ROP) in one case report68. Sildenafil is also an inhibitor of PDE6 receptors, 
and PDE6 is the regulator of cGMP in rod and cone photoreceptors. This association was 
not found in several series with small sample sizes69-72. In fact, in a mouse model silde-
nafil significantly decreased retinal vaso-obliteration and neovascularization73. Only one 
study evaluated neurodevelopmental outcome in a small group and found normal MRI, 
EEG, and neurological examination after the use of sildenafil61. In some case reports, 
intracerebral hemorrhagic events in premature infants have been linked to sildenafil. 
Such association has not been confirmed in trials74.
For other patient groups, only retrospective data are available. A decrease in PVRI 
and an increase in cardiac output were found in a small group of oral sildenafil-treated 
infants with CDH refractory to iNO75. Intravenous sildenafil in CDH patients was associ-
ated with improved OI and the right-to-left shunt ratio over the PDA was reversed76. 
Oral sildenafil treatment in infants with chronic lung disease improved systolic PAP and 
interventricular septal flattening77,78. Despite the lack of randomized controlled trials in 
these groups, sildenafil is increasingly used in the acute and more chronic phases. A trial 
investigating the chronic use of sildenafil in CDH patients was terminated early due to 
change in clinical practice (NCT00133679).
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Sildenafil is increasingly being used, also in infants. Even more so since the intrave-
nous formulation became available. A few RCTs have shown a positive effect in that OI 
and mortality in infants with PPHN decreased in resource-limited settings. More studies 
with good pharmacodynamics measurement tools are needed to confirm this and to 
enable comparison of sildenafil with more commonly used vasodilators, such as iNO. All 
referred trials and studies have been summarized in Table 3.
2.3 nitroglycerin
Nitroglycerin is metabolized to iNO to produce vasodilatation through smooth muscle 
cell relaxation in the vascular endothelium. Intravenous nitroglycerin has been used 
in patients with pulmonary hypertension but due to lack of selectivity for pulmonary 
vasculature its role in PH is limited79. However, inhalation of the drug has demonstrated 
significant decreases in PA pressure and PVRI without these systemic side effects in 
adults after cardiac surgery and in children during cardiac catheterization. But because 
of its short duration of action and risk of tachyphylaxis it is less suitable for long-term 
therapy in PH. Still there might be a role for inhaled nitroglycerin in the acute periopera-
tive phase80-82.
2.4 riociguat
Riociguat is the first drug of a novel class of soluble guanylate cyclase (sGC) stimula-
tors or agonists. sGC is an enzyme that catalyzes the synthesis of cGMP. The binding of 
NO to sGC increases the conversion of GTP to cGMP approximately 200-fold. Riociguat 
stabilizes the binding site on sGC for NO and also enhances the functioning of sGC in a 
NO-independent fashion. This new drug has not yet been studied in children. The few 
RCTs conducted in adults showed improved exercise capacity and PVR in patients with 
pulmonary arterial hypertension and chronic thromboembolic pulmonary hyperten-
sion83,84.
3 mEDiCAtion inflUEnCinG tHE EnDotHElin PAtHWAY
3.1 Bosentan
3.1.1 Introduction to bosentan
Bosentan is a potent oral endothelin-1 receptor antagonist for both endothelin A and B. 
Binding of bosentan to ETA is much more patent than its binding to ETB. Endothelin-1 
(ET-1) is a very potent pulmonary vasoconstrictor produced in endothelial cells as a 
response to hypoxia, and plays a major role in pulmonary vascular remodeling and right 
heart hypertrophy. ET-1 binds to two receptor subtypes, ETA and ETB receptors, and the 
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binding of ET-1 to the ETA receptors on pulmonary smooth muscles causes vasoconstric-
tion. On the other hand, activating ETB receptors causes vasorelaxation via prostacyclin 
and NO, but ETB receptors can also mediate vasoconstriction87-90. Bosentan is approved 
in adult patients with PAH; a pediatric formulation is approved only in Europe but it is 
available only as an oral drug91.
3.1.2 Pharmacokinetics and metabolism of bosentan
Bosentan is administered orally, usually twice daily 1 mg/kg. The metabolism of bosen-
tan is dependent on the activity of CYP2C9 and 3A4 isoenzymes, and elimination oc-
curs mostly via the bile92. In children, the pharmacokinetic profile is characterized by a 
median peak concentration after 3 hours, followed by rapid disposition. An exposure 
plateau of its plasma levels is reached at 2 mg/kg/day, in accordance with the non-
dose-proportional pharmacokinetics of bosentan in adults, but children’s plasma con-
centrations are lower than those of adults. Age and body weight do not seem to have 
an effect on pharmacokinetics over the age of 2 years93. In younger children, however, 
pharmacokinetics are influenced by age, showing more inter individual differences in 
clearance, possibly due to difference in hepatic development92. There are no data avail-
able on children under the age of 25 days94.
3.1.3 Clinical efficacy and role of bosentan in current PH management
Currently, only two RCTs with bosentan in infants have been performed, both in PPHN. 
Mohamed et al. treated 47 patients with bosentan twice daily or placebo in a single cen-
ter without availability of iNO or ECMO95. Bosentan significantly improved oxygenation 
index and SpO2 compared to placebo from six hours onwards after initiation of therapy. 
There was no evidence of rebound hypoxemia after discontinuation of bosentan. No 
adverse events were reported95. Steinhorn et al. treated 21 patients in 9 centers who 
were already on iNO with bosentan or placebo88. Bosentan did not improve oxygenation 
compared to placebo. However, steady state concentrations comparable to those in 
adult patients were achieved by day 5, and most patients received treatment for only 
5 days88. A striking difference between these two studies besides the use of iNO is the 
difference in OI at the beginning of the study. Mean OI in the first trial was 43.6 and 
45.1, respectively, in the second study mean OI was 21.1 and 17.3, respectively. Although 
these trials did not report any adverse events, cardiac failure, syncope, blood bilirubin 
increase, thrombocytopenia, and liver function test abnormalities have been reported 
by the FDA. However, the incidence of elevated aminotransaminase levels seems to be 
lower in children96,97.
There is only observational experience with bosentan in infants with elevated vascular 
resistance pre- and post-operatively, before and after repair of cardiac defects with 
excess lung flow. Postoperative treatment of a small group of infants decreased PAP and 
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improved right and left ventricle cardiac index in most of them, even when refractory to 
sildenafil98,99. Preoperative treatment of an infant with PH due to complete atrioventricu-
lar septal defect also decreased PH100. Bosentan has also been used to decrease PH in 
patients in need for right-sided heart bypass surgery. Treatment with bosentan for 5 - 17 
months showed a decrease of mPAP and PVR and also the blood marker BNP decreased 
significantly101.
In a few case reports a positive clinical effect from bosentan was seen in children with 
refractory PH in CLD and in patients with transposition of the great arteries and PH102-104.
A few trials are underway to evaluate the clinical effect and pharmacokinetics of 
bosentan. A new FUTURE 3 trial is ongoing, investigating twice daily dosing versus three 
times daily in PH patients (NCT01338415). One trial aims to evaluate the postoperative 
residual PH and mortality rate in patients with cardiac defects treated for weeks before 
surgery, and is recruiting (NCT01548950). Another trial in patients with PH and functional 
single ventricle has been completed but data are not yet available (NCT01662037).
3.2 other endothelin-1 receptor antagonists
For adult use only, selective endothelin-1 receptor antagonists are available. Ambris-
entan is selective for the type A endothelin-1 receptor; macitentan is non-selective 
but has a 50-fold higher selectivity for type A receptors compared to type B. No data 
are available on the use of these drugs in infants. Ambrisentan given to newborn rats 
with hyperoxia-induced lung injury prolonged survival by reversing PAH and RVH and 
reducing fibrin deposition in the lung. However, no benefits were seen on inflammation, 
alveolar enlargement, and vascularization105. In children with PH, retrospective data of 
ambrisentan showed significant improvement of PAP and WHO functional class. The 
table 4 – Trials concerning the endothelin pathway
Study number of 
patients
indication methods Age of 
patients
outcome 
parameter
Pharmaco-
dynamics
outcome
Steinhorn 
et al, 201488
21 PPHN Bosentan 
versus 
placebo
newborn OI, time on 
ventilator, 
time on iNO, 
treatment 
failure
unknown No difference 
between 
groups
Mohamed 
et al, 201295
47 PPHN Bosentan 
versus 
placebo
newborn OI, PAP OI, PAP, 
SpO2
Significant 
decrease in 
OI and SpO2 
in bosentan 
group, fewer 
sequelae after 
6 months
Notes: PPHN: persistent pulmonary hypertension of the newborn. OI: oxygenation index. iNO: inhaled nitric 
oxide. PAP: pulmonary arterial pressure.
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WHO functional classification system reflects the special physiology of PH in view of 
the importance of syncope and near-syncope. However, 26% of these children had side 
effects, mainly nasal congestion and headache106.
So far, bosentan is the only endothelin receptor antagonist used in children and it 
cannot be recommended for the routine treatment of PH in infants due to a lack of 
valid data. Studies are on the way to evaluate the role of bosentan in PH in children and 
infants. All referred RCTs are summarized in Table 4.
4 mEDiCAtion inflUEnCinG tHE ProStACYClin-CAmP PAtHWAY
4.1 Prostanoids
4.1.1 Introduction to prostanoids
Prostanoids are arachidonic acid metabolites and include prostaglandins (PGI) and pros-
tacyclins as well thromboxanes107. They play an important role in inflammation, platelet 
aggregation, and vasoconstriction and vasorelaxation107. The first prostanoid approved 
for the therapy of PH was epoprostenol in 1995, followed by treprostinil (subcutaneous 
2002, intravenous 2004, inhaled 2009), iloprost (2004), and in 2010 room temperature 
stable epoprostenol91. Inhaled PGI is proven to be effective as a pulmonary vasodilator 
in adults with PH and acute respiratory distress syndrome (ARDS) and is recommended 
as standard therapy in adults108-110.
4.1.2 Pharmacokinetics and metabolism
Epoprostenol is the intravenous formulation of prostaglandin I2. It is rapidly degraded 
in blood into two primary metabolites and is excreted in urine. The half-life of epopros-
tenol is around 6 minutes111. The plasma steady-state concentration is reached within 15 
minutes. The usual dose in children is 1-10ng/kg/min.
The synthetic prostacyclin analogue iloprost can be given via inhalation. The hemo-
dynamic effects occur rapidly but will also decrease within 30 - 90 minutes. Therefore, it 
must be inhaled at least six to nine times a day.
4.1.3 Clinical efficacy and role of prostanoids in current PAH management
We identified four RCTs of prostanoids in infants and children37,38,40,52,112. Three focused 
on patients after cardiac surgery37,38,52 and one on neonates with hypoxic respiratory 
failure112.
Sood et al. initiated two pilot multicenter Phase II RCTs on the effect of inhaled prosta-
glandin E1 (IPGE1) on neonatal hypoxemic respiratory failure (NHRF). The first pilot study 
failed to recruit enough patients because prior administration of iNO was an exclusion 
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criterion. The next re-designed pilot study allowed for possible co-medication of iNO 
and IPGE1 but was also stopped prematurely for lack of enough suitable patients112.
Goldman et al. studied the effects on vasodilation of iNO versus intravenous prostacy-
clin in infants with PH after cardiac surgery52. They included 13 patients between three 
days and 12 months of age who either received 20 ppm iNO or 20 ng/kg/min prostacyclin. 
Both groups showed a reduction of mPAP, but iNO lowered the mPAP more effectively 
than did prostacyclin (28.5 ± 2.9 mmHg versus 35.4 ± 2.1 mmHg). Furthermore, the PAP/
SAP ratio was also significantly lower during iNO inhalation. It was concluded that iNO 
was preferable52.
Loukanov et al. and Gorenflo et al. investigated the effect of iNO versus iloprost37,38. 
Gorenflo et al. initiated two different trials, one in children after cardiac surgery and one 
testing the acute pulmonary vasoreactivity in children with severe PH due to congenital 
heart disease38. The former showed no difference in the primary endpoint (occurrence 
of major or minor PHTC) between groups. In the latter, the effects on cardiac index and 
PVR did not differ between groups38.
Loukanov et al. included 15 infants with left-to right shunt, of whom 11 children with 
Down syndrome. They received either 10 ppm iNO or 0.5 microgram/kg iloprost every 2 
hours. Mean PAP and Pp/Ps ratio did not differ between the two groups, and neither did 
the primary endpoint (major or minor PHTC)37.
In some centers prostanoids are routinely used in infants but so far RCTs are lacking. 
All referred trials and studies have been summarized in Table 5.
In 2014 Kahveci et al. published a clinical study which addressed the problem of treat-
ment of PPHN in countries where expensive treatment methods such as iNO and ECMO 
are not wide available. The effect of sildenafil versus inhaled iloprost was evaluated in 
47 neonates with PPHN. The iloprost group did not show any side effects and regarding 
the clinical parameters iloprost was more effective than sildenafil113. The use of iloprost 
might therefore be of interest for resource-poor countries.
4.2 others
4.2.1 Milrinone
Milrinone is a phosphodiesterase 3 (PDE3) inhibitor which induces pulmonary vasodila-
tation by its action on cAMP in cardiac and vascular muscle. It has positive inotropic and 
vasodilator effects114. Milrinone is administered intravenously. It has been evaluated for 
inhalation in the setting of PH in older children with successful decrease of PAP and PVRI 
without significant effects on systemic hemodynamics80.
In infants milrinone has only been used for PPHN in case series. Patients unresponsive 
to iNO had a substantial improvement of OI, PAP, left and right ventricular output, right 
ventricular strain, and strain rate after start of milrinone115-117. However, in a very small 
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case series there seemed to be an association with intraventricular hemorrhage118,119. 
To clarify the role of milrinone in PPHN and the risk of IVH due to milrinone treatment 
larger trials are needed. The upcoming MINT-1 trial will randomize PPHN patients on iNO 
to milrinone or placebo (ISRCTN12949496) and will hopefully provide some answers.
One retrospective study reports the use of milrinone in infants with CDH and PH 
combined with cardiac dysfunction. RV systolic and diastolic myocardial velocities were 
significantly increased and OI was significantly reduced without change in blood pres-
sure120.
Adverse events are not uncommon in milrinone-treated infants; hypotension requir-
ing pressors was seen in 20% and PDA requiring treatment in 13% of patients. Throm-
bocytopenia is the commonest laboratory adverse event. Renal clearance of milrinone 
is age-dependent and in cases of renal impairment milrinone accumulates and leads to 
adverse events121.
5 ComBinAtion tHErAPY
The guidelines for the treatment of PH in adults also prescribe combination therapy2. 
Combinations of sildenafil with bosentan or prostanoids have been found reasonable 
because they influence different pathways. The literature on this issue concerning in-
fants is scarce. A few case reports have described positive effects of the use of sildenafil 
and iloprost or PGE1122,123. Combinations with iNO, sildenafil, and bosentan have also 
been described124. In a piglet model of PH due to meconium aspiration, combination 
treatment with iNO and sildenafil synergistically decreased PVR and PAP. Still, while 
sildenafil also increased cardiac output, it also significantly decreased arterial pO2125. 
For extremely compromised infants, a combination therapy is regularly used on the 
basis of trial and error but there are no large case studies or RCTs available to support 
this use.
6 ConClUSion
Treatment of PH in infants includes different medications influencing the three path-
ways involved in PH.
iNO has been investigated in many large RCTs in patients with PPHN and is widely 
used in general practice even though improved mortality rates have not been shown. 
However, iNO seems to exert a positive effect on PaO2 and on the duration of ventila-
tion. The few RCTs concerning sildenafil show a positive effect on OI and mortality in 
infants with PPHN. Only two studies, with few patients, looked at the pharmacodynamic 
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effects of bosentan in infants with PPHN, with contradictory results. A trial designed to 
investigate the effects of iloprost failed to recruit enough patients.
In cardiac infants iNO did not significantly reduce the incidence of PHTC or the dura-
tion of ventilation, except for one well conducted trial. The pre-operative use of sildenafil 
did not decrease PH, the trials evaluating the role of sildenafil in the postoperative phase 
are underpowered. Furthermore, iloprost has not been proven to be superior to iNO in 
post-cardiac surgery patients in two studies, both of which did not include a placebo 
group. RCTs on bosentan are still lacking.
iNO did not improve the outcome of patients with CDH. There are no reliable data on 
the use of sildenafil, bosentan, or prostacyclin in patients with CDH.
In premature infants iNO used as a rescue therapy did not improve survival and did 
not prevent the development of BPD. Its early routine use did not seriously affect the 
brain however. The use of iNO later in the course of the disease showed some beneficial 
effect to prevent BPD. Overall, PH in infancy is treated mainly on the basis of findings 
from case studies and personal experience and not on the basis of sufficiently powered 
RCTs. Furthermore, systematic survey’s with a focus on the best pharmacodynamics 
outcome parameter in these patients are lacking.
7 ExPErt oPinion
The three major pathways influencing PH are the nitric oxide-cGMP pathway, the en-
dothelin pathway, and the prostacyclin cAMP pathway. Medications affecting the nitric 
oxide-cGMP pathway are iNO and sildenafil. The endothelin pathway can be influenced 
using bosentan and other endothelin antagonists, and the prostacyclin pathway is af-
fected with prostanoids. All of these medications are used in infants with PH mainly 
due to PPHN, premature infants, and post-cardiac surgery patients. Especially when 
considering the overall better survival of preterm infants and patients with CDH, it is 
expected that the number of affected infants with PH will increase. But so far RCTs in 
these patients are sparse. Even this broad literature review identified only 44 RCTs on 
PH in infants, mainly on iNO. For sildenafil, bosentan, and prostanoids further research is 
needed. The biggest challenge for the coming years is to set up large international RCTs 
for each group of patients separately as pathophysiology is likely to be different in every 
group and numbers per center are small.
The current pharmacokinetic knowledge of drugs like sildenafil and bosentan is 
inadequate, especially in newborns. To identify the therapeutic range and prevent both 
undertreatment and toxicity we need to know the plasma concentrations needed. 
Furthermore, bosentan is available only as an oral formulation and absorption is prob-
ably impaired in very ill infants. An intravenous formulation would solve this problem 
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and might increase its role in the treatment of PH in infants. The newer drug riocuguat 
influencing a new cGMP pathway seems very promising, but has not been adequately 
tested in infants so far. Though combination therapy is common practice in adults and is 
also used in infants with severe PH on a trial and error basis, more research is needed to 
elucidate the synergetic effects of these different drugs.
In adults, the pharmacodynamic effects of the different medications are evaluated 
with invasive measurements of PH, or through clinical parameters such as the NYHA 
classifications or the 6-minutes walking test. Heart catheterization or the use of PA 
catheters is seldom applied in infants because these procedures bear an increased 
risk of complications. Pharmacodynamic effects are commonly measured indirectly, 
for example through changes in OI or saturation, mortality and need for ECMO and 
not through actual measurement of improvement in mPAP. The lack of solid outcome 
parameters reflecting the actual changes of PH makes assessment of the different drugs 
more difficult and a comparison almost impossible. International consensus on the 
optimal cardiac ultrasound parameter could also help to solve the problem as well as 
consensus about the level of expertise needed to raise conclusions.
Plasma biomarkers could help with this dilemma. The biomarker BNP for example is 
used in PH, but has not been proven to be reliable enough so far for infants. Normal values 
of BNP and NT-proBNP in neonates both widely vary just after birth reflecting the physi-
ological changes in this period126. On the other hand, it seems that BNP and NT-proBNP 
levels may serve as relative values as they correlated well with mortality127. There is a 
need for further research for other plasma biomarkers which are more reliable to detect 
and monitor PH, especially in infancy. Troponine T might be such a plasma biomarker re-
flecting myocardial damage which might be evident in PH with right ventricular failure. 
So far, there is no study investigating troponine T in infants with PH. Echocardiography 
is a well-established tool to estimate PH; it is available in most centers worldwide and 
can be performed easily in severely diseased infants. Echocardiography cannot replace 
invasive measurements. Even when using a broad echocardiogram-based definition of 
PH, most studies correlate these findings with clinical parameters such as the duration 
of oxygen supplementation or the occurrence of bronchopulmonary dysplasia128. Over 
the last years more advanced echocardiographic techniques have been introduced, 
such as TAPSE (Tricuspid annular plane systolic excursion), tissue Doppler imaging, and 
strain and strain rate imaging, which seem to have an additional benefit in the context 
of general echocardiographic evaluation1,129,130. These techniques might pave the way 
for trials in infants with a focus on more standardized pharmacodynamic effects of the 
different medications.
In conclusion, there is enough evidence for a positive effect of iNO on outcome in 
infancy – without a positive effect on mortality. Large international RCTs concerning 
the use of sildenafil, bosentan, and prostanoids in this age group are needed, using reli-
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able and preferably noninvasive tools to measure the actual changes on PH itself. In the 
future, the use of newer medications and an upfront combination therapy might further 
improve the outcome in infants suffering from this life-threatening disease.
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ABStrACt
In 2010, the congenital diaphragmatic hernia (CDH) EURO Consortium published a 
standardized neonatal treatment protocol. Five years later, the number of participating 
centers has been raised from 13 to 22. In this article the relevant literature is updated, 
and consensus has been reached between the members of the CDH EURO Consortium. 
Key updated recommendations are: 1) planned delivery after a gestational age of 39 
weeks in a high-volume tertiary center; 2) neuromuscular blocking agents to be avoided 
during initial treatment in the delivery room; 3) adapt treatment to reach a preductal 
saturation between 80 and 95% and postductal saturation >70%; 4) target PaCO2 to be 
between 50 and 70 mmHg; 5) conventional mechanical ventilation to be the optimal 
initial ventilation strategy; and 6) intravenous sildenafil should be considered in CDH pa-
tients with severe pulmonary hypertension. This article represents the current opinion 
of all consortium members in Europe for the optimal neonatal treatment of CDH.
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introDUCtion
In 2008, the congenital diaphragmatic hernia (CDH) EURO Consortium was set up and 
during a consensus meeting drafted a standardized neonatal treatment protocol to 
improve outcome and permit comparison of outcome data1. Since then the number 
of participating centers has increased from 13 to 22 specialized CDH centers from all 
over Europe, and the guidelines from 2010 have been widely cited. Moreover, after the 
implementation of the protocol, the survival rate has increased from 67% to 88% in 2 
centers. This indicates the impact of the original standardized protocol. After 5 years of 
additional research including a multicenter randomized clinical trial on initial ventilation 
strategy (VICI-trial, Netherlands Trial Register NTR 1310), we aimed to update the stan-
dardized neonatal treatment protocol for CDH. All recommendations were summarized 
and compared to the protocol in 2010 (supplementary table 1).
mEtHoDS
The studies were graded according to the Scottish Intercollegiate Guidelines Network 
(SIGN) criteria2. Five experts individually primarily determined the levels of evidence 
on the guidance of the SIGN checklist. Differences in opinion were primarily discussed 
between the five experts until full consensus was reached, and thereafter consensus 
was reached between all participating centers. The final consensus statement, there-
fore, represents the opinion of all participating centers based on the interpretation of 
the recent literature from 2010- 2015 and includes the main findings of the so-called 
VICI-trial3. A consensus meeting, in which neonatologists, pediatric intensivists, gyne-
cologists, prenatal physicians, pediatric surgeons, pediatric cardiologists, and general 
pediatricians from 22 centers participated, was organized to discuss the most contro-
versial recommendations. If it was very hard to reach consensus on a specific issue, the 
consortium concurred to investigate those issues in future randomized trials. The levels 
of evidence and grades of recommendation according to the SIGN criteria are presented 
in supplementary tables 2 and 3, respectively.
rESUltS
Prenatal management
With the increased use of second trimester 2D ultrasound and/ or MRI, CDH has become 
a prenatal diagnosis. Subsequently, a more detailed expert evaluation should be per-
formed to determine the location of the defect, the observed/expected lung-to-head 
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ratio (O/E LHR) and the position of the liver (intra-abdominal or intrathoracic), in addition 
to ruling out additional congenital anomalies or syndromes4,5. Associated congenital 
anomalies, such as chromosomal or genitourinary anomalies, are present in about 25%6 
and cardiac anomalies in about 20% of cases7. Comprehensive assessment will also in-
clude invasive sampling for high-resolution genetic testing. Only once a comprehensive 
assessment has been made, multidisciplinary prenatal counseling by clinicians in ter-
tiary centers can be offered to inform parents about the estimated prognosis after birth. 
Several other additional imaging methods, such as lung volumetry, 3D ultrasound and 
Doppler studies of the pulmonary vascularization, have been shown in individual series 
to be prognostic for pulmonary hypertension, the need for extracorporeal membrane 
oxygenation (ECMO), and survival8. All of these remain research tools, however, but may 
ultimately improve the predictive value of prenatal testing.
An experienced tertiary center with a high case volume (≥ 6 CDH patients per year) is 
the optimal environment for the delivery and neonatal treatment of prenatally diagnosed 
CDH fetuses9,10. Prenatal intervention by fetal endoscopic tracheal occlusion (FETO) has 
been proposed to promote lung growth11. Therefore, FETO is being evaluated in two 
randomized clinical trials both in moderate (first interim analysis stage reached; >100 
patients randomized) and severe cases (>25 patients randomized) in centers in Europe, 
Australia and Canada ((TOTAL trial)12 ; (NCT01240057)). Current reported survival rates are 
on average around 50%, yet there is a significant impact of gestational age at delivery. 
In the largest cohort study of which 17.1% of all patients were born under 32 weeks, 
the survival rate was 49.4% for isolated left CDH and 37.9% for isolated right CDH13. This 
suggests that FETO introduces a significant risk for prematurity and all its consequences. 
It is recommended therefore that – while waiting for the results – FETO should not be 
performed outside the trial11. According to the consensus statement of the National 
Institutes of Health (NIH), CDH fetuses at risk for delivery before 34 weeks of gestation 
should be given prenatal steroid therapy.
Delivery
The timing and preferred mode of delivery in CDH pregnancies are still controversial. 
Hutcheon et al. showed that neonatal and infant mortality significantly decreased with 
advancing gestation, from 25 and 36% at 37 weeks of gestation, respectively, to 17 and 
20% at 40 weeks of gestation, respectively14. Moreover, a study from Odibo et al. among 
107 CDH cases found that gestational age at delivery was inversely correlated to the 
need for ECMO15. However, Safavi et al. found no difference in mortality when divid-
ing gestational age at delivery categorically as under 37 weeks; 37- 38 weeks and 39 
weeks or beyond16. Neither did they find a difference in mortality between vaginal and 
cesarean delivery16. In the absence of true convincing data it seems intuitive to schedule 
delivery (induced delivery or cesarean section) carefully in the best possible conditions 
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also dependent of maternal indications, i.e. at 39 weeks or beyond and in the presence 
of the relevant clinicians.
Recommendations (prenatal management and delivery)
– Following prenatal diagnosis, disease severity should be assessed at an experienced 
center. This will involve measurement of the O/E LHR and position of the liver (grade 
of recommendation = D).
– In case of an anticipated birth prior to 34 weeks of gestation, antenatal steroids 
should be given (grade of recommendation = D).
– Delivery after a gestational age of 39 weeks in a high-volume tertiary center should 
be planned (grade of recommendation = D).
Delivery room management and treatment in the initial postnatal phase
Initial treatment and procedures in the delivery room are based on the updated Guide-
lines of the International Consensus on Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care Science with Treatment Recommendations17.
Monitoring and goal of treatment
Measurements of heart rate, pre- and postductal saturations, and intra-arterial blood 
pressure are recommended. The key principles are the avoidance of high airway pres-
sures and the establishment of adequate perfusion and oxygenation (based on preduc-
tal arterial saturation, SpO2 measurements). In a study from Dawson et al. in term and 
preterm healthy neonates, the overall SpO2 values at 10 min after birth were median 
94% (interquartile range 91- 97%) in preterm infants and median 97% in term infants 
(interquartile range 92- 98%)18. Based on expert opinion, the consortium agreed on 
preductal SpO2 boundaries in the delivery room of 80-95%. In the first 2 hours after 
birth, preductal SpO2 levels as low as 70% are acceptable if they are improving without 
ventilator changes, if organ perfusion is satisfactory, as indicated by a pH > 7.2, and if 
ventilation is adequate (PaCO2 <65 mmHg (8.6 kPa)). Since there is growing evidence 
that room air is less harmful than 1.0 fractional inspired oxygen (FiO2) in the resuscita-
tion of term infants19,20, it may be better for CDH infants to start with fractional inspired 
oxygen lower than 1.0. The aim for preductal saturation is 80- 95% after the first hour of 
life. Thus, to avoid hyperoxia, supplemental oxygen should be diminished by reducing 
the oxygen fraction when preductal saturation exceeds 95%.
Intubation and ventilation
The consortium recommends intubating infants with prenatally diagnosed CDH im-
mediately after birth as a standard of care. The position of the endotracheal tube should 
be confirmed by end-tidal CO2 monitoring. However, based on expert opinion, in those 
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infants who are predicted to have good lung development based on their prenatal as-
sessment (e.g. left sided defect, O/E LHR > 50%, and liver down), spontaneous breathing 
could be considered instead to prevent ventilator-induced lung injury. Low peak pres-
sures, preferably <25cm H2O, are recommended to avoid lung damage to the ipsilateral 
and contralateral lung.
Sedation and analgesia/paralysis for intubation
Carbajal et al. have studied physiological responses of neonates to awake intubation, 
and they reported significant rises in systemic arterial blood pressure and intracranial 
pressure, as well as significant decreases in heart rate and transcutaneous oxygen satura-
tions21. In 166 infants Caldwell and Watterberg found that premedication for intubation 
significantly attenuated both the clinical pain score and the increase in blood glucose as 
marker of acute stress22. Moreover, it seems that intubation success rates progressively 
improve with premedication, although in some cases this is not possible due to a lack 
of vascular access23. Murthy et al. have shown no beneficial effects of administration of 
neuromuscular blocking agents immediately after intubation; in fact lung compliance 
deteriorated upon administration24.
Naso- or orogastric tube
The consortium recommends immediate placing an oro- or nasogastric tube with 
continuous or intermittent suctioning in order to prevent bowel distension and any 
additional ipsilateral lung compression.
Vascular access
As preductal PaO2 measurements reflect the delivered oxygen to the brain, the arterial 
line should preferably be inserted into the right radial artery, also for blood sampling 
and monitoring of the arterial blood pressure. Alternatively, an umbilical arterial line 
may be placed. This is less desirable, however, than a right radial artery line because it 
reflects the postductal situation, but on the other hand, it may give more secure longer 
-term arterial access. Each procedure should be performed as soon as possible. It is 
important, however, to prevent further agitation from recurrent insertion attempts as 
this may impair postnatal adaptation25.
Blood pressure control
Measures to increase the systemic blood pressure may minimize the right-to-left shunt-
ing. However, there is no need to increase blood pressure levels to supranormal values 
if the preductal saturation remains above 80%. Therefore, the consortium recommends 
maintaining arterial blood pressure at normal levels for gestational age if preductal 
saturations remain between 80 and 95%. In the case of hypotension and/or poor tissue 
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perfusion, a fluid bolus of 10-20 ml/kg NaCl 0.9% should be administered, although no 
more than 2 times. If tissue perfusion and blood pressure do not improve, inotropic 
and/ or vasopressor medication should be considered according to local practice. 
Hydrocortisone may be used in the early phase for the treatment of hypotension after 
other treatment has failed26.
Surfactant
There is no rationale for surfactant therapy because in CDH patients surfactant amounts 
are likely to be appropriate to lung size27.
Recommendations
– After delivery, the infant should be intubated routinely without bag and mask venti-
lation (grade of recommendation = D).
– The goal of treatment in the delivery room is achieving acceptable preductal satura-
tion targets, i.e. between 80 and 95% (grade of recommendation = D).
– Ventilation in the delivery room should be done with a peak pressure as low as pos-
sible, preferably with 25 cm H2O, or below that (grade of recommendation = D).
– An oro- or nasogastric tube with continuous or intermittent suction should be placed 
(grade of recommendation = D).
– Arterial blood pressure has to be maintained at a normal level for gestation. In the 
case of hypotension and/ or poor tissue perfusion, 10- 20 ml/kg NaCl 0.9% should be 
administered 2 times (grade of recommendation = D).
– In cases of persistent hypotension after the administration of NaCl 0.9%, inotropic 
and vasopressor agents should be considered (grade of recommendation = D).
– In CDH infants who are predicted to have good lung development based on their 
prenatal assessment (e.g. left-sided defect, O/E LHR > 50%, and liver down), sponta-
neous breathing could be considered (grade of recommendation = D).
– Premedication should be given before intubation if possible (grade of recommenda-
tion = D).
– Neuromuscular blocking agents should be avoided during initial treatment in the 
delivery room (grade of recommendation = D).
– No routine use of surfactant in either term or preterm infants with CDH (grade of 
recommendation = D).
Ventilation management in the intensive Care Unit
Permissive hypercapnia and ‘gentle ventilation’ have been reported to increase survival 
in neonates with CDH28,29. A ventilation strategy aiming for preductal saturation be-
tween 80 and 95%, postductal saturation above 70% and arterial CO2 levels between 
50 and 70 mmHg (6.9- 9.3 kPa) (permissive hypercapnia) is well accepted. In the first 2 
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hours after birth, preductal SpO2 levels as low as 70% are acceptable provided they are 
slowly improving and organ perfusion is satisfactory (indicated by a pH >7.2, and if ven-
tilation is adequate (PaCO2 <65 mmHg, 8.6 kPa). Thereafter, preductal saturation levels 
are preferably kept between 85 and 95%. In individual cases, however, levels down to 
80% may be accepted, providing organs are well perfused, as indicated by a pH >7.2, 
lactate levels < 5 mmol/l and urinary output >1 ml/kg/h. Postductal saturations should 
remain above 70%. Oxygen toxicity can be avoided by decreasing FiO2 on the guidance 
of the saturation levels described above. The optimal initial ventilation strategy was 
investigated in a collaborative initiative from the CDH EURO Consortium (VICI-trial, NTR 
1310)30. Although the primary outcome (death/ bronchopulmonary dysplasia at day 
28) was not significantly different between the two groups, it was found that infants 
initially ventilated by conventional mechanical ventilation required a significantly 
shorter duration of ventilation, had less need for inhaled nitric oxide (iNO) or sildenafil, 
had a shorter duration of vasoactive medication and were less likely to require ECMO3. 
Therefore, the CDH EURO Consortium recommends conventional mechanical ventila-
tion as the initial ventilation strategy. Recommendations for initial ventilation settings 
for pressure-controlled ventilation are summarized below. In the case of weaning, the 
peak pressure should primarily be reduced. Thereafter, frequency or PIP/ PEEP may be 
reduced as long as pCO2 <50 mmHg (6.7 kPa). In general, the consortium recommends 
aiming for a limitation of peak pressures to 25 cm H2O or less, a PEEP of 3-5 cm H2O and 
adjustment of the ventilator rate to obtain PaCO2 between 50 and 70 mmHg (6.9- 9.3 
kPa). If a PIP of >28 cm H2O is necessary to achieve pCO2 and saturation levels within the 
target range, other treatment modalities (such as high-frequency oscillatory ventilation 
or ECMO) should be considered.
Chest radiograph
To assess the patient’s initial condition, a chest radiograph should be obtained as soon 
as possible.
Recommendations
– Conventional mechanical ventilation is the optimal initial ventilation strategy (grade 
of recommendation = C).
– High-frequency oscillatory ventilation can be used as rescue therapy if conventional 
mechanical ventilation fails (grade of recommendation = D).
– Adapt ventilation settings to reach a preductal saturation between 80 and 95% and 
a postductal saturation above 70% (grade of recommendation = D).
– The target PaCO2 should be between 50 and 70 mm Hg (6.9- 9.3 kPa) (grade of rec-
ommendation = D).
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– Pressure-controlled ventilation: initial settings are a PIP <25 cm H2O and a PEEP of 
3- 5 cm H2O; ventilator rate of 40- 60/ min (grade of recommendation = D).
– After stabilization, reduce FiO2 if the preductal saturation is above 95% (grade of 
recommendation = D).
further management in the intensive Care Unit
Sedation and analgesia
A wide range of sedative and analgesic practices has been described31,32. Most centers 
use opioids such as morphine sulfate or fentanyl. Although there is no specific evidence 
in infants with CDH, neuromuscular blockade is associated with side-effects such as 
hypoxemia – and thus should be avoided. Infants should remain sedated during me-
chanical ventilation until weaning form mechanical ventilation is commenced.
Monitoring
Heart rate, invasive blood pressure, pO2 and pCO2, and pre- and postductal saturation 
should be monitored routinely. A head ultrasound scan should be performed at a time 
when there is little danger of arousing the newborn. Monitoring the regional cerebral 
oxygenation saturation with near infrared spectroscopy and transcutaneous saturation 
measurements may be indicated,33 although its additional value in CDH infants is not yet 
clear. Sedation and analgesia should be started as soon as venous access is established. 
Careful monitoring of the blood pressure is then warranted because more fluid volumes 
or vasoactive drugs may be needed in view of the potential adverse hemodynamic effect 
of sedatives, in particular midazolam. Supportive care such as cocooning and swaddling 
is recommended to prevent stress from too much noise, light and nociceptive stimula-
tion. The infant’s condition should be regularly assessed using validated analgesia and 
sedation scoring systems, such as the COMFORT behavior score34.
Hemodynamic management
Hemodynamic management should be aimed at achieving appropriate end-organ 
perfusion determined by heart rate, urine output, and lactate levels. If the heart rate 
is within the normal range35, urine output is over 1.0 ml/kg/hour, lactate concentration 
is <3 mmol/l and there are no other symptoms of poor tissue perfusion, inotropic or 
vasopressor support is not required. Echocardiography is indicated if there are signs of 
poor perfusion or if the blood pressure is below the normal level for gestation with a 
preductal saturation below 80%. This may show whether the poor perfusion is due to 
hypovolemia or myocardial dysfunction. If there is hypovolemia, saline fluid therapy 
should be given (10-20 ml/kg NaCl 0.9% or Ringer lactate) up to 2 times during the first 2 
hours)36. If necessary, this should be followed by inotropic and/ or vasopressor therapy. 
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Hydrocortisone may be used for the treatment of hypotension after other treatment has 
failed.
Recommendations
– Infants should be sedated and be monitored using validated analgesia and sedation 
scoring systems (grade of recommendation = D).
– Neuromuscular blocking agents should be avoided if possible (grade of recommen-
dation = D).
– If symptoms of poor perfusion and/or blood pressure below the normal level for 
gestation occur and are associated with preductal saturation below 80%, echocar-
diographic assessment should be performed (grade of recommendation = D).
– In case of hypovolemia, fluid therapy (10-20 ml/kg NaCl 0.9% or Ringer lactate) up to 
2 times during the first two hours may be given and followed if necessary by admin-
istration of inotropic and/ or vasopressor agents (grade of recommendation = D).
Pulmonary hypertension
A 2D echocardiography performed within the first 24 hours after birth remains the 
best modality to 1) rule out the presence of cardiac anomalies; 2) assess the right heart 
function; and 3) determine the amount of pulmonary hypertension classified accord-
ingly (less or more than 2/3 systemic blood pressure)37,38. Especially in severe cases of 
pulmonary hypertension, a cardiac ultrasound may help to evaluate right ventricular 
dysfunction and/or right ventricular overload, which condition can also lead to left 
ventricular dysfunction39.
There is no evidence for the usefulness of increasing systemic vascular resistance to 
treat right-to-left shunting, but a number of centers from the consortium suggest using 
inotropic or vasopressor agents such as dopamine, dobutamine and (nor)epinephrine 
to maintain blood pressure at normal levels for gestation40. If preductal saturation falls 
below 85% and/ or if there are signs of poor organ perfusion, treatment of pulmonary 
hypertension should be initiated. The first choice would be iNO, which is a pulmonary 
vasodilator. In neonates with pulmonary hypertension of the newborn (PPHN) or 
severe hypoxic respiratory failure, iNO improves oxygenation and decreases the need 
for ECMO41,42. At an oxygenation index of 20 or higher and/or a pre- and postductal 
saturation difference of 10% or more, iNO may be given for at least 1 hour. A consistent 
dose-dependent effect of iNO has not yet been shown43. As in one study43 more infants 
treated with NO needed ECMO, we recommend to stop iNO therapy if no effect is seen 
after its initiation.
If there is no or an insufficient response to iNO, intravenous prostacyclin, intravenous 
phosphodiesterase type 5 inhibitor (sildenafil) or medication involving the endothelin 
pathway should be considered. These agents have been used successfully in treating 
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PPHN in neonates with and without CDH44,45. The effects of treatment may be best ad-
dressed by repeated cardiac evaluation46. This can lead to insufficient filling of the left 
ventricle and thereby to poor systemic perfusion. Re-opening of the ductus arteriosus 
with prostaglandin E1 may protect the right ventricle from excessive overload due to 
increased afterload47. Phosphodiesterase-3 inhibitor (Milrinone) was investigated in 
only 6 CDH patients by Patel et al. Right ventricular function and oxygenation index 
significantly improved48. Sildenafil® has been used in the treatment of pulmonary hyper-
tension in infants with CDH. Intravenous sildenafil has recently become available, but its 
use has not yet been FDA approved.
Recommendations
– Perform echocardiography within the first 24 hours after birth to rule out structural 
cardiac anomalies (grade of recommendation = D).
– Blood pressure support should be given to maintain arterial blood pressure levels at 
normal levels for gestation (grade of recommendation = D).
– iNO administration for at least 1 hour in a dose of 10-20 ppm should be considered 
if there is evidence of extrapulmonary right-to-left shunting and the oxygenation 
index is above 20 and/or the saturation difference is more than 10% (grade of recom-
mendation = D).
– In nonresponders iNO should be stopped. iNO responders are defined as follows: 
decline of 10- 20% in the pre-postductal saturation difference, or an increase of 10- 
20% of PaO2, or improvement in hemodynamic parameters meaning a 10% increase 
in mean blood pressure, or a decrease in lactate levels (grade of recommendation = 
D).
– Intravenous sildenafil should be considered in CDH patients with severe pulmonary 
hypertension (grade of recommendation = D).
– In case of suprasystemic pulmonary artery pressure and right-to-left shunting 
through the foramen ovale, intravenous prostaglandin E1 should be considered 
(grade of recommendation = D).
Extracorporeal membrane oxygenation
The benefit of ECMO in the treatment of infants with CDH remains unclear. The ELSO 
registry showed a survival rate of 51% of patients with CDH who required ECMO49. The 
use of ECMO has decreased in recent years50; it is more used for preoperative stabiliza-
tion, and the preferred method (venoarterial vs. venovenous) is still being debated. The 
VICI-trial showed no difference in survival between patients born in ECMO centers and 
patients born in non-ECMO centers3.
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recommendations
– Criteria for ECMO (grade of recommendation = D):
 •  Inability to maintain preductal saturations >85% or postductal saturations >70%
 •  Increased PaCO2 and respiratory acidosis with pH <7.15 despite optimization of 
ventilator management.
 •  Peak inspiratory pressure >28 cm H2O or mean airway pressure >17 cm H2O is 
required to achieve saturation >85%.
 •  Inadequate oxygen delivery with metabolic acidosis as measured by elevated 
lactate ≥ 5 mmol/L and pH <7.15.
 •  Systemic hypotension, resistant to fluid and inotropic therapy, resulting in urine 
output <0.5 mL/kg/h for at least 12- 24 hours
 •  Oxygenation index ≥ 40 present for at least 3 hours.
Surgical repair
Surgery should be performed electively. The effect of hospital volume on mortality is 
unclear. While a large study (2203 infants) concluded that hospitals with a high-volume 
of CDH repair have lower in-hospital mortality51, a more recent study in 3738 infants 
showed no difference in mortality between lower and higher surgical volume centers52. 
Controversies about the exact timing of the surgical repair in patients on ECMO remain53. 
A recent study from Partridge et al. showed improved outcomes with surgical repair after 
ECMO, i.e. a higher likelihood of survival, less surgical bleeding and shorter duration of 
ECMO54. A relative small study (n=46) from Fallon et al. found that repair within the first 
72 hours of ECMO correlated with a shorter duration of ECMO, less circuit complications 
and a trend towards improved survival55.
The routine use of a chest tube postoperatively to drain the effusion filling the pleural 
cavity has been abandoned. This does not preclude its use in individual cases to drain 
an effusion that is symptomatic, for example due to chylothorax existing before surgery.
The optimal surgical technique also remains under debate. Minimal access surgery is 
gaining ground on the open approach (thoracotomy or laparotomy)56. Minimal access 
surgery has esthetic advantages and may be performed in patients with a left-sided 
defect and liver down, but carries a significantly higher risk of recurrence56,57. There is 
also concern about absorption of CO2 used for insufflation in minimal access surgery58, 
and CO2 insufflation pressures should therefore be minimized. A meta-analysis from 
Lansdale et al. showed that thoracoscopic repair had greater recurrence rates and opera-
tive times but similar survival and patch usage compared with open surgery59. Recently, 
Costerus et al. concluded that thoracoscopic primary closure seems a safe and effective 
procedure, but efficacy of thoracoscopic patch repair has not been established60. To 
allow for better comparison of patient groups between studies it is recommended to 
record the diaphragmatic defect size37 in all surgeries.
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recommendations
– Surgical repair of the diaphragmatic defect should be performed after clinical stabi-
lization, defined as follows (grade of recommendation = D):
 • Mean arterial blood pressure normal for gestation.
 • Preductal saturation levels of 85- 95% on fractional inspired oxygen below 50%.
 • Lactate below 3 mmol/L. 
 • Urine output more than 1 mL/kg/h.
– No routine chest tube placement postoperatively (grade of recommendation = D)
– Repair can be performed while the patient is on ECMO (grade of recommendation = 
D)
fluid management, parenteral feeding, entering enteral feeding and 
gastroesophageal reflux
Restrictive fluid management in the first 24 hours after birth consists of 40 mL/kg/day 
of fluids including medication, with additional saline volume top-up for intravascular 
filling in the case of inadequate tissue perfusion or hypotension. Parenteral nutrition 
only is allowed until surgical repair and until postoperative enteral feeding has been 
achieved. Gastroesophageal reflux may be treated both by antireflux medication and 
by surgical intervention61. Maier et al. did not show evidence for profit beyond the first 
year of life after prophylactic Thal-procedure at primary CDH repair62. Diuretics should 
be given in the case of persisting positive fluid balance without hypovolemia, aiming for 
diuresis of >1 mL/kg/hour63.
recommendations
– 40 mL/kg/day saline including medication for the first 24 hours after birth; increase 
intake thereafter (grade of recommendation = D).
– Diuretics should be considered in case of persisting positive fluid balance; aim for a 
diuresis >1 mL/kg/hour (grade of recommendation = D).
– Preventive antireflux therapy should be started in combination with enteral feeding 
(grade of recommendation = D).
– Pre-operatively, patients should only receive parenteral nutrition (grade of recom-
mendation = D).
ConClUSion
The European task force for CDH (CDH EURO Consortium) has agreed on an updated 
protocol for standardized postnatal treatment guidelines. Although it is eminence- 
based medicine and many recommendations are level D, we think that a consensus of 
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many specialized centers on the use of a standardized treatment protocol will contribute 
to making more valid comparisons of patient data in ongoing and future multicenter 
prospective clinical studies.
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Supplementary table 1 – Recommendations
2010 2015
Prenatal management and delivery
Following prenatal diagnosis, the absolute and O/E 
LHR and the position of the liver should be evaluated*
Following prenatal diagnosis, disease severity should 
be assessed at an experienced center. This will involve 
high resolution genetic testing, determination of the 
O/E LHR and position of the liver *
Planned vaginal delivery or caesarean section after a 
gestational age of 37 weeks in a high-volume tertiary 
center should be pursued*
Delivery after a gestational age of 39 weeks in a high-
volume tertiary center, should be planned*
In case of preterm labor prior to 34 weeks of gestation, 
antenatal steroids should be given*
Unchanged
Delivery room management and treatment in a very early phase
After delivery, the infant should be intubated 
immediately without bag and mask ventilation*
Unchanged
The goal of treatment in the delivery room is 
achieving acceptable preductal saturations levels 
between 80 and 95%*
Unchanged
Ventilation in the delivery room may be done by 
conventional ventilator or ventilation bag with a peak 
pressure as low as possible, preferably below 25 cm 
H2O*
Unchanged
An oro- or nasogastric tube with continuous or 
intermittent suction should be placed*
Unchanged
Arterial blood pressure has to be maintained 
at a normal level for gestational age. In case of 
hypotension and/ or poor perfusion, 10- 20 ml/kg 
NaCl 0.9% should be administered 2 times*
Unchanged
Sedatives and analgesics should be given* Neuromuscular blocking agents should be avoided 
during initial treatment in the labour ward*
In CDH infants who are predicted to have good lung 
development based on their prenatal assessment 
(e.g. left sided, O/E LHR > 50%, and liver down), 
spontaneous breathing could be considered*
No routine use of surfactant in either term or preterm 
infants with CDH*
Unchanged
In cases of persistent hypotension after administration 
of NaCl 0.9%, inotropic and vasopressor agents should 
be considered*
Premedication should be given before intubation if 
possible*
Ventilation management in the intensive Care Unit
Adapt treatment to reach a preductal saturation 
between 85 and 95% and a postductal saturation 
above 70%*
Adapt treatment to reach a preductal saturation 
between 80 and 95% and a postductal saturation 
above 70%*
In individual cases, preductal saturation above 80% 
might be acceptable, as long as organs are well 
perfused*
Unchanged
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Supplementary table 1 – (continued)
2010 2015
The target PaCO2 range should be between 45 and 60 
mmHg*
The target PaCO2 should be between 50 and 70 mm 
Hg (6.9- 9.3 kPa)*
Pressure-controlled ventilation initial settings are a PIP 
of 20-25 cm H2O and a PEEP of 2-5 cm H2O; ventilator 
rate of 40- 60/min*
Pressure controlled ventilation: initial settings are a PIP 
of <25 cm H2O and a PEEP of 3- 5 cm H2O; ventilator 
rate of 40- 60/ min
HFOV: initial setting mean airway pressure 13-17 cm 
H2O, frequency 10 Hz, ΔP 30-50 cm H2O depending on 
chest wall vibration*
High-frequency oscillatory ventilation can be used as 
rescue therapy if conventional mechanical ventilation 
fails*
After stabilization, the FiO2 should be decreased if 
preductal saturation is above 95%*
Unchanged
Conventional mechanical ventilation is the optimal 
initial ventilation strategy**
further management in the intensive Care Unit
Infants should be sedated and be monitored using 
validated analgesia and sedation scoring systems*
Unchanged (however in 2010, this recommendation 
was presented in a separate section).
Neuromuscular blocking agents should be avoided if 
possible*
Unchanged (however in 2010, this recommendation 
was presented in a separate section).
If symptoms of poor perfusion and/or blood pressure 
below the normal level for gestational age occur and 
are associated with preductal saturation below 80%, 
echocardiographic assessment should be performed*
Unchanged
In case of hypovolemia, isotonic fluid therapy 10-20 
ml/kg NaCl 0.9% up to 3 times during the first 2 hours 
may be given and inotropics should be considered*
In case of hypovolemia, fluid therapy (10-20 ml/
kg NaCl 0.9% or lactated Ringers) up to two times 
during the first two hours may be given and followed 
if necessary, by administration of inotropic and/ or 
vasopressor agents should be considered*
Pulmonary hypertension
Perform echocardiography within the first 24 h after 
birth*
Perform echocardiography within the first 24 hours 
after birth to rule out structural cardiac anomalies
Blood pressure support should be given to maintain 
arterial blood pressure levels at normal levels for 
gestational age*
Unchanged
iNO should be considered if there is evidence of 
extrapulmonary right-to-left shunting and the 
oxygenation index is above 20 and/or the saturation 
difference is more than 10%*
iNO administration for at least one hour in a dose of 
10- 20 ppm should be considered if there is evidence 
of extrapulmonary right-to-left shunting and the 
oxygenation index is above 20 and/or the saturation 
difference is more than 10%.
In non-responders iNO should be stopped. iNO 
responders are defined as follows: decline of 10- 20% 
in the pre-postductal saturation difference, or increase 
of 10- 20% of PaO2, or improvement in hemodynamic 
parameters meaning a 10% increase in mean blood 
pressure, or decrease of lactate levels*
Intravenous sildenafil should be considered in CDH 
patients with severe pulmonary hypertension*
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Supplementary table 1 – (continued)
2010 2015
In case of suprasystemic pulmonary artery pressure 
and right-to-left shunting through the foramen ovale, 
i.v. prostaglandin E1 has to be considered*
Unchanged
Extracorporeal membrane oxygenation (ECmo)
Criteria for ECMO*:
–  Inability to maintain preductal saturations >85% or 
postductal saturations >70%.
–  Increased PaCO2 and respiratory acidosis with 
pH <7.15 despite optimization of ventilatory 
management.
–  Peak inspiratory pressure >28 cm H2O or mean 
airway pressure >17 cm H2O is required to achieve 
saturation >85%.
–  Inadequate oxygen delivery with metabolic 
acidosis as measured by elevated lactate ≥5 mmol/l 
and pH <7.15.
–  Systemic hypotension, resistant to fluid and 
inotropic therapy, resulting in urine output <0.5 ml/
kg/h for at least 12- 24 hours
–  Oxygenation index (mean airway pressure x FiO2 x 
100/PaO2) ≥40 consistently present
Criteria for ECMO*:
Unchanged
Unchanged
Unchanged
Unchanged
Unchanged
Oxygenation index (mean airway pressure x FiO2 x 
100/PaCO2) ≥40 at least three hours present*
Surgical repair
Surgical repair of the diaphragmatic defect should be 
performed after physiological stabilization, defined as 
follows*
•  Mean arterial blood pressure normal for gestation;
•  Preductal saturation levels of 85- 95% on fractional 
inspired oxygen below 50%;
•  Lactate below 3 mmol/ l;
•  Urine output more than 2 ml/kg/h
Surgical repair of the diaphragmatic defect should be 
performed after physiological stabilization, defined as 
follows*
•  Unchanged
•  Unchanged
•  Unchanged
•  Urine output more than 1 ml/kg/h
No routine chest tube placement* Unchanged
Repair can be performed while the patient is on 
ECMO*
Unchanged
fluid management, parenteral feeding, entering enteral feeding and gastroesophageal reflux
40 ml/kg/day including medication for the first 24 
hours after birth, increase intake thereafter*
Unchanged
Diuretics should be considered in case of persisting 
positive fluid balance, aim for diuresis 1- 2 ml/kg/
hour*
Diuretics should be considered in case of persisting 
positive fluid balance, aim for a diuresis >1 ml/kg/
hour*
Preventive antireflux therapy should be started in 
combination with enteral feeding*
Unchanged
Pre-operatively, patients should only receive 
parenteral nutrition*
*Grade of recommendation = D. ** Grade of recommendation = C.
192 • Chapter 10
Supplementary table 2 – Levels of evidence
Level Description of evidence
1++ High quality meta-analyses, systematic reviews of randomized controlled trials, or randomized 
controlled trials with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of randomized controlled trials, or randomized 
controlled trials with a low risk of bias
1- Meta-analyses, systematic reviews or randomized controlled trials, or randomized controlled trials 
with a high risk of bias
2++ High-quality systematics reviews of case-control or cohort studies, or high-quality case-control or 
cohort studies with a very low risk of confounding, bias or chance, and a high probability that the 
relationship is causal
2+ Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance, and a 
moderate probability that the relationship is causal
2- Case-control or cohort studies with a high risk of confounding, bias or chance, and a significant risk 
that the relationship is not causal
3 Nonanalytic studies, e.g. case reports, case series
4 Expert opinion
Supplementary table 3 – Grades of recommendation
Grade Description of grade
A At least 1 meta-analysis, systematic review, or randomized controlled trial rated as 1++ and directly 
applicable to the target population, or a systematic review of randomized controlled trials or a body 
of evidence consisting principally of studies rated as 1+ directly applicable to the target population 
and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++ directly applicable to the target population and 
demonstrating overall consistency of results, or extrapolated evidence from studies rated as 1++ or 1-
C A body of evidence including studies rated as 2+ directly applicable to the target population and 
demonstrating overall consistency of results, or extrapolated evidence from studies rated as 2++.
D Evidence level 3 or 4, or extrapolated evidence from studies rated as 2+
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ABStrACt
Background: Since mortality in congenital diaphragmatic hernia (CDH) is decreasing, 
morbidity such as neurodevelopmental outcome is becoming increasingly important.
objectives: We evaluated neurodevelopmental outcome in high-risk CDH patients 
treated according to the CDH EURO Consortium standardized treatment protocol.
methods: This observational, prospective cohort study was conducted in two European 
centers. Neurodevelopment of 88 patients (Rotterdam n=49; Rome n=39) was assessed 
at 12 and 24 months with the Bayley Scales of Infant Development (BSID)-II-NL (Rot-
terdam) or BSID-III (Rome). Data of the centers were analyzed separately.
results: Cognition was normal in 77.8% of children from Rotterdam and in 94.8% from 
Rome at 12 months, and in 70.7 and 97.4%, respectively, at 24 months. Motor function 
was normal in 64.3% from Rotterdam and in 81.6% from Rome at 12 months and in 45.7 
and 89.8%, respectively, at 24 months. Longer length of hospital stay (LoS) was associ-
ated with worse cognitive outcome and motor function; LoS, low socioeconomic status, 
and ethnicity were associated with lower cognition.
Conclusions: At 2 years, most CDH patients have normal cognition, but are at risk for 
motor function delay. Due to differences in outcomes between centers, careful interpre-
tation is needed before conclusions can be drawn for other centers. Future multicenter 
collaboration should not only focus on standardization of postnatal care, but also on 
international standardization of follow-up to identify risk factors and thereby reduce 
morbidity.
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introDUCtion
Congenital diaphragmatic hernia (CDH) affects approximately 1 in 3000 newborns1. It 
is a life-threatening disease caused mainly by persistent pulmonary hypertension and 
pulmonary hypoplasia1. Severely ill CDH patients may receive extracorporeal mem-
brane oxygenation (ECMO)1. In 2008, a standardized neonatal treatment protocol was 
developed at a consensus meeting of the CDH EURO Consortium1. The mortality rate 
has decreased from 33 to 12% since this protocol was implemented2. Consequently, 
worldwide the focus of interest has shifted to morbidity3-5.
Previous studies found associated morbidity in about 87% of CDH survivors, mainly 
related to the lungs or the gastrointestinal tract6,7. While most follow-up studies have 
focused on morbidity, few have examined neurodevelopment. Most of those studies 
were cross-sectionally performed in small series in single centers8-10. Recently, longitu-
dinal studies have shown neurodevelopmental delays in CDH patients3,4,11. To date, no 
published studies have examined neurodevelopmental outcome after implementation 
of a standardized treatment protocol in a multicenter setting.
We longitudinally investigated neurodevelopmental outcome in high-risk patients 
managed according to the CDH EURO Consortium standardized treatment protocol1 in 
two high-volume CDH centers. Secondly, we identified determinants of neurodevelop-
mental outcome.
mAtEriAlS AnD mEtHoDS
This is an observational, prospective cohort study in patients born between January 
2009 and May 2012 with high-risk CDH, i.e. antenatal diagnosis/ respiratory insufficiency 
within 6 hours postnatally. All patients were treated according to a standardized treat-
ment protocol1; however, ECMO was only offered in Rotterdam. Rotterdam and Rome 
are two of the largest European CDH centers. As standard of care, survivors were offered 
a structured, longitudinal follow-up program, initiated in Rotterdam in 199911 and in 
Rome in 200412. We evaluated prospectively collected data of repeated measurements at 
corrected ages of 12 and 24 months. Since subjects were not submitted to any handling 
and no rules of human behavior were imposed, institutional review board approval was 
waived. Parents were informed that data were used for research purposes.
Patient characteristics
Patient characteristics were retrieved from medical records. Prenatal, perinatal, periop-
erative, postnatal, demographic data and data at discharge were retrieved from medical 
records:
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Prenatal: lung-to-head ratio (LHR), observed/ expected LHR (O/E LHR)13 determined if 
ultrasound was performed before 32 weeks gestation, application of fetoscopic endolu-
minal tracheal occlusion (FETO).
Perinatal and postnatal: sex, birth weight, gestational age, Score for Neonatal Acute 
Physiology-II (SNAP-II score)14, ECMO duration if applicable, initial ventilation type, 
length of ventilation, severity of chronic lung disease (CLD)15, duration of morphinomi-
metics/ sedatives, use of anticonvulsants, length of initial hospital stay (LoS) in tertiary 
hospital, and episodes of general anesthesia within first 24 months.
Perioperative: age at repair, side of hernia, liver position, surgical approach (thoracos-
copy or laparotomy), type of repair (patch or primary closure).
At discharge: tube feeding, physical therapy and involvement of a speech language 
pathologist for feeding problems or oral aversion. 
Demographic: Ethnicity was classified as native or non-native. Socioeconomic status 
(SES) was classified by maternal highest education level16.
Neurodevelopmental outcome was assessed with the Bayley Scales of Infant Develop-
ment (BSID). In Rotterdam, the Dutch-language version of the BSID-II (BSID-II-NL) was 
administered with Dutch normative data17. In both centers cognitive development was 
assessed at both time points (by two developmental psychologists per center). Psycho-
motor development was assessed by developmental psychologists at both time points 
in Rome and at 12 months in Rotterdam. In Rotterdam, psychomotor development was 
assessed by one physiotherapist at 24 months. Nonverbal and verbal performance are 
combined in the Mental Developmental Index (MDI), and gross motor and fine motor 
developmental aspects are combined in the Psychomotor Developmental Index (PDI). 
In Rome, the Italian translation of the BSID-III18 with American normative data was ad-
ministered. The BSID-III provides three norm-reference index scores: cognition, motor 
(subscale: gross and fine motor) and language (subscale: receptive and expressive lan-
guage) domains. The normalized population mean (SD) of each composite score is 100 
(15) and that of the subscale domains is 10 (3). Scores were grouped as normal (>−1SD), 
mildly delayed (−2<SD<−1) and severely delayed (<−2SD).
Data analysis
Descriptive statistics are presented as number (%), mean (SD) or median (range). Inde-
pendent samples t test, χ2 tests and Mann-Whitney U tests, where appropriate, were 
used to compare characteristics between centers. One-sample t tests served to compare 
mean scores to the normalized population mean. Linear mixed models were used to 
estimate neurodevelopmental outcome over time. These models included only the time 
point (12 or 24 months) as the independent variable, and a random intercept to account 
for the within-subject correlations. Perinatal factors associated with adverse neurode-
velopment were determined using multivariate linear regression. Cognition and motor 
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outcome were chosen as dependent variables in two different models; the data were 
analyzed separately for each assessment, age and each center. Based on clinical experi-
ence and the literature, the following independent variables were included in the linear 
regression analysis: tube feeding at discharge, ECMO support, ethnicity and SES as cat-
egorical variables, and SNAP-II score and length of hospital stay (LoS) (log-transformed 
due to skewed distribution) as continuous variables. Analyses were performed using 
SPSS version 20.
rESUltS
In the study period, 141 CDH patients were admitted (Rotterdam n=76; Rome n=65). 
Thirty-eight children died (Rotterdam n=19; Rome n=19) and 5 were not high-risk CDH 
patients; thus, 98 children were eligible for follow-up. Ultimately, 88 patients were as-
sessed (Figure 1).
Baseline characteristics of participants (Table 1) were not significantly different from 
nonparticipants. Four patients (Rotterdam n=1, Rome n=3) underwent fetoscopic en-
figure 1 – Flowchart of inclusion of all patients
Children born between January 2009 and May 2012
n=141
Rotterdam n=76 Rome n=65
Eligible for follow-up
n=98 (69.5%)
Rotterdam n=53 Rome n=45
No follow-up assessment at all 
Rotterdam  Rome
Lost to follow-up n=1 n=2  
Refusal n=2 n=2    
Follow-up elsewhere    n=1    NA     
Organisatorial reasons  NA n=1
Organisatorial at 12 mo&
not cooperative at 24 mo NA     n=1
Follow-up Rome
n=39 (86.7%)
Excluded (reason: died)
Rotterdam n=19* (25.0%)    Rome n=19 (29.2%)
* 12 ECMO patients (63.2%)
Follow-up Rotterdam
n=49 (92.5%)
Excluded (reason: not high-risk patient)
Rotterdam n=4 (5.3%)         Rome n=1 (1.5%)
Assessment at 24 months
Cognition and motor function 
assessed: n=40
Assessment of cognition only: n=1
Organisatorial reason: n=1
Assessment of motor function only: 
n=6
Non cooperative: n=5
Organisatorial reason: n=1
No developmental assessment: n=2
Died: n=1
Refusal: n=1
Assessment at 24 months
Cognition and motor 
function assessed: n=39
Assessment at 12 months
Cognition and motor function 
assessed: n=42
Assessment of cognition only: n=3
Organisatorial reason: n=3
Assessment of motor function only: 
NA
No developmental assessment: n=4
Refusal: n=2
Organisatorial: n=2
Assessment at 12 months
Cognition and motor function 
assessed: n=38
Assessment of cognition only: NA
Assessment of motor function only: NA
No developmental assessment: n=1
Organisatorial: n=1
Abbreviations: NA: not applicable
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table 1 – Background characteristics
Rotterdam (n=49) Rome (n=39) p-value*
Perinatal and postnatal characteristics
LHR 1.9 (0.8) 2.2 (0.8) 0.32
Missing 15 13
O/E LHR 51.6 (17.4) 53.3 (15.8) 0.71
Missing 21 13
Male sex 28 (57.1%) 25 (64.1%) 0.51
Birth weight, kg 3.07 (0.56) 2.99 (0.41) 0.45
Born before 37 weeks of gestation 8 (16.3%) 4 (10.3%) 0.41
SNAP-II score 18 (12) 13 (9) 0.07
Age at repair, days 3.8 (2.7) 3.6 (2.1) 0.77
Left-sided CDH 42 (85.7%) 38 (97.4%) 0.06
Liver: intrathoracic 19 (38.8%) 12 (30.8%) 0.44
Defect size 0.24
A 5 (10.2%) 4 (10.3%)
B 18 (26.7%) 22 (56.4%)
C 24 (49.0%) 11 (28.2%)
D 2 (4.1%) 2 (5.1%)
Patch repair 35 (71.4%) 11 (28.2%) <0.001
Defect size A n=1 n=0
Defect size B n=8 n=1
Defect size C n=24 n=8
Defect size D n=2 n=2
Initial ventilation 0.83
CMV 24 (49.0%) 20 (51.3%)
HFO 25 (51.0%) 19 (48.7%)
Length of ventilation, days 8 (1- 271) 8 (2- 70) 0.55
Length of initial hospital stay, days 28 (6- 387) 30 (15-161) 0.54
CLD 0.12
No CLD 29 (59.2%) 32 (82.1%)
Mild CLD 8 (16.3%) 2 (5.1%)
Moderate CLD 1 (2.0%) 0 (0%)
Severe CLD 11 (22.4%) 5 (12.8%)
Length of morphinomimetics/ sedatives 0.28
<1 week 25 (51.0%) 14 (35.9%)
1 week to 1 month 17 (34.7%) 20 (51.3%)
>1 month 7 (14.3%) 5 (12.8%)
Episodes of general anesthesia 0-24 months 2 (1- 13) 1 (1- 3) 0.01
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dotracheal occlusion. In Rotterdam, 28 patients underwent thoracoscopic repair and 7 
were converted to laparotomy. In Rome, all children underwent laparotomy. None of the 
children received anticonvulsants. Six patients from Rotterdam had a genetic or chro-
mosomal abnormality that was not associated with neurodevelopment. Patch repair, 
episodes of general anesthesia 0-24 months, and involvement of physical therapist and 
speech-language pathologist were significantly different between Rotterdam and Rome 
(Table 1). After exclusion of ECMO-treated patients (Supplementary Table 1a), episodes 
of general anesthesia 0-24 months and involvement of physical therapy were not signifi-
cantly different between the two centers (Supplementary Table 1b).
Based on the cutoff scores from the BSID manuals, cognition was normal in 71 chil-
dren (85.5%) and motor function was normal in 58 children (72.5%) at 12 months; this 
held true for 67 patients (83.8%) and 56 patients (65.9%), respectively, at 24 months. 
Proportions of mild and severe neurodevelopmental delay are shown in Figure 2. Table 
2 shows means (SD) of neurodevelopmental outcome. In supplementary Figure 2a and 
supplementary Table 2a, data were presented after exclusion of ECMO-treated patients.
table 1 – (continued)
Rotterdam (n=49) Rome (n=39) p-value*
At discharge
Tube feeding 29 (59.2%) 20 (51.3%) 0.46
Physical therapy at home 20 (40.8%) 7 (17.9%) 0.02
Speech language pathologist involved 19 (38.8%) 3 (7.7%) 0.001
Demographic variables
Ethnicity 0.13
Native 34 (69.4%) 33 (84.6%)
Nonnative 14 (28.6%) 6 (15.4%)
Unknown 1 (2.0%) 0 (0%)
SES mother 0.12
Low 13 (26.5%) 9 (23.1%)
Medium 15 (30.6%) 21 (53.8%)
High 18 (36.7%) 9 (23.1%)
Unknown 3 (6.1%) 0 (0%)
Categorical variables are shown as n (%) and compared between centers between centers using χ2 tests, 
normally distributed variables are shown as means (SD) and compared between groups using independent 
samples t tests, and continuous variables that are not normally distributed are shown as medians (range) 
and compared between centers using Mann Whitney U tests.
Abbreviations: LHR = lung-head ratio; O/E LHR = observed to expected lung to head ratio; SNAP-II score: = 
Score for Neonatal Acute Physiology-II; CMV = conventional mechanical ventilation; HFO = high-frequency 
oscillation; CLD = chronic lung disease; SES= socioeconomic status.Comparison between Rotterdam and 
Rome.
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figure 2 – Neurodevelopmental outcome in CDH survivors at 12 and 24 months
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Black: Rotterdam; Grey: Rome.
table 2 – Neurodevelopmental outcome scores at 12 and 24 months (corrected for prematurity)
12 months 24 months
rotterdam1 p-value2 rome
(n=38)
p-value2 rotterdam3 p-value2 rome
(n=39)
p-value2
Cognitive outcome4 97.8 (19.8) 0.46 97.9 (11.8) 0.28 96.0 (18.4) 0.17 102.1 (13.9) 0.36
Motor outcome4 87.7 (18.8) <0.001 93.2 (12.2) 0.002 82.9 (16.7) <0.001 98.2 (14.8) 0.45
Language outcome4 – – 97.7 (8.6) 0.10 – – 97.7 (12.6) 0.26
Receptive language5 – – 9.4 (1.7) 0.04 – – 10.2 (2.4) 0.60
Expressive language5 – – 9.8 (1.9) 0.51 – – 8.9 (2.5) 0.01
Fine motor skills5 – – 10.1 (2.1) 0.76 – – 10.5 (2.6) 0.23
Gross motor skills5 – – 7.7 (2.5) <0.001 – – 8.9 (2.7) 0.01
1Cognitive outcome: n= 45; motor outcome: n= 42. 2Outcome scores were compared to the expected nor-
mal score of reference population; Rotterdam: BSID-II-NL; Rome: BSID-III. 3Cognitive outcome: n=41; motor 
outcome: n =46. 4Mean (SD) of expected normal score of reference population is 100 (15). 5Mean (SD) of 
expected normal score of reference population is 10 (3).
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table 3 – Determinants of impaired neurodevelopmental outcome; results of linear regression models
independent variables
rotterdam rome
Parameter
estimate
95% CI Parameter
estimate
95% CI
Cognition at 12 
months
SNAP-II score 0.5 −0.2 to 1.2 0.1 −0.0 to 0.33
ECMO 2.3 −25.8 to 30.3 – –
Length of hospital stay, days1 −9.6 −20.0 to 0.7 −13.7 −21.2 to −6.2
Tube feeding at discharge −0.2 −19.2 to 19.0 −1.9 −10.6 to 6.8
Ethnicity 13.3 −7.7 to 34.3 1.5 −8.1 to 11.1
SES mother
 Low −11.5 −34.9 to 11.9 1.9 −8.4 to 12.1
 Medium 4.6 −16.1 to 25.2 1.2 −7.7 to 10.1
 High2 – – – –
Cognition at 24 
months
SNAP-II score 0.1 −0.4 to 0.5 0.0 −0.2 to 0.3
ECMO 20.8 −9.0 to 50.6 – –
Length of hospital stay, days1 −5.8 −14.1 to 2.6 −10.2 −20.0 to −0.4
Tube feeding at discharge −3.5 −18.4 to 11.3 −4.1 −16.2 to 8.0
Ethnicity 25.1 5.9 to 44.2 −2.1 −15.5 to 11.4
SES mother
 Low −36.2 −58.1 to −14.3 −7.0 −21.3 to 7.4
 Medium −11.5 −27.9 to 4.8 −3.6 −16.0 to 8.7
 High2 – – – –
motor function 
at 12 months
SNAP-II score 0.6 −0.0 to 1.2 0.0 −0.2 to 0.2
ECMO 5.6 −22.3 to 33.5 – –
Length of hospital stay, days1 −10.5 −21.6 to 0.5 −9.5 −17.7 to −1.4
Tube feeding at discharge −0.2 −18.4 to 17.9 −6.6 −16.1 to 2.8
Ethnicity 15.3 −5.6 to 36.3 3.6 −6.8 to 14.1
SES mother
 Low −0.8 −23.2 to 21.6 −3.1 −14.2 to 8.1
 Medium 1.2 −18.8 to 21.2 −2.4 −12.1 to 7.3
 High2 – – – –
motor function 
at 24 months
SNAP-II score 0.3 −0.2 to 0.8 0.1 −0.2 to 0.3
ECMO 14.4 −7.8 to 36.6 – –
Length of hospital stay, days1 −7.8 −15.3 to −0.3 −16.7 −25.1 to −8.2
Tube feeding at discharge 3.0 −11.0 to 17.0 0.8 −9.7 to 11.3
Ethnicity 6.2 −7.4 to 19.9 2.1 −9.5 to 13.7
SES mother
 Low −15.4 −32.1 to 1.4 −0.2 −12.7 to 12.2
 Medium −2.7 −17.2 to 11.8 5.5 −5.2 to 16.2
 High2 – – – –
SNAP-II score = Score for Neonatal Acute Physiology II. 1Because of skewed distribution, these variables 
were log-transformed before including them into the linear regression model. 2Reference category.
206 • Chapter 11
In Rotterdam, cognition and motor function remained stable over time. In Rome, cog-
nition and motor function improved over time (mean differences 4.1 (p=0.02) and 5.8 
(p=0.003), respectively).
In Rotterdam, cognitive outcome at 24 months was negatively associated with low 
socioeconomic status (SES) (B −36.2; 95% CI: [−58.1 to −14.3]) and non-Dutch ethnicity 
(B 25.1; 95% CI: [5.9 to 44.2]) (Table 3). Motor function was negatively associated with 
longer LoS at 24 months (B −7.8; 95% CI: [−15.3 to −0.3]). For example, taking into ac-
count the logarithmic transformation of LoS, children who were hospitalized twice as 
long scored 5.4 points lower (calculation: B x ln2= −7.8 x ln2) on motor function at 24 
months. In non-ECMO- treated patients, the SNAP-II score was significantly associated 
with cognition and motor function at 12 months. At 24 months, low SES and non-Dutch 
ethnicity were associated with poor cognition, and low SES and LoS were associated 
with poor motor function (Supplementary Table 3a). In Rome, longer LoS was signifi-
cantly associated with cognition at 12 months (B −13.7; 95% CI: [−21.2 to −6.2]) and 
24 months (B −10.2; 95% CI: [−20.0 to −0.4]), and longer LoS and motor function at 12 
months (B −9.5; 95% CI: [−17.7 to −1.4]) and 24 months (B −16.7, 95% CI: [−25.1 to −8.2]).
DiSCUSSion
This longitudinal study was performed in two European high-volume centers that use 
the same neonatal treatment protocol1 in high-risk CDH patients. We found normal cog-
nition in 78% of children aged 12 months in Rotterdam and 95% in Rome. At 24 months 
this was 71% in Rotterdam and 97% in Rome. Normal development of motor function 
occurred in 64% in Rotterdam and 82% in Rome at 12 months. At 24 months, this was 
46% in Rotterdam and 90% in Rome.
A few cross-sectional studies have reported neurodevelopmental outcome in CDH pa-
tients8-10,19. Danzer et al. reported delayed cognition in 32% of 41 children, assessed with 
BSID-II or BSID-III at a median age of 24 months9, and 24% of 42 prospectively enrolled 
patients at 2-4 years assessed with BSID-III8. The prevalence of cognitive problems us-
ing similar outcome categories was comparable for Rotterdam, whilst fewer patients in 
Rome had cognitive delays. It is possible that patients in the study by Danzer et al. were 
more severely ill since they were ventilated longer and more infants received ECMO8. 
In a multicenter study by Wynn et al., mean cognitive scores –obtained with BSID-III in 
48 CDH patients at 24 months – were significantly below normal (mean 93; SD 15)19. We 
found the same trend; although different BSID versions were applied, results from Rot-
terdam are comparable and results from Rome are better. Many factors may contribute 
to cognitive delay in CDH. Consistent with previous studies, low SES was a significant 
determinant of cognitive delay19. Previously reported predictive factors, such as tube 
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feeding at discharge and ECMO need19, were not confirmed in our study. However, fail-
ure to reach statistical significance for ECMO need may have been due to the fact that 6 
survivors needed ECMO treatment.
In general, impaired motor function is more frequent than cognitive problems in CDH. 
Our results on motor function were more favorable than those of Danzer et al., who 
reported mild (23%) and severe (31%) delay on motor function at 24 months9. Friedman 
et al.3 reported motor problems in 60% at 1 year and 73% at 3 years. They retrospectively 
evaluated medical records documenting motor function. It is conceivable that standard-
ized developmental assessment would have given other outcomes. On the other hand, 
Wynn et al.19 found that motor function at 24 months was significantly lower than the 
population norm (mean 95; SD 11), which is comparable to Rome. Scores in Rotterdam, 
however, were on average 12 points lower. We could not confirm their results of adverse 
motor function in patients with low SES, but could confirm the result of another study4 
that LoS was associated with poorer motor function.
The strengths of our study were that children were treated according to a standardized 
protocol1 and followed in a prospective, longitudinal, standardized follow-up program. 
We collected data on ethnicity and SES, which are well-known modifiers of neurodevel-
opmental outcome19.
Neurodevelopmental outcomes were different between the centers, and changes 
between the two measurement moments were only seen in Rome. We suggest three 
possible reasons. The first is the use of different assessment instruments. Since recent 
studies reported that BSID-II and BSID-III are not comparable20, we refrained from pooling 
the data. In the transition from BSID-II to BSID-III, 23 items from the BSID-II mental scale 
were moved to the BSID-III fine motor scale. Thus, with a higher proportion of items in 
the fine motor function domain in BSID-III compared to BSID-II (48 vs 28%, respectively) 
the fine motor score contributes relatively much to the total motor composite score in 
BSID-III. This is reflected by the fact that in Rome gross motor scores are lower than fine 
motor scores at both ages. We assume that the outcome for patients who have a devel-
opmental delay in both cognition and motor function will not be very different for the 
two BSID versions. However, results may differ for patients with CDH, who will typically 
show impaired motor function. Moreover, recent studies showed differences in refer-
ence scores of BSID-III between populations21,22. These considerations possibly explain 
the underestimation of neurodevelopmental delay in Rome. We have few standardized 
neurodevelopmental tests with population-matched reference data and the best option 
seems to compare neurodevelopmental outcome with healthy reference populations 
in each country. The use of American reference data in Rome might also have caused 
bias. In another study, neurodevelopmental outcomes were not different from those of 
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healthy matched controls aged 12 and 36 months10. Disease-determining parameters 
were not reported, which precludes comparison with our study.
Second, professional background may have played a role. In Rotterdam, motor function 
at 24 months was assessed by a pediatric physical therapist, whereas in Rome assess-
ments were performed by developmental psychologists. Since results of our study did 
not significantly differ from the PDI assessed by developmental psychologists in a previ-
ous study of our group11, we assume that this may not fully explain differences in motor 
function. Moreover, this contradicts our assumption that neurodevelopmental outcome 
has worsened due to survival of severely ill patients2.
Third, center-specific differences may have played a role. Although both tertiary inten-
sive care centers have a comparable referral area, patients from Rotterdam may have 
been more critically ill than those from Rome (higher proportion of large diaphrag-
matic defects and higher patch use). However, SNAP-II scores and observed to expected 
lung-to-head ratio were not significantly different. The surgical approach differed, too. 
Primarily, a thoracoscopic approach was performed in more than 50% in Rotterdam 
versus open surgery in all patients in Rome. A randomized controlled trial of open 
versus thoracoscopic repair in CDH concluded that thoracoscopic repair was associated 
with more prolonged and severe intraoperative hypercapnia and acidosis than open 
surgery23. Moreover, only in Rotterdam was ECMO available. Since only 6 survivors re-
ceived ECMO and patient characteristics did not significantly change after exclusion of 
these children, we assume that this hardly contributes to the outcome differences. The 
influence of center-specific differences such as surgical care on neurodevelopmental 
outcome remains speculative, but these observations emphasize the need for multi-
center studies with standardized protocols. Since scores in Rotterdam slowly deteriorate 
at 24 months, and it is known that early adverse development in children with major 
congenital anomalies is predictive of development at 5 years5, follow-up was planned 
for patients from Rotterdam.
Next to the differences in study design, the fact that not every child was tested at both 
time points could be considered a limitation. However, the numbers of drop-outs were 
relatively low and the use of linear mixed models in the analysis over time accounted for 
missing data, provided that these outcomes were missing at random24.
Interpreting outcomes in the context of international multicenter studies is difficult 
if the follow-up program is not standardized. International guidelines on standardiza-
tion of follow-up programs in CDH, however, are still lacking. So far, the international 
CDH registry25 collects only prenatal, perinatal and early postnatal data. We recommend 
setting up standardized follow-up programs using population-appropriate reference 
data and similar assessment instruments as well as assessments performed by profes-
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sionals of the same background. In multicenter collaboration, video assessments should 
be included in the training sessions. We like to make an appeal for not only interna-
tional standardization of postnatal care, but also for follow-up care beyond the neonatal 
period, as this is essential to improve outcome for CDH patients. This would require 
standardization of treatment protocols and decision flowcharts of referring criteria to 
pediatric physical therapists/ speech-language pathologists should be involved. More-
over, children should be followed up to adolescence since deficits may worsen.
In conclusion, although most CDH patients have normal neurodevelopment within the 
first 2 years of life, they are at risk for impaired motor function. Standardization of mul-
ticenter long-term follow-up programs using standardized assessment instruments and 
stratification to illness severity is necessary to compare neurodevelopmental outcomes 
between centers and to evaluate long-term effects of interventions.
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Supplementary table 1a – Background characteristics (selection of no ECMO treated patients)
Rotterdam
(n=43)
Rome
(n=39)
p-value
Perinatal and postnatal
LHR 2.0 (0.9) 2.2 (0.8) 0.52
Missing 13 13 
O/E LHR 52.5 (17.9) 53.3 (15.8) 0.88
Missing 18 13 
Male sex 24 (55.8%) 25 (64.1%) 0.45
Birth weight (kg) 3.03 (0.58) 2.99 (0.41) 0.69
Born before 37 weeks of gestation 7 (16.3%) 4 (10.3%) 0.42
SNAP-II score 18 (12) 13 (9) 0.09
Age at repair (days) 3.5 (2.5) 3.6 (2.1) 0.77
Left sided CDH 39 (90.7%) 38 (97.4%) 0.20
Liver: intrathoracic 14 (32.6%) 12 (30.8%) 0.86
Defect size 0.57
A 5 (11.6%) 4 (10.3%)
B 18 (41.9%) 22 (56.4%)
C 18 (41.9%) 11 (28.2%)
D 2 (4.7%) 2 (5.1%)
Patch repair 29 (67.4%) 11 (28.2%) <0.001
Defect size A n=1 n=0
Defect size B n=8 n=1
Defect size C n=18 n=8
Defect size D n=2 n=2
Initial ventilation 0.68
CMV 24 (55.8%) 20 (51.3%)
HFO 19 (44.2%) 19 (48.7%)
Length of ventilation (days) 7 (1- 177) 8 (2- 70) 0.10
Length of initial hospital stay (days) 21 (6- 387) 30 (15-161) 0.11
CLD 0.21
No CLD 29 (67.4%) 32 (82.1%)
Mild CLD 8 (18.6%) 2 (5.1%)
Moderate CLD 1 (2.3%) 0 (0%)
Severe CLD 5 (11.6%) 5 (12.8%)
Length of morphinomimetics/ sedatives 0.10
< 1week 25 (58.1%) 14 (35.9%)
1 week- 1 month 16 (37.2%) 20 (51.3%)
> 1 month 2 (4.7%) 5 (12.8%)
Episodes of general anesthesia 0-24 months 1 (1- 12) 1 (1- 3) 0.09
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Supplementary table 1a – (continued)
Rotterdam
(n=43)
Rome
(n=39)
p-value
At discharge
Tube feeding 23 (53.5%) 20 (51.3%) 0.84
Physical therapy at home 14 (32.6%) 7 (17.9%) 0.13
Speech language pathologist involved 14 (32.6%) 3 (7.7%) 0.006
Demographic variables
Ethnicity 0.15
Native 30 (69.8%) 33 (84.6%)
Non-native 12 (27.9%) 6 (15.4%)
Unknown 1 (2.3%) 0 (0%)
SES mother 0.17
Low 8 (18.6%) 9 (23.1%)
Medium 15 (34.9%) 21 (53.8%)
High 17 (39.5%) 9 (23.1%)
Unknown 3 (7.0%) 0 (0%)
* Comparison between Rotterdam and Rome. Categorical variables are shown as n (%) and compared be-
tween centers between centers using chi-square tests, normally distributed variables are shown as mean 
(SD) and compared between groups using independent samples t-tests, and continuous variables that 
are not normally distributed are shown as median (range) and compared between centers using Mann-
Whitney U tests. Abbreviations: LHR: lung to head ratio. O/E LHR: observed to expected lung to head 
ratio. SNAP-II score: Score for Neonatal Acute Physiology-II14. CDH: congenital diaphragmatic hernia. CMV: 
conventional mechanical ventilation. HFO: high frequency oscillation. CLD: chronic lung disease15.
Supplementary table 1b – Episodes of general anesthesia 0-24 months and associated anomalies
rotterdam
n=49
rome
n=39
EPISODES OF GENERAL ANESTHESIA 0-24 MONTHS
CDH repair
Primary 49 49
Recurrence 16 3
ECmo related
ECMO cannulation* 7 0
ECMO cannulation removal* 7 0
Other ECMO related procedures 1 0
Ventilation related
Tracheostomy 5 0
Laryngeal tracheal cleft operation 0 1
Gastro-intestinal related
Laparotomy (including 2nd and 3rd looks) 9 5
Nissen fundoplication 4 2
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Supplementary table 1b – (continued)
rotterdam
n=49
rome
n=39
Gastrostomy 2 1 (during a Nissen)
Ileostomy or colostomy closure 2 0
Esophageal dilatation after Nissen fundoplication 1 0
Laparoscopy because of ileus 1 0
Posterior sagittal anorectoplasty 1 0
Anal dilatation 1 0
Diagnostic procedures
Laryngotracheoscopy 5 0
Heart catheterization 4 0
Cystoscopy 3 0
Urodynamic investigation 2 0
Change of tracheal cannula 1 0
Bronchoscopy 1 0
other
Central venous line/ Broviac catheter placement 9 0
Orchidopexy/ orchidectomy 4 3
Hernia inguinal repair 3 0
Hypospadia 1 0
Bladder exstrophy procedure 0 1
Incisional hernia repair 1 0
Adenotonsillectomy 1 0
Surgical treatment of abscess 1 0
*1 patient had a second ECMO run.
ASSOCIATED ANOMALIES
Cardiopulmonary related
Partial Anomalous Pulmonary Venous Return and ASD 1 0
Very mild aortic bow hypoplasia 0 1
Very mild hypoplasia left pulmonary artery 0 1
Pulmonary sequester left basal 0 2
Atrial septal defect 0 2
Mild hydronephrosis (also partial ASD) 1 0
Urogenital related
Double system left kidney 1 0
Bladder hypotrophy, hypospadias, laryngeal cleft 0 1
other
Very mild epidermolysis bullosa 0 1
Anorectal malformation, bifid scrotum 1 0
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Supplementary table 1b – (continued)
rotterdam
n=49
rome
n=39
Generalized brain atrophy 1 0
Stroke left hemisphere 1 0
GENETIC/ CHROMOSOMAL ANOMALIES
Duplications/ deletions
Duplication in 1p21.2, duplication in 8q11.23 and deletion 2q37.3 1 0
Duplication in 15q11.2q13.1 1 0
Duplication in 10q26.13 1 0
Duplication in 2p13.1 and 8p11.21p11 1 0
Deletion in 16p13.3 and duplication 12p12.1 1 0
Deletion in 13q12.11 1 0
Supplementary table 2a – Neurodevelopmental outcome scores at 12 and 24 months (corrected for pre-
maturity) in no-ECMO treated patients
12 months 24 months
rotterdam
(n=***)
p-valuea rome
(n=38)
p-valuea rotterdam
(n=****)
p-valuea rome
(n=39)
p-valuea
Cognitive outcome* 99.7 (19.0) 0.91 97.9 (11.8) 0.28 98.4 (17.0) 0.57 102.1 (13.9) 0.36
Motor outcome* 89.0 (17.7) <0.001 93.2 (12.2) 0.002 83.7 (16.3) <0.001 98.2 (14.8) 0.45
Language outcome* – – 97.7 (8.6) 0.10 – – 97.7 (12.6) 0.26
Receptive language** – – 9.4 (1.7) 0.04 – – 10.2 (2.4) 0.60
Expressive language** – – 9.8 (1.9) 0.51 – – 8.9 (2.5) 0.01
Fine motor skills** – – 10.1 (2.1) 0.76 – – 10.5 (2.6) 0.23
Gross motor skills** – – 7.7 (2.5) <0.001 – – 8.9 (2.7) 0.01
a Outcome scores were compared to the expected normal score of reference population.
Rotterdam: BSID-II-NL. Rome: BSID-III.
* Mean (SD) of expected normal score of reference population is 100 (15).
** Mean (SD) of expected normal score of reference population is 10 (3).
*** Cognitive outcome: n=40. Motor outcome: n=38.
**** Cognitive outcome: n=37. Motor outcome: n=42.
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Supplementary figure 2a – Selection of no-ECMO treated patients
Neurodevelopmental outcome in CDH survivors at 12 and 24 months
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Supplementary table 3a – Selection of no-ECMO treated patients
Determinants of impaired neurodevelopmental outcome; results of linear regression models
independent variables
rotterdam rome
Parameter
estimate 95% CI
Parameter
estimate 95% CI
Cognition at 12 
months
SNAP-II score 0.7 0.1 to 1.3 0.1 −0.0 to 0.33
Length of hospital stay (d)* −8.3 −18.4 to 1.9 −13.7 −21.2 to −6.2
Tube feeding at discharge −2.8 −20.5 to 14.9 −1.9 −10.6 to 6.8
Ethnicity 20.2 −1.3 to 41.7 1.5 −8.1 to 11.1
SES mother
 Low −23.7 −47.5 to 0.2 1.9 −8.4 to 12.1
 Medium −1.3 −20.7 to 18.2 1.2 −7.7 to 10.1
 High** – – – –
Cognition at 24 
months
SNAP-II score 0.2 −0.3 to 0.6 0.0 −0.2 to 0.3
Length of hospital stay (d)* −4.7 −12.1 to 2.7 −10.2 −20.0 to −0.4
Tube feeding at discharge −4.8 −17.9 to 8.4 −4.1 −16.2 to 8.0
Ethnicity −24.9 8.0 to 41.9 −2.1 −15.5 to 11.4
SES mother
 Low −37.5 −56.9 to −18.1 −7.0 −21.3 to 7.4
 Medium −12.4 −26.9 to 2.0 −3.6 −16.0 to 8.7
 High** – – – –
motor function 
at 12 months
SNAP-II score 0.8 0.2 to 1.4 0.0 −0.2 to 0.2
Length of hospital stay (d)* −8.2 −19.6 to 3.1 −9.5 −17.7 to −1.4
Tube feeding at discharge −3.2 −20.1 to 13.7 −6.6 −16.1 to 2.8
Ethnicity 17.5 −4.7 to 39.6 3.6 −6.8 to 14.1
SES mother
 Low −6.7 −29.7 to 16.2 −3.1 −14.2 to 8.1
 Medium −1.7 −20.5 to 17.0 −2.4 −12.1 to 7.3
 High** – – – –
motor function 
at 24 months
SNAP-II score 0.5 0.0 to 0.9 0.1 −0.2 to 0.3
Length of hospital stay (d)* −7.3 −14.4 to −0.2 −16.7 −25.1 to −8.2
Tube feeding at discharge 1.8 −10.9 to 14.5 0.8 −9.7 to 11.3
Ethnicity 7.7 −5.9 to 21.3 2.1 −9.5 to 13.7
SES mother
 Low −17.5 −32.9 to −2.2 −0.2 −12.7 to 12.2
 Medium −3.5 −16.6 to 9.6 5.5 −5.2 to 16.2
 High** – – – –
Abbreviations: ECMO: extracorporeal membrane oxygenation. CI: confidence interval. SNAP-II score: score 
for neonatal acute physiology II. SES: socio-economic status. *Because of skewed distribution, these vari-
ables were log-transformed before including them into the linear regression model. **Reference category.
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ABStrACt
objective: We aimed to determine trends in survival over the last decade. Secondly, we 
compared patient populations and survival rates between four high-volume centres and 
investigated which factors were associated with survival.
Summary Background Data: Congenital diaphragmatic hernia (CDH) is a severe con-
genital anomaly with significant mortality.
methods: In four high-volume CDH centres from the CDH EURO Consortium, data from 
all CDH patients born between 2004- 2013 were analysed. The predictive value of vari-
ables known at birth, and influence of centre specific treatments (ECMO and FETO) on 
survival were evaluated in multivariable logistic regression analyses.
results: Nine hundred and seventy-five patients were included in the analysis; 274 pa-
tients (28.1%) died. ECMO was performed in 259 patients of whom 81 (31.3%) died. 145 
patients (14.9%) underwent FETO and from those 76 patients (52.4%) survived. Survival 
differed significantly between years (p=0.006) and between the four centres (p<0.001). 
In the multivariable logistic regression analysis, lung-to-head ratio, gestational age, 
ECMO, centre of birth, and year of birth were significantly associated with survival, 
whereas FETO was not.
Conclusions: There is a significant variability in survival over years and between cen-
tres which should be taken into consideration in the planning of future trials. Patient 
populations are highly different between centres which influences outcome. ECMO was 
significantly predictive for death, whereas FETO was not.
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introDUCtion
Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly with a high vari-
ability of outcome1. High-volume CDH centres achieve better survival rates as compared 
to low-volume CDH centres2. Moreover patient characteristics such as fetal liver position 
(intra-abdominal or intrathoracic)3, stomach position4, and lung-to-head ratio (LHR)5/ 
observed-to expected LHR6 (O/E LHR) and the diaphragmatic defect size7 are associated 
with outcome.
There are differences in opinion about whether extracorporeal membrane oxygen-
ation (ECMO) improves outcome as no specific trials have ever been conducted with 
the primary aim to evaluate the role of ECMO in the treatment specifically for high-risk 
CDH patients8,9. The UK ECMO trial has investigated the role of ECMO for neonates of 
whom only 19% of the included patients had CDH, and no significant difference in this 
subgroup on survival was found10. In a multicentre randomized clinical trial (RCT) of ini-
tial ventilation strategy, both centres with and without ECMO availability were included, 
and no difference in survival between those centres was observed11. In the trial, nine 
CDH centres were included with different CDH populations. Many CDH centres chose 
not to use ECMO because of poor outcome of infants requiring ECMO12. Therefore, an 
important question is how CDH populations vary between centres and how that influ-
ences outcome. Moreover in the last decade individual centres have reported their very 
high survival rates up to 95% for cases with late presentation but no long-term reports 
on the consistency of these numbers are available in the literature13.
In the most severe prenatally detected CDH cases, fetoscopic endotracheal occlu-
sion (FETO) may improve outcome14,15. Ruano et al. recently performed a RCT of FETO 
versus postnatal management and found in 20 severe CDH patients that survival was 
significantly better in the FETO group16. In the TOTAL trial (NCT01240057), whether FETO 
improves outcomes in severe and moderate CDH infants is being assessed17.
In four high-volume CDH centres with different treatment options and patient popula-
tions, we aimed to identify survival rates over the last decade. Secondly, we compared 
patient populations between four high-volume centres and investigated whether ECMO 
or FETO are associated with survival.
mEtHoDS
This is an observational cohort study in patients with CDH who were born between Janu-
ary 2004 and December 2013 and treated in four high-volume centres of the CDH EURO 
Consortium. The four centres were Rotterdam, London, Mannheim, and Rome. Since 
2008, all patients have been treated according to a standardized treatment protocol18, 
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although ECMO was only used routinely in some centres. In Rotterdam and Mannheim, 
ECMO therapy was available during the whole inclusion period, in Rome ECMO was 
available in 2013 only, and in London infants could be transferred to an ECMO centre.
FETO therapy was only offered within the context of research trials (NCT01240057) 
from 2010 onwards and before 2010 as compassionate use. Inclusion criteria for FETO 
are: isolated left-sided CDH and severe pulmonary hypoplasia defined as observed-to-
expected LHR <25% irrespective of the liver position as measured prior to 29 weeks+ 6 
days at the FETO centre. ECMO criteria are: inability to maintain preductal saturations 
>85% or postductal saturations >70%; increased PaCO2 and respiratory acidosis with pH 
<7.15 despite optimization of ventilatory management; peak inspiratory pressure >28 
cm H2O or mean airway pressure >17 cm H2O is required to achieve saturation >85%; 
inadequate oxygen delivery with metabolic acidosis as measured by elevated lactate 
>5 mmol/l and pH <7.15; systemic hypotension, resistant to fluid and inotropic therapy, 
resulting in urine output <0.5 ml/kg/h for at least 12–24 h; oxygenation index (mean 
airway pressure x FiO2 x 100/PaO2) ≥40 consistently present. Before 2008, in Mannheim, 
above mentioned ECMO criteria were different on oxygenation index (>35 for 0.5- 6 
hours) and pH (<7.25) or worse oxygenation or worse ventilation without strict limits.
Patient characteristics were retrieved from the medical records. Patient demograph-
ics, including prenatal diagnosis, LHR, FETO, gestational age, birth weight, gender, side 
of the defect, liver position (intrathoracic or intra-abdominal determined during surgical 
repair), type of repair (primary closure or patch repair), age at surgical repair, ECMO, ven-
tilation days in survivors, inhaled nitric oxide (iNO) and survival were collected. Survival 
during the first year of life was determined.
Statistical analysis
Patient characteristics are described as number (%) or median (interquartile range; 
IQR). To determine whether differences in the demographics of the four centres were 
statistically significant, chi-square tests for categorical data, or Kruskal-Wallis tests for 
continuous data were used. Mann-Whitney U tests for continuous data and chi-square 
tests for categorical data were applied to compare centre of birth and patient charac-
teristics that were known at birth between survivors and non-survivors. In these uni-
variate comparisons, year of birth was treated as a categorical variable. Independent 
associations between prenatal diagnosis, LHR, FETO, gestational age, gender, side of 
the defect, ECMO, centre, and year of birth (coded as a continuous variable) as inde-
pendent variables and survival were determined using multivariable logistic regres-
sion analysis. The goodness-of-fit of the logistic regression model was assessed using 
the Hosmer-Lemeshow test. Analyses were performed using SPSS 22.0 for Windows 
(SPSS, Inc., Chicago, IL). A two-sided p-value less than 0.05 was considered statistically 
significant.
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rESUltS
In the study period, 975 CDH patients were included. Overall, 274 patients (28.1%) patients 
died. A prenatal diagnosis was made in 820 (84.1%) patients. Prenatal diagnosis, LHR, FETO, 
gestational age, birth weight, gender, liver position at surgical repair, type of repair, age 
at surgical repair, ECMO, ventilation days in survivors, iNO and survival were significantly 
different between the four centres (Table 1). FETO was performed in 145 patients.
table 1 – Background characteristics 2004-2013
rotterdam
n= 195
london
n= 127
mannheim
n= 469
rome
n= 184
p-value
Prenatal diagnosis 139 (71.3%) 125 (98.4%) 407 (86.8%) 149 (81.0%) <0.001
lHr 1.47 (1.00- 1.99) 1.65 (1.33- 2.20) 1.60 (1.25- 1.99) 1.82 (1.44- 2.55) <0.001
fEto 9 (4.6%) 84 (66.1%) 48 (10.2%) 4 (2.2%) <0.001
Missing 0 (0%) 0 (0%) 108 (23.0%) 0 (0%)
Gestational age 
(weeks)
38.3 (37.1- 39.1) 35.7 (33.7- 38.6) 37.6 (36.1- 38.4) 38.0 (37.0- 39.0) <0.001
Birth weight 
(grams)
3000 (2598- 3239) 3200 (2345- 3600) 2870 (2480- 3210) 2930 (2600- 3230) 0.004
male gender 113 (57.9%) 58 (45.7%) 274 (58.4%) 112 (60.9%) 0.04
Side of the defect 0.11
Left 164 (84.1%) 115 (90.6%) 381 (81.2%) 151 (82.1%)
Right 31 (15.9%) 12 (9.4%) 83 (17.7%) 30 (16.3%)
Bilateral 0 (0%) 0 (0%) 3 (0.6%) 3 (1.6%)
Missing 0 (0%) 0 (0%) 2 (0.4%) 0 (0%)
liver position: 
intrathoracic
70 (40.2%) 48 (54.5%) 237 (58.5%) 48 (36.9%) <0.001
type of repair <0.001
Primary closure 42 (21.5%) 38 (43.2%) 88 (18.8%) 89 (48.4%)
Patch repair 132 (67.7%) 50 (56.8%) 306 (65.2%) 41 (22.3%)
No repair 21 (10.8%) 39 (30.7%) 64 (13.6%) 54 (29.3%)
Missing 0 (0%) 0 (0%) 11 (2.3%) 0 (0%)
Age at surgical 
repair (days)
4.0 (3.0- 6.0) 5.0 (3.0- 7.0) 6.0 (3.0- 12.0) 3.0 (2.0 - 4.0) <0.001
ECmo 62 (31.8%) 0 (0%) 196 (41.8%) 1 (0.5%) 0.01
Ventilation days in 
survivors
9.8 (6.0- 20.1) 13.0 (9.0- 18.0) 21.3 (11.0- 30.1) 9.0 (6.0- 15.0) <0.001
ino 105 (53.8%) 68 (53.5%) 266 (56.7%) 79 (43.2%) <0.001
Survival 142 (72.8%) 75 (59.1%) 370 (78.9%) 114 (62.0%) <0.001
Abbreviations: LHR: lung-to-head ratio; FETO: fetoscopic tracheal occlusion; ECMO: extracorporeal mem-
brane oxygenation; iNO: inhaled nitric oxide. Liver position was determined at surgical repair.
Data were presented as n (%), median (interquartile range).
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Overall, we found a significant difference in survival over the years (p=0.006) (Figure 
1). In Mannheim, 196 patients (41.8%) received ECMO and 153 (78.1%) of the ECMO-
treated patients survived. In Rotterdam 62 patients (31.8%) received ECMO and 25 
(40.3%) of the ECMO-treated patients survived. ECMO treated patients in Rotterdam 
had lower LHRs and more often a patch repair was performed compared to the ECMO 
treated patients in Mannheim. In Rome, ECMO was available from 2013 onwards, and in 
2013 one patient received ECMO who died. None of the patients from London received 
ECMO. ECMO use between survivors and non-survivors was not statistically significant. 
FETO was significantly more often used in non-survivors (25%) than in patients who 
survived (13%). Furthermore, survivors had significantly less often a prenatal diagnosis, 
survivors had significantly higher LHRs and gestational ages, and more often left-sided 
defects (Table 2).
In the multivariable logistic regression analysis, we found that lower LHR, lower ges-
tational age, ECMO, centre of birth and year of birth were significantly associated with 
death (Table 3). FETO was not significantly associated with death. The p-value of the 
Hosmer-Lemeshow test was larger than 0.05, indicating an adequate model calibration.
figure 1 – Survival of CDH by centre over the years
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table 2 – Background characteristics for survivors and non-survivors
Survivors
n=701
non-survivors
n=274
p-value
Prenatal diagnosis 570 (81.4%) 250 (85.0%) <0.001
lHr 1.73 (1.40- 2.20) 1.35 (1.00- 1.73) <0.001
fEto 76 (12.5%) 69 (25.2%) <0.001
Missing 92 (13.1%) 16 (5.8%)
Gestational age (weeks) 38.0 (37.0- 38.9) 37.0 (35.0- 38.0) <0.001
Gender 0.50
Male 405 (57.8%) 152 (55.5%)
Female 295 (42.1%) 122 (44.5%)
Side of the defect 0.02
Left 595 (84.9%) 216 (78.8%)
Right 103 (14.7%) 53 (19.3%)
Bilateral 2 (0.3%) 4 (1.5%)
Missing 1 (0.1%) 1 (0.4%)
ECmo 178 (25.4%) 81 (29.6%) 0.20
Centre <0.001
Rotterdam 142 (20.3%) 53 (19.3%)
London 75 (10.7%) 52 (19.0%)
Mannheim 370 (52.9%) 99 (36.1%)
Rome 114 (16.3%) 70 (25.5%)
Year of birth 0.01
2004 51 (58.6%) 36 (41.4%)
2005 69 (78.4%) 19 (21.6%)
2006 67 (63.2%) 39 (36.8%)
2007 58 (67.4%) 28 (32.6%)
2008 91 (81.2%) 21 (18.8%)
2009 74 (67.9%) 35 (32.1%)
2010 86 (75.4%) 28 (24.6%)
2011 76 (71.7%) 30 (28.3%)
2012 68 (75.6%) 22 (24.4%)
2013 61 (79.2%) 16 (20.8%)
Data are presented as n (%), or median (interquartile range).
Abbreviations: LHR: lung-to-head ratio; FETO: fetoscopic tracheal occlusion; ECMO: extracorporeal mem-
brane oxygenation.
Numbers do not always add up to the total number of the group because of missing data.
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DiSCUSSion
In this study of prospectively collected data, we showed that there is a variability in sur-
vival between the centres and years. Secondly, patient populations were highly different 
between high-volume centres and this influenced outcome. ECMO was significantly 
related to reduced survival, whereas FETO did not reach statistical significance in the 
multivariable analysis.
The survival rate of CDH has significantly increased in recent decades19. Where 50 years 
ago fewer than 50% of the patients survived20, nowadays about 75% of the patients 
survive21. Whereas in the 1980s significant improvements in survival were obtained by 
the introduction of delayed surgical repair22 and the ‘gentle ventilation strategy’ with 
permissive hypercapnia23, nowadays smaller improvement of survival rates may be 
reached by standardization of therapy and improvements such as medication for pul-
monary hypertension24. The survival rate was very different each year (Figure 1), though 
these differences can be partly attributed to sampling variance. The variation in survival 
rate demonstrated over the years emphasizes the importance of a sufficient inclusion 
period in future studies to prevent that the natural variability is considered a positive 
trial effect.
In the univariable analysis, we did not find a significant difference in ECMO use 
between survivors and non-survivors. In the multivariable analysis with correction for 
table 3 – Multivariable logistic regression analysis
Variable or 95% Ci p-value
lHr 4.30 2.98- 6.21 <0.001
fEto 0.67 0.36- 1.26 0.21
Gestational age 1.22 1.10- 1.35 <0.001
Gender 0.87 0.59- 1.29 0.87
Side 0.39
Left Ref
Bilateral 0.32 0.04-2.68 0.29
Right 1.27 0.73-2.20 0.40
ECmo 0.49 0.30- 0.81 0.005
Centre <0.001
London Ref
Rotterdam 1.70 0.73- 3.95 0.22
Rome 0.35 0.15- 0.79 0.01
Mannheim 3.39 1.61- 7.14 0.001
Year of birth 1.09 1.01- 1.17 0.03
Abbreviations: LHR: lung-to-head ratio; FETO; fetoscopic tracheal occlusion; ECMO: extracorporeal mem-
brane oxygenation; OR: odds ratio; 95% CI: 95% confidence interval; Ref: reference category.
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patient characteristics, however, we found that ECMO was significantly related to death. 
This may be explained by the fact that only the most severe CDH cases receive ECMO 
who subsequently die in approximately 50%. Therefore, the frequency of ECMO use is 
almost equally divided between survivors and non-survivors, thus no significant differ-
ences were expected in the univariable analysis. In the multivariable analysis, however, 
with correction for other patient characteristics, ECMO had a relatively large impact on 
survival.
The frequency of ECMO was very different between centres. In Mannheim 42% of the 
patients received ECMO and 78% of them survived, whereas in Rotterdam 32% of the 
patients received ECMO and only 41% of them survived. It may be that in Rotterdam in 
the most severe cases only, an ECMO procedure was initiated, whereas in Mannheim less 
severe CDH patients received ECMO, who would also have survived without ECMO. This 
is also supported by the fact that ECMO treated patients in Rotterdam had lower LHRs 
and more often a patch repair was performed compared to the ECMO treated patients 
in Mannheim. Moreover, despite standardized ECMO criteria including an oxygenation 
index of ≥ 4018 from 2008 onwards in both centres, differences in ECMO criteria before 
2008 are that in Rotterdam a slightly higher oxygenation index and lower pH were used 
as compared to Mannheim. In this retrospective study, most often the reason for initia-
tion of ECMO in Mannheim was based on worse oxygenation or worse ventilation with-
out documenting exact numbers. We can therefore doubt whether decisions to start 
ECMO therapy were strictly based on firm ECMO criteria18 in both centres. To identify for 
which subgroup of CDH patients would be most beneficial, predictive postnatal clinical 
models such as the SNAP-II score25 or the clinical prediction score by Brindle et al.26 may 
have additional value. Therefore future studies should focus on this subject.
The percentage of FETO use in the different centres was very different, and by far the 
highest percentage of FETO treated patients was observed in London, which is a FETO 
referral centre. FETO was significantly more often used in non-survivors than in patients 
who survived. However, in the multivariable analysis FETO was not significantly related 
to survival demonstrating FETO improves survival in high-risk fetuses. A recent random-
ized trial performed by Ruano et al. found improved survival in the 20 patients treated 
with FETO16, however the survival rate of 5% in the control group of 21 patients was 
extremely low. The TOTAL trial17 may give a definitive answer to the benefit of FETO for 
patients with severe CDH.
Patient characteristics were very different between the four centres. Despite correc-
tion for patient characteristics in the multivariable analysis, we still found that centre 
significantly influenced survival. This emphasizes the need for correction for centre in 
all analyses in future multicentre studies on CDH. High-volume CDH centres have more 
experience in treating CDH infants than low-volume centres thus outcomes between 
high-volume CDH centres may be more comparable. Strengths of the current study 
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were the relatively large sample size (n=975) over a long period of time in four different 
high-volume centres. Our study is limited by the fact that although treatment strategies 
in general remained constant during the study period after 2008, we cannot rule out 
the possibility that differences of treating physicians, nursing staff and training may also 
have influenced our results. Second, although it is well known that diaphragmatic defect 
size and O/E LHR are associated with outcome6,7, because of the start of the inclusion 
period in 2004, defect size was not documented for all patients. We think that analyses 
in future studies should also be corrected for this parameter7,21. However, since patch 
repair is more often performed in CDH patients with larger defect sizes, and patch repair 
was one of the collected parameters, an indication of defect size is provided.
In conclusion, variations in survival with differences in patient populations and over 
time between centres suggest that in future multicentre studies outcomes should be 
evaluated over a sufficient period of time and corrected for centre. Moreover, ECMO was 
significantly related to a decreased survival rate, whereas FETO was not.
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The research described in this thesis concerned a wide spectrum of clinical care issues 
after the introduction of standardized postnatal management of infants with congenital 
diaphragmatic hernia (CDH) in Europe1. Most studies were performed in a multicentre 
context: the CDH EURO Consortium, which is a collaboration between tertiary European 
centres with an expertise in CDH and the willingness to adhere to guidelines and con-
duct clinical studies to enhance the level of care in patients with CDH. In fact, for years 
the therapy is at best trial and error due to the lack of properly conducted studies. The 
number of participating centres has increased from 13 to 22 specialized CDH centres 
from all over Europe. Additional insight in ventilation strategies for CDH was obtained in 
the VICI-trial, a multicentre randomized clinical trial to identify the best initial ventilation 
strategy.
PrEDiCtion
Clinical prediction models
The high variability in severity of illness in CDH means that outcomes can differ widely 
among patients. Both parents and clinicians would like to have optimal insight in the 
prognosis of the individual patient as soon as possible. Ideally, the anomaly is detected 
early during gestation so that a more detailed expert evaluation can be performed to 
determine the location of the defect, the observed/expected lung-to-head ratio (O/E 
LHR), the position of the liver (intra-abdominal or intrathoracic), in addition to ruling out 
additional congenital anomalies and genetic syndromes2-5. Multidisciplinary prenatal 
counselling on the basis of the prognosis can then be offered to the parents. It contrib-
utes to guide them on decisions such as termination of pregnancy or foetal therapy. 
The role of fetal therapy for severe and moderate pulmonary hypoplasia in CDH is being 
investigated in the international randomized Tracheal Occlusion To Accelerate Lung 
growth (TOTAL) trial (NCT0240057)6.
We found that prenatal ultrasound lung measurements (observed-to-expected 
lung-to-head ratio (O/E LHR) can reliably predict survival and development of chronic 
lung disease in CDH survivors with a left-sided diaphragmatic defect. This is in line with 
studies from Jani and colleagues3,7,8. One of the strengths of our study is the two-centre, 
nationwide design in which postnatal neonatal treatment was standardized. Second, 
one single investigator performed all prenatal measurements. To study inter-observer 
variability of the O/E LHR measurements, a set of prenatal ultrasound measurements 
should be evaluated by several experienced investigators and their measurements 
should be compared.
The lung area in our study was measured by manual tracing of the limits of the lung 
(mm2). This measurement together with the head circumference were used to calculate 
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the O/E LHR. Other techniques to calculate the O/E LHR are the method by multiply-
ing the two longest perpendicular diameters, or by multiplying the anteroposterior 
diameter by the perpendicular diameter located at the midpoint. Britto et al. concluded 
that standardization of each of the measurements improved prediction of neonatal 
outcomes9. Therefore, a lack of standardization of prenatal lung measurements may lead 
to variations in the measurements and hence in accuracy of prediction.
Postnatally, the Score for Neonatal Acute Physiology-II (SNAP-II score) can be calculat-
ed after the first 12 hours of life. This clinical prediction score was initially developed for 
prematurely born neonates10, but previous retrospective and single-centre studies11-13 
found that it had predictive value in neonates with CDH as well. We confirmed this in a 
large multicentre cohort of prenatally diagnosed CDH patients with regard to survival 
and the need for ECMO support (chapter 3). A new finding is that the SNAP-II score after 
adjustment for several parameters including ECMO did not predict the development of 
BPD in surviving CDH infants. Since the SNAP-II score is based on physiological param-
eters during the first 12 hours of life and the development of BPD is also dependent on 
ventilator-induced lung injury, the time point of 12 hours after birth might be too early 
to predict BPD in survivors.
Apart from having a reliable predictive value, a prediction score should be quick and 
easy to calculate. Since it takes only two to four minutes to collect data of the six scoring 
items, the SNAP-II score meets this criterion. A prediction model like that of Brindle et 
al14 includes the presence of major cardiac anomaly, severe pulmonary hypertension 
and chromosomal anomaly, parameters for which several investigations such as genetic 
testing and echocardiography are needed. The results of these investigations are prob-
ably not yet known at 12 hours of life. Still, the combined results of both prediction 
models may well lead to a better prediction for CDH patients, which is an issue for new 
prospective studies. However, a perfect prediction of prognosis for the individual pa-
tient cannot be obtained. Clinical prediction scores such as SNAP-II cannot be used as a 
sole criterion for clinical decision making, such as initiation of ECMO. They nevertheless 
could be used for risk stratification.
Biomarkers
A biomarker is defined as “a characteristic that is objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic processes, or pharmacologic 
response to therapeutic intervention”15. An ideal biomarker should be easy to use, 
consistent in repetitive measurements with a high sensitivity and specificity for early 
detecting, and have cut-offs to allow for risk stratification in the individual patient. In 
the design of the VICI-trial, blood, urine and tracheal aspirate samples were collected 
at predetermined time points (days 1, 3, 7, 14 and 28). We were confronted with an 
organizational issue during this study in that the day 1 sample could be taken within the 
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time span of immediately after delivery until 24 hours after birth. The “baseline” level of 
a biomarker could therefore have been influenced by the timing of the measurement in 
relation to therapeutic interventions. Collection of the first sample as soon as possible 
after birth, for example from arterial umbilical cord blood may overcome this problem. 
In clinical practice, however, it may be difficult to achieve this when it is not clear who 
is responsible for sample collection since many clinicians are involved in clinical care. 
The result may be a large number of missing values. Dedicated researchers are crucial 
in such studies.
For the two biomarkers investigated (NT-proBNP and hs-Troponin T), reference 
ranges are available for infants, which vary widely, however, also depending on the 
assay used16-18. Therefore, data of CDH infants often fall in the normal range. In the 
individual patient it may be more useful to measure biomarkers over a period of time 
and relate the course to severity of illness in this period. For example, an increase or 
decrease of biomarker level after start of an intervention might provide information for 
the predictive effect on the outcome of that intervention. A combination of biomarkers, 
such as endothelin-119, vascular endothelial growth factor A (VEGF-A)20 and circulating 
microparticles from damaged endothelial cells (CD62e+)21,22 might have better predic-
tive value than a single biomarker in patients with pulmonary arterial hypertension and 
CDH. Non-invasive biomarkers, such as biomarkers that can be measured in exhaled 
breath or urine, would be preferable. Since urinary F2-isoprostance was independently 
associated with mortality in adult patients with PAH23 and fractional exhaled nitric oxide 
is shown to rise in concentration in response to therapy24, these biomarkers might also 
be useful in CDH patients.
trEAtmEnt
The most important milestones in the treatment of CDH are the introduction of ‘delayed 
surgical repair’25 and ‘gentle ventilation with permissive hypercapnia’26. Cartlidge et al. 
performed a study in 33 CDH patients who were treated by either early surgery or de-
layed surgery after preoperative stabilisation. The preoperative stabilisation was aimed 
at correcting acidosis and hypoxia, thereby reducing the severity of foetal circulation. 
Survival improved from 13% after early surgery to 53% after delayed surgery25. Wung et 
al found that permissive hypercapnia was successful in 15 infants suffering from persis-
tence of foetal pulmonary circulation and presenting with severe respiratory failure. All 
infants survived and only one of them developed chronic lung disease26. Ventilation was 
focussed on minimizing barotrauma and PaCO2 was not used as a controlling parameter. 
The most challenging aspects in the treatment of the individual patient with CDH nowa-
days are pulmonary hypertension and lung-related problems. Severe lung hypoplasia, 
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pulmonary hypertension and ventilator-induced lung injury are the most important risk 
factors of poor outcome. Ventilator-induced lung injury may lead to long-term pulmo-
nary dysfunction including BPD and chronic pulmonary hypertension27.
The primary outcome measure in the VICI-trial was ‘mortality or development of BPD 
by day 28’. BPD was defined according to the definition of Jobe and Bancalari (oxygen 
dependency at day 2828). It can be debated, however, that the term chronic lung disease 
is more appropriate in CDH infants. During early lung development, terminal airspaces 
are formed, which are divided by the process of secondary septation29. This progressively 
generates an increasing number of alveoli with smaller size, and thereby substantially 
increases the surface area over which gas exchange takes place. Arrest of alveolarization 
may lead to BPD. In preterm born neonates, BPD is characterized by a heterogeneous 
pattern of persistent airway inflammation, parenchymal fibrosis, oedema and abnormal 
pulmonary vascular development30. In CDH patients, not arrested alveolarization, but 
rather a structural defect in early foetal development causes pulmonary hypoplasia and 
maldevelopment of the lungs. Pulmonary hypoplasia in CDH is characterized by thick-
ened alveolar walls, increased interstitial tissue, reduced alveolar air space and reduced 
gas-exchange surface area31. In contrast to the lungs of prematurely born neonates, 
lungs of foetuses with CDH are not surfactant deficient32, and surfactant replacement 
therapy has no beneficial effect in term neonates with CDH33. Even in prematurely born 
neonates with CDH, surfactant replacement therapy did not improve survival rates34. 
Therefore, although in the VICI-trial BPD was used, the term chronic lung disease may be 
more appropriate to use in future studies of CDH patients.
Ventilation
Because of the abnormal lung development, ventilation remains a challenge in CDH 
infants. Ventilator-induced lung injury must be prevented so as to reduce the risk of 
pulmonary morbidity including BPD35. A prospective evaluation of lung function in 
CDH survivors found decreased expiratory flows and higher functional residual capacity 
within the first year of life, the latter of which was associated with longer duration of 
ventilation and higher mean airway pressure36. Moreover, in two studies in 98 CDH survi-
vors in total, longer duration of ventilation was associated with worse lung function37,38. 
None of these studies, however, addressed a possible impact of type of ventilation on 
lung function.
Two ventilation modalities were investigated in a multicentre international random-
ized clinical trial (chapter 6). The combined outcome of mortality or BPD in prenatally 
diagnosed CDH neonates born after a gestation of >34 weeks did not significantly differ 
between those who were initially ventilated by conventional mechanical ventilation 
(CMV) and those initially ventilated by high-frequency oscillation (HFO). In the CMV 
group, however, the duration of ventilation and inotropic support was significantly 
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shorter, and these neonates were less likely to receive vasoactive medication or phos-
phodiesterase type 5 inhibitors or be placed on ECMO.
Other ventilation modalities than CMV and HFO, such as (partial) liquid ventilation, 
might be better suited for patients with the most severe lung hypoplasia (chapter 7). 
Lung compliance can be improved by eliminating the air-liquid interface. Perfluorooc-
tylbromide, which has dense characteristics, can then gravitate to the dependent part 
of the lungs, so that collapsed regions are re-opened and the ventilation/perfusion ratio 
will improve39. On the other hand, spontaneous breathing, instead of routine intubation 
immediately after delivery, may be preferable in the less severely ill patients, so as to 
prevent ventilator-induced lung injury.
Although it was planned to include 400 infants with prenatally diagnosed CDH in the 
VICI-trial in three years, only 171 infants could be included in more than five years. In 
this period 619 CDH patients were born in one of the participating centres. Reasons for 
non-inclusion are summarized in Figure 1, distinguished in expected and unexpected 
non-inclusions.
The planned number of inclusions seemed reasonable since more than 600 patients 
were born in the study period. On the basis of the number of expected non-inclusions 
(192) still more than 400 patients could have been included. Expected non-inclusions 
are inevitable and should be taken into account, also in future trials. Only efforts to raise 
the consent rate may have any effect.
figure 1
VICI-trial
Total n=171
HFO
n=80 (46.8%)
CMV
n=91 (53.2%)
CDH patients 
Nov 2008- Dec 2013
n=619
Reason no inclusion (n=448):
Expected: n=192
Not inborn  n=61
Antenatally unknown n=41
No consent                  n=41
Gestational age <34 weeks    n=37
Associated severe anomalies       n=5
Antenatally expected renal problems   n=4
Severe cardiac anomaly                    n=3
Unexpected: n=256
Parents not approached for consent n=237
Logistical problem                        n=7
Unknown                                           n=5
Mother in labour before consent  n=4
Severe language problem         n=1
Died before ventilation started  n=1
Immediate need of ECMO        n=1
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Reasons for the unexpected non-inclusions can be divided into research infrastruc-
ture/ organisational issues and human factors. Logistical problems and failure to ask 
parents for consent are examples of the first category. In one high-volume centre, 
seeking consent was stopped two years after the start of inclusion because a dedicated 
researcher was no longer available. This has resulted in a loss of 237 possible inclusions, 
which highlights that a good research infrastructure is a crucial element in trials.
Second, next to enrollment problems, some practical issues were present. With regard 
to human factors, one limiting factor was the large amount of time needed to complete 
the case record form. In many centres, clinicians were responsible for this and other 
aspects of the trial, which took much time in addition to their clinical shifts. This has 
probably contributed to lower inclusion rates and “trial fatigue” after several years in 
some centres. Girling recommended to collect only data necessary for answering the 
trial questions, and to check the reliability of data40. Therefore, in future studies the 
variables in the case record form should be strictly selected. A second potentially rel-
evant human factor is discontinuity in management, and consequently communication 
between the centres, as three different study coordinators were involved over the five 
years’ enrollment period.
One of the measures taken to increase the inclusion rate was to include more CDH 
centres in the trial. In the end, 13 centres officially participated, but patient inclusion 
took place in only nine centres. What is more, two centres each included only one pa-
tient, and two other centres fewer than ten patients in more than five years. Thus, in only 
five centres, more than 10 patients per centre were included. Although much effort was 
invested in adding more CDH centres to participate in the trial, the increased inclusion 
rate was less than expected. Therefore, in future studies, the research infrastructure 
should be optimized before any centre could join such a trial.
Nevertheless, the inclusion rate of the VICI-trial was relatively high for a RCT on a 
severe congenital anomaly. It might have helped that participation was discussed with 
parents early during prenatal counselling and that parents had enough time to over-
think consequences and could ask questions in a later consultation. In future studies, 
this approach should be continued.
One of the strengths of the trial is the block randomization stratified per centre using 
a computer-generated randomization schedule for each centre by a 24-hour interactive 
web response system. Second, all patients were treated according to a standardized 
neonatal treatment protocol implemented prior to the start of inclusion. Zwitter et al 
recommended that the recruitment period should be short, and pointed out that unbi-
ased randomisation, attention to the treatment protocol and to the rules of good clinical 
practice and honest evaluation of experience are essential41. Our trial largely met these 
essential criteria. Although much effort should be undertaken to achieve standardized 
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treatment for all centres, it is very important in multicentre studies especially when they 
concern a rare disease or congenital anomaly such as CDH.
Other research groups also had problems in setting up and performing multicentre 
trials. For example, Brown et al. mentioned some of the above-mentioned issues and 
noted that their study would have been better facilitated by a working administrative 
relationship between centres established at an early stage42. The National Institutes 
of Health, also recognizing the huge effort needed to conduct multicentre trials, has 
established clinical trial planning grants to support researchers43. The European Com-
mission encourages to set up European reference networks (ERNs) and aims to join 
best specialists from across Europe to tackle complex or rare medical conditions that 
require highly specialised healthcare and a concentration of knowledge and resources44. 
If trials can be organized within such ERNs, and if support would be given to organize 
and maintain the research infrastructure, a part of research grants might be invested in 
research infrastructures.
Surgery
CDH used to be a surgical emergency, with surgical repair performed soon after birth 
when the infant was still unstable, based on a very mechanical concept that reduction 
of the intrathoracic contents would save the baby. From the 1980s onwards it was rec-
ognized that delayed surgical repair, after a period of clinical stabilization, improved 
survival rates25,45. Several triggers such as hypoxemia, hyperoxia (oxygen radicals and in-
flammation), and pulmonary vascular damage caused by mechanical ventilation sustain 
pulmonary hypertension through reactive vasoconstriction and vascular remodelling. 
Therefore, it would seem best to achieve optimal cardiopulmonary management and 
prevent further damage to the lung before surgical repair of the diaphragmatic defect 
is performed.
The CDH EURO Consortium members have reached consensus on criteria for surgical 
repair1. It would be interesting to evaluate whether this protocol is indeed followed for all 
patients in all participating centres. Different forms of surgical repair are possible: open 
repair via subcostal laparotomy/thoracotomy and minimal access surgery46. Advantages 
of the latter technique are better cosmetic results, less or at least no more postoperative 
pain and possibly improved respiratory compliance47-50. In a pilot randomized clinical 
trial of thoracoscopic versus open repair, however, thoracoscopic repair was found as-
sociated with prolonged and severe intraoperative hypercapnia and acidosis51. Besides, 
thoracoscopic repair is associated with significantly more recurrences52-54. Therefore, in 
many CDH centres thoracoscopic CDH repair is not performed and until research can 
prove that minimal access surgery is a safe procedure in CDH, it should not be performed 
outside a randomized trial. A major challenge for such a trial, next to the organisational 
problems of multicentre studies as described for the VICI-trial, would be the multidis-
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ciplinary collaboration with anesthesiologists, pediatric surgeons, neonatologists and 
paediatric intensivists.
Pulmonary hypertension
In infants with CDH, pulmonary vascular resistance often remains elevated after birth 
resulting in pulmonary hypertension. Elevated pulmonary vascular resistance can lead 
to right-to-left shunting, resulting in hypoxia and a difference in preductal and post-
ductal saturations55. It may be caused by either structural of functional abnormalities 
of pulmonary vasculature56. Consequences of pulmonary hypertension and pulmonary 
hypoplasia are the main determinants of survival, and therefore research has increas-
ingly focused on this topic57. The altered vasoreactivity in combination with pulmonary 
vascular remodelling and varying degrees of pulmonary vascular bed hypoplasia may 
account for the extremely challenging management of this form of pulmonary hyper-
tension57.
Several drugs that act upon the three different pathways involved in the development 
of pulmonary hypertension have been used for pharmacotherapy. Pharmacodynamic 
considerations in the treatment of pulmonary hypertension in infants were described 
in chapter 9. Nitric oxide (NO) is a selective vasodilator affecting the NO-cGMP pathway. 
Inhaled nitric oxide (iNO) improved oxygenation in infants with persistent pulmonary 
hypertension or severe hypoxic respiratory failure58,59, but so far has not shown a clear 
benefit in CDH infants60. Still many CDH centres use it as the first treatment choice in 
CDH patients with pulmonary hypertension. Moreover, since in one study more infants 
treated with iNO needed ECMO61, this therapy should be stopped if no effect is seen 
after its initiation. The non-response to iNO-therapy is relatively high, and medications 
targeting other pathways of pulmonary hypertension might therefore be more suit-
able. Sildenafil, for example, is a selective phosphodiesterase type 5 (PDE5) inhibitor 
and PDE5 enzyme specifically degrades cGMP. A Cochrane analysis found that sildenafil 
significantly decreased mortality in neonates with pulmonary hypertension62.
Increased endothelin-1 plasma concentrations have been found in neonates with per-
sistent pulmonary hypertension and in CDH infants19. Bosentan is an endothelin antago-
nist, thus involved in the endothelin pathway, and can improve pulmonary hypertension 
in neonates63. Bosentan is available only as an oral formulation, however, which limits 
its application in very ill infants with impaired absorption. An intravenous formulation 
might increase its potential in treatment of pulmonary hypertension. Prostacyclin and 
treprostinil, which target the prostacyclin pathway, improved pulmonary hypertension 
in infants64,65. Lastly, milrinone is a phosphodiesterase 3 (PDE3) inhibitor which induces 
pulmonary vasodilation by its action on cAMP in cardiac and vascular muscle cells. In 
six CDH infants with severe pulmonary hypertension, milrinone significantly improved 
systolic and diastolic function in the right ventricle, and decreased oxygenation index 
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without changes of blood pressure66. Randomized clinical trials evaluating the effects of 
pharmacological therapies specifically for infants with CDH who have severe pulmonary 
hypertension are still lacking.
monitoring of cardiopulmonary status
A two-dimensional echocardiography performed within the first 24 hours after birth 
remains the best modality to rule out the presence of cardiac anomalies, next to assess-
ing the right heart function and the degree of pulmonary hypertension67,68. Pulmonary 
hypertension is most classified by the definition of Keller et al19. This definition was 
also used in our studies based on data of the VICI-trial69. In the VICI-trial the degree of 
pulmonary hypertension was measured within the first 24 hours of life. It appeared 
that about two-thirds of the patients had already pulmonary hypertension at the time, 
possibly because they were still in the transitional phase from intra-uterine to extra-
uterine environment. Thus, to evaluate the persistence of pulmonary hypertension, 
echocardiographic assessment should also be performed at standardized time points 
later in life, for example at days 3, 7 and 14. A protocol describing measurements during 
echocardiographic evaluations should be developed to standardize the evaluation of 
severity of pulmonary hypertension, and assessment of ventricular function should be 
included in this protocol. An electronic system should be set up for training of individual 
centres to guarantee the level of evaluation.
Standardized treatment
Standardized treatment is the key to effective multicentre research. Standardized treat-
ment1 also significantly improved clinical outcome by lowering the mortality rate from 
33% to 12% in two high-volume centres70, and reducing the use of ECMO. In our studies, 
however, we found a higher mortality rate, which suggests that in the first years after 
implementation of the standardized protocol CDH patient populations with a relatively 
good prognosis were born.
Survival rates over the last decade in one high-volume CDH centre (Erasmus MC, Rot-
terdam, the Netherlands) are plotted in Figure 2. It is clear that there is a wide variation 
over the years. In the period after the inclusion period of Van den Hout et al70, survival 
decreased again for some years. Thus this reflects a variation of survival over the years 
and the importance of a sufficient inclusion period in future studies. Another important 
consequence is the power calculation of future studies on interventions to prevent mea-
suring the normal variation in survival which might be misinterpreted as a real effect of 
an alternative therapeutic approach.
Frequency of ECMO use and survival rates after ECMO over the last decade in the 
same centre are shown in Figures 3a and 3b. Figure 3a suggests that use of ECMO has 
decreased after the implementation of the standardized protocol. Since survival rates of 
248 • Chapter 13
ECMO-treated CDH patients are about 50%, it is recommended to initiate ECMO treat-
ment only in the most severe cases, based on the ECMO criteria from the protocol.
Chapter 10 of this thesis presents an update of this standardized treatment protocol. 
The effect on outcome of this updated protocol should be evaluated in the coming years. 
To guarantee that treatment in CDH is based on the most recent available evidence, the 
standardized neonatal treatment protocol should be renewed every 5 to 10 years during 
consensus meetings of the CDH EURO Consortium. Most of the recommendations are 
currently still based on expert opinions, and consensus meetings offer the opportunity 
to discuss conceptions and designs of future trials.
figure 2 – Survival over the years in Erasmus MC, Rotterdam, the Netherlands
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oUtComE
The study described in chapter 11 found that neurodevelopmental outcome was sig-
nificantly different between two high-volume CDH centres (Rotterdam71 and Rome72)73. 
Those two centres used standardized prospective long-term follow-up programs and 
the same standardized neonatal treatment protocol, but differed in assessment instru-
ments used (Bayley Scales of Infant Development (BSID) version 2 and 3), reference 
data, and experience of staff in follow-up care. Since those differences probably have 
contributed to the differences in outcome, this study highlights the importance of stan-
dardized follow-up programs next to standardized care. Recently, several studies have 
suggested that there are differences in outcome score between the BSID-II and BSID-
III74-78. For example, a healthy Australian cohort scored higher than the standardised 
norms on four of the subscales of BSID-III tests with American reference scores79, which 
may lead to underestimation of neurodevelopmental delays since minor delays may not 
be identified. Therefore, ideally nationwide reference scores should be developed from a 
healthy population for each of the countries in which assessment instruments are used. 
In future studies, internationally validated tests making use of country-specific reference 
values should be used so that neurodevelopment can be reliably compared between 
populations.
As resources are limited and standardized long-term follow-up programs are costly, 
ideally children at high risk for neurodevelopmental problems should be identified. 
Screening tools such as the Parent-report Perceived Cognitive Function (PedsPCF) or 
Ages and Stages Questionnaire (ASQ), which both can be filled in by parents, may con-
tribute to patient selection80. In paediatric oncology clinics, the PedsPCF significantly 
differentiated between patients with various clinical characteristics81. In a Dutch popula-
tion, the ASQ-3 identified most of the children without a developmental delay according 
to the BSID-III-NL82. It should be tested whether the PedsPCF and ASQ can reliably differ-
entiate between CDH patients with high and low risk of neurodevelopmental problems. 
If this should be the case, only patients with a high-risk on the PedsPCF test should then 
be assessed by BSID tests.
Next to neurodevelopmental problems, CDH survivors may suffer from long-term 
problems on other domains such as the gastrointestinal tract and the respiratory tract36,83. 
As mentioned earlier, a prospective evaluation of lung function in CDH survivors found 
decreased expiratory flows and higher functional residual capacity within the first year 
of life, the latter of which was associated with longer duration of ventilation and higher 
mean airway pressure36. Moreover, in two studies in 98 CDH survivors in total, longer du-
ration of ventilation was associated with worse lung function37,38. None of these studies, 
however, addressed a possible impact of type of ventilation on lung function. Spoel et al 
found in a small cohort of CDH survivors that functional and microstructural changes of 
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the lung persist into adulthood84. None of these studies, however, has addressed a pos-
sible impact of type of ventilation on lung function. Although we have not focused on 
long-term pulmonary morbidity in this thesis, it would be interesting to further explore 
this aspect.
In conclusion, risk stratification is essential to identify infants with subtle impairments 
who are at risk for long-term problems such as neurodevelopmental delays and pulmo-
nary morbidity. Possible determinants of long-term problems need to be established, 
therefore, such as long duration of hospital stay/ventilation time, low socioeconomic 
status and other ethnicity.
ConSiDErAtion
Multicentre research has advantages, but these can be undermined by centre-specific 
differences in for example the patient population and availability of treatment modalities, 
even though the same standardized neonatal treatment protocol is in place. In chapter 
12 we described that not in all high-volume CDH centres ECMO was available. Although 
ECMO criteria were included in the standardized neonatal treatment protocol, in one 
centre ECMO was used much more often used than in the other centre. Moreover, one 
centre often made use of fetoscopic tracheal occlusion (FETO), which is only reserved 
for the prenatally most severely ill patients. We have also shown that patient mix can 
have an impact on outcome, as even after correction for patient characteristics, centre 
of birth was still significantly associated with survival. Therefore, in future multicentre 
studies all analyses should be corrected for centre, next to patient characteristics that 
influence outcome. Differences in outcome between centres can partly be explained 
by differences in available treatment options such as ECMO and FETO. Moreover, ex-
perience in treatment options such as ECMO may account for differences in outcome 
between CDH populations.
The additional contribution of ECMO to outcome is still being debated. In the VICI-trial, 
mortality rates were not significantly different between centres with ECMO availability 
and centres without ECMO availability69. In 2006 a meta-analysis of randomized con-
trolled trials with small sample sizes indicated a reduction in early mortality with ECMO, 
yet did not demonstrate a long-term benefit85. The same study included a meta-analysis 
of the retrospective studies and concluded that the introduction of ECMO has improved 
survival in infants with CDH85. The use of ECMO has decreased in recent years86, with a 
shift to preoperative stabilization. The best suited mode (veno-arterial vs. venovenous) 
remains unclear87 and this aspect should be studied prospectively in a randomized trial. 
The still high morbidity in ECMO survivors, for example reflected by the fact that more 
than 90% of the patients developed BPD (chapter 3), suggests that only severely ill in-
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fants are kept alive by ECMO. Therefore, future studies should focus on the true benefit 
of ECMO in CDH; and if a benefit can be proven, criteria should be developed for the 
selection of patients who would benefit most from ECMO.
Another point of consideration is testing of the rate of compliance with the standard-
ized treatment protocol in each of the centres participating in a multicentre trial. For 
example, compliance with initiating an ECMO procedure when the ECMO criteria are 
met could be tested. If compliance would be found to be low in some of the centres, and 
outcomes of ECMO survivors would differ between centres, the ECMO criteria should 
perhaps be adjusted.
fUtUrE rESEArCH PErSPECtiVES
Since many aspects of the current treatment are based on expert opinion only and are 
not evidence-based, there is plenty of room for further research. Also taking into ac-
count the findings from the studies presented in this thesis, we propose the following 
recommendations, in line with the issues addressed in the four parts of this thesis:
Prediction
• Combining several prenatal and postnatal clinical prediction scores, such as the O/E 
LHR, prenatal liver position (intrathoracic/ intra-abdominal), SNAP-II score10 and the 
prediction model of Brindle et al14, may further improve risk stratification of CDH 
infants.
• Instead of the current “trial-and-error application” of biomarkers with possible 
predictive value in CDH, a pathophysiological based approach should be used. 
For example, since most CDH infants die from consequences of severe pulmonary 
hypertension, biomarkers in one of the three pathways involving development 
of pulmonary hypertension, such as VEGF or endothelin, should be considered. It 
should be studied whether biomarkers could predict cardiopulmonary status at later 
age (such as chronic pulmonary hypertension).
• Since routine measurements of biomarkers do not seem useful, future research 
should include a baseline level, such as umbilical cord blood, and study whether 
biomarker levels determined before and after the start of clinical interventions (such 
as iNO or ECMO) could better predict outcome.
treatment
• Regular communication between all participating centres in a multicentre trial 
is essential to evaluate patient inclusion rates and discuss practical problems that 
limit patient inclusion. For example in the form of three-monthly teleconferences on 
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the initiative of the coordinating centre. Then, each centre should report inclusion 
numbers so that interventions can be initiated if these are lagging behind.
• It might be useful to ask the advice of patient organisations on trial designs and 
research objectives from the patient’s perspective. Moreover, involving patient sup-
port groups in the information provision on clinical trials to future parents may help 
improve patient inclusion rates.
• Very low volume centres or centres with a lack of a research infrastructure should not 
participate in multicentre trials. Despite much effort to organize the participation 
of those centres (such as ethical committee consent), it is doubtful whether those 
centres indeed can enrol patients.
• A web-based portal should be set up for the international collection of data which 
all members of the CDH EURO Consortium can use to answer specific research ques-
tions. Electronical case record forms should be incorporated so that all changes can 
automatically be saved and no patient data are lost. The portal should also offer a 
central randomization procedure for future multicentre RCTs.
• A part of the budget for research should be invested in the research infrastructure 
and data management, for example to cover the salary of a dedicated researcher or 
research nurse. This will ensure the continuity of patient inclusion and continuity 
of (blood) sampling, independent of working hours or presence of the responsible 
clinician.
Next to the above-mentioned recommendations for future multicentre trial designs, 
several randomized clinical trials on important aspects of CDH can be proposed to 
further improve outcome;
• Pulmonary hypertension: Model-based dosing with population pharmacokinetic 
models of commonly used drugs such as sildenafil should primarily be defined. Then, 
a multicentre randomized clinical trial should be initiated to identify the optimal 
treatment strategy of severe pulmonary hypertension in CDH infants; for example 
early intravenous sildenafil versus inhaled nitric oxide.
• Extracorporeal membrane oxygenation: RCT on ECMO versus no ECMO treatment in 
CDH patients who fulfil the ECMO criteria1.
• Surgical repair: Minimal access surgery versus open repair in selected CDH patients 
(left sided, liver down). Importantly, standard operative procedures should be devel-
oped, as well as follow-up programs to evaluate intra- and postoperative morbidity 
including recurrences, musculoskeletal abnormalities and neurodevelopment. The 
cost-effectiveness of both strategies, including direct and indirect costs, should also 
be addressed.
General discussion • 253
Ch
ap
te
r 1
3
outcome
• Most importantly, in the coming years centres should focus on international standard-
ization of follow-up programs on cardiopulmonary status and neurodevelopment, 
which should include standardized cardiac evaluation and standardized neurodevel-
opmental assessment tests. It would be interesting to find if and how ventilation strat-
egy influences long-term pulmonary morbidity. Therefore, CDH survivors from the 
VICI-trial should be examined at later age by lung imaging, cardiopulmonary exercise 
tests and lung function tests, next to standardized neurodevelopmental assessment.
• Because of limited resources, a minimal generic dataset on risk stratification for the 
different domains of morbidity should be developed to identify patients who are at 
highest risk for long-term problems.
• Centre-specific “specialties” as research approaches may be helpful to answer many 
research questions in a relatively short period of time.
• A system for international data collection should provide for electronic data transfer 
to expert centres.
ConClUSionS
In conclusion, there is a huge need for multicentre research. Since CDH is a rare con-
genital anomaly, multicentre collaboration is necessary to evaluate significant numbers 
of patients over time. Preferably, future randomized clinical trials should be performed 
in multicentre collaboration. CDH centres participating in the CDH EURO Consortium 
are listed in the appendix and their logos appear in Figure 4. Standardized treatment 
between centres is essential to evaluate patient populations and to ensure that infants 
are treated according to the latest evidence. Therefore, the treatment protocol should 
regularly be updated during consensus meetings. In addition, monitoring including 
cardiac assessment and follow-up programs should be standardized between centres. A 
good research infrastructure providing for sufficient financial resources and data man-
agement is essential for multicentre collaboration. In this thesis we have shown that 
despite of practical problems, multicentre collaboration is possible and can indeed lead 
to improved insights and thereby improved clinical outcome.
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APPEnDix
Members of the CDH EURO Consortium Group:
Austria, Graz, Medical University Graz: B. Urlesberger; Belgium, Leuven, University Hospital 
KU Leuven: K. Allegaert, A. Debeer and J. Deprest; Canada, Manitoba, University of Manitoba: 
R. Keijzer; France, Paris, Hôpital Antoine-Béclère: A. Benachi; France, Lille, Hôpital Jeanne 
de Flandre, L. Storme; France, Paris, South Paris University Hospitals: P. Tissieres; Germany, 
Bonn, Universitätsklinikum Bonn, F. Kipfmueller; Germany, Mannheim, Universitätsklinikum 
Mannheim: T. Schaible and L. Wessel; Ireland, Dublin, Our Lady’s Children’s Hospital: C. Breat-
nach; Scotland, Glasgow, Royal Hospital for Sick Children: N. Patel; Italy, Milano, Fondazione 
IRCCS Cà Granda, Ospedale maggiore policlinico, E. Leva, F. Ciralli; Italy, Rome, Bambino Gesu 
Children’s Hospital: P. Bagolan, I. Capolupo, A. Dotta, F. Morini, A. di Pede; Norway, Oslo, Oslo 
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The research described in this thesis addressed several aspects of the management of 
congenital diaphragmatic hernia (CDH) after the introduction of a standardized neonatal 
treatment protocol. Most studies involved multicentre collaborative efforts of members 
of the CDH EURO Consortium. This is a collaboration between tertiary European centres 
with an expertise in CDH.
Part ii focusses on clinical parameters and biomarkers with a potential predictive role. 
In part iii different aspects of the treatment of CDH patients are described, including 
findings of a randomized clinical trial on initial ventilation strategy. Part iV studies the 
neurodevelopmental outcome in high-risk CDH infants at the ages of one and two years. 
In Part V the influences of patient characteristics and center specific differences are 
evaluated with respect to outcome.
PArt i – introDUCtion
In Chapter 1 the history of CDH is described, and attention is paid to the antenatal period 
in which the diaphragmatic defect should be discovered by prenatal ultrasonography. 
Antenatal predictive markers for outcome such as the lung-to-head ratio (LHR) and 
observed-to-expected LHR (O/E LHR) are explained. In the postnatal period the focus 
is on clinical prediction models including their limitations, next to biomarkers related 
to pulmonary hypertension. The way in which the CDH EURO Consortium was founded 
is described, as well as achievements such as consensus on the standardized neonatal 
treatment protocol and initiation of a randomized clinical trial on initial ventilation strat-
egy. Then, a short overview of morbidity and neurodevelopment related to CDH. Lastly, 
differences between CDH centres such as availability or unavailability of extracorporeal 
membrane oxygenation (ECMO) are discussed.
PArt ii – PrEDiCtion
Chapter 2 describes a nationwide study in the Netherlands on the predictive role of 
the O/E LHR on survival of CDH infants in an era of standardized postnatal treatment. 
O/E LHR was measured using 2D ultrasonography at ≤24 weeks gestational age (GA), 
between 24-30 weeks GA, and ≥30 weeks GA by one single observer who performed all 
prenatal measurements. The first measured O/E LHR per patient significantly predicts 
survival and development of chronic lung disease in survivors (defined as oxygen de-
pendency at day 28). Longitudinal analyses of the O/E LHR measurements over time 
during gestation showed no significant association with survival.
264 • Chapter 14
Chapter 3 concerns a prospective study of 171 prenatally diagnosed CDH patients 
in which we found that the Score for Neonatal Acute Physiology– II (SNAP-II) predicts 
mortality and need for ECMO, after adjustment for side of the defect, liver position, 
ventilation mode, gestational age, centre, and O/E LHR. This simple and rapid scoring 
system provides further insight into the prognosis within one day after birth.
Sphingolipid profiles were investigated in chapter 4. Tracheal aspirates were collected 
at days 1, 3, 7, and 14 in 72 patients from four centres. In multivariable logistic regression 
analysis with correction for side of the defect, liver position and O/E LHR, none of the 
changes in sphingolipid levels was significantly associated with mortality/development 
of bronchopulmonary dysplasia. At day 14, long-chain ceramides 18:1 and 24:0 were 
significantly elevated in patients initially ventilated by conventional mechanical ventila-
tion compared to high-frequency oscillation, which could be explained by high peak 
inspiratory pressures and remodelling of the alveolar membrane.
In chapter 5, the value of high-sensitivity Troponin T (hsTnT) and N-terminal pro-brain 
natriuretic peptide (NT-proBNP) as predictive biomarker was investigated at days 1, 3, 7, 
and 14. In the multivariable analysis with correction for multiple testing, none predicted 
severe pulmonary hypertension, death, need for ECMO or bronchopulmonary dysplasia. 
Future research should study whether biomarker levels determined before and after the 
start of clinical interventions (such as start of iNO or initiation of an ECMO procedure) 
could better predict outcome.
PArt iii – trEAtmEnt
In chapter 6, a multicenter international randomized clinical trial on initial ventilation 
strategy is described. The trial included 171 prenatally diagnosed CDH infants born 
after a gestational age of more than 34 weeks. They were randomized to either high-
frequency oscillation (HFO) or conventional mechanical ventilation (CMV). The primary 
outcome measure was bronchopulmonary dysplasia (BPD)/ death at day 28. Forty-one 
(45.1%) of the 91 patients randomized to CMV died/ had BPD compared with 43 (53.8%) 
of the 80 patients in the HFO group. The odds ratio for death/ BPD for CMV vs. HFO was 
0.62, after adjustment for centre, head-lung ratio, side of the defect, and liver position. 
Patients initially ventilated by CMV were ventilated for fewer days, less often needed 
ECMO support, inhaled nitric oxide, sildenafil, had a shorter duration of vasoactive drugs 
and less often failed treatment as compared with infants initially ventilated by HFO. A 
major limitation was that the calculated sample size was not achieved due to limited 
financial resources and a lack of research infrastructure in one high-volume centre.
An editorial on liquid ventilation is presented in chapter 7. This editorial was based on 
a laboratory study of fetal instillation of perfluorocarbon in rabbits with induced CDH. 
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We reviewed studies on liquid ventilation in CDH and concluded that once adverse long-
term effects of liquid ventilation have been excluded, a randomized clinical trial for the 
most severe CDH cases could be the next step.
Chapter 8 describes the prenatal and postnatal clinical course of five newborns with a 
prenatal diagnosis of CDH who were not routinely intubated immediately after birth. We 
concluded that this strategy is feasible in a selected subgroup of CDH infants (LHR >2.5 
or O/E LHR >50%, liver down) depending on the nature of the child’s transitional phase.
Pulmonary hypertension is the major cause of death in infants with CDH. In chap-
ter 9 we reviewed pharmacodynamics of drugs used in the treatment of pulmonary 
hypertension in infants. We concluded that reliable data of pharmacodynamics tested 
in adequate series or in randomized controlled trials in children are lacking for most of 
these drugs.
Chapter 10 provides an update of the original standardized neonatal treatment 
protocol published in 2010. Consensus was reached between the 22 centres of the 
CDH EURO Consortium. Five experts individually determined the levels of evidence. 
Differences in opinion were discussed until full consensus was reached. Key updated 
recommendations are: 1) planned delivery after a gestational age of 39 weeks in a high-
volume tertiary centre; 2) neuromuscular blocking agents should be avoided during 
initial treatment in the delivery room; 3) adapt treatment to reach a preductal satura-
tion between 80- 95% and postductal saturation >70%; 4) target PaCO2 to be between 
50- 70 mmHg; 5) conventional mechanical ventilation is the optimal initial ventilation 
strategy; and 6) intravenous sildenafil should be considered in CDH patients with severe 
pulmonary hypertension.
PArt iV – oUtComE
In an observational, prospective cohort study, presented in chapter 11, neurodevelop-
mental outcome was evaluated of 88 high-risk CDH patients treated according to the 
standardized neonatal treatment protocol. Patients from two centres in the CDH EURO 
Consortium (Rotterdam or Rome), were included. Cognition and motor function were 
assessed with the Bayley Scales of Infant Development (BSID). In Rotterdam the BSID-
II version with Dutch normative data was used and in Rome the BSID-III version with 
American normative data was used. At 12 months, cognition was normal in 77.8% of 
children from Rotterdam and in 94.8% from Rome; at 24 months, in 70.7% and 97.4%, 
respectively. Motor function was normal in 64.3% of children from Rotterdam and in 
81.6% from Rome at 12 months, and in 45.7% and 89.8%, respectively, at 24 months. 
These striking differences between the two centres warrant careful interpretation of 
results for other centres. Future multicentre collaboration should not only focus on 
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standardization of postnatal care but also on international standardization of follow-up 
to identify risk factors and thereby reduce morbidity.
PArt V – ConSiDErAtion
In chapter 12, differences between patient populations from four high-volume centres 
(two of which with ECMO availability) were retrospectively evaluated. 975 CDH patients, 
born between 2004 and 2013, were included. We found a significant variability in 
survival over the years and between centres. Characteristics of the patient populations 
were highly different between centres, which influences outcome. Therefore we sug-
gested that in future multicentre studies outcomes should be evaluated over a sufficient 
period of time and corrected for centre.
PArt Vi – GEnErAl DiSCUSSion
The general discussion in chapter 13 addresses the research described in this thesis 
in connection with the literature, as well as the implications for future multicentre re-
search. Both the strengths and limitations of the presented studies are discussed. The 
major findings and recommendations are the following:
– Multicentre collaboration is essential in a relatively rare congenital anomaly such as 
CDH.
– Standardized treatment between centres is essential to evaluate patient popula-
tions.
– Crucial for multicentre research collaborations is a good research infrastructure 
including financial resources and data management.
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nEDErlAnDSE SAmEnVAttinG
Het onderzoek van dit proefschrift beschrijft verschillende aspecten van congenitale 
hernia diaphragmatica (CDH) na de introductie van een gestandaardiseerd neonataal 
behandelingsprotocol. De meeste studies betreffen multicenter samenwerkingsverban-
den van het CDH EURO Consortium. Dit is een samenwerking tussen tertiaire Europese 
centra met een expertise in CDH.
Deel ii richt zich op klinische parameters en biomarkers met een mogelijk voorspel-
lende waarde. In deel iii worden verschillende aspecten van de behandeling van CDH 
patiënten beschreven, waaronder de uitkomsten van een gerandomiseerde klinische 
studie over initiële beademingsstrategie. In deel iV wordt op de leeftijd van één en 
twee jaar de neuropsychologische ontwikkeling onderzocht in hoog-risico kinderen 
met CDH. In deel V wordt het effect van patiëntkarakteristieken en centra specifieke 
verschillen op uitkomst onderzocht.
DEEl i – introDUCtiE
In hoofdstuk 1 wordt de geschiedenis van CDH beschreven. Daarnaast wordt de ante-
natale periode waarin het diafragma defect ontdekt zou moeten worden door prenatale 
echoscopie toegelicht. Antenataal voorspellende markers voor uitkomst zoals de “long-
hoofd ratio” (LHR) en de “geobserveerde ten opzichte van de verwachte long-hoofd 
ratio” (O/E LHR) worden uitgelegd. Vervolgens wordt de postnatale periode besproken 
waarin de focus ligt op predictiemodellen en daarnaast biomarkers die betrokken zijn 
bij pulmonale hypertensie. Hiervan worden ook de beperkingen besproken. De manier 
waarop het CDH EURO Consortium was opgericht, wordt beschreven. Vervolgens wordt 
uitgelegd wat er momenteel al door het consortium bereikt is, zoals de consensus van 
het gestandaardiseerde behandelingsprotocol en het opzetten van de klinische studie 
naar initiële behandelingsstrategie. Vervolgens wordt kort de morbiditeit besproken en 
de neuropsychologische ontwikkeling van CDH patiënten. Tot slot worden verschillen 
tussen CDH centra bediscussieerd zoals de beschikbaarheid van extracorporele mem-
braan oxygenatie (ECMO).
DEEl ii – PrEDiCtiE
In hoofdstuk 2 wordt een landelijke studie in Nederland beschreven over de voorspel-
lende waarde van de O/E LHR voor overleving van CDH patiënten in een tijdperk van 
gestandaardiseerde postnatale behandeling. De O/E LHR werd middels 2D echografie 
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gemeten op drie tijdsmomenten; <24 weken zwangerschapsduur, tussen 24- 30 weken 
zwangerschap en na 30 weken zwangerschapsduur. Alle metingen werden verricht 
door één persoon. De eerst gemeten O/E LHR per patiënt voorspelde significant overle-
ving en ontwikkeling van chronische long ziekte in de overlevenden. Chronische long 
ziekte was gedefinieerd als zuurstofafhankelijkheid op dag 28. Longitudinale analyse 
van de O/E LHR metingen tijdens de zwangerschap liet geen significante associatie met 
overleving zien.
Hoofdstuk 3 betreft een prospectieve studie van 171 prenataal gediagnosticeerde 
CDH patiënten waarin we vonden dat de Score voor Neonatale Acute Fysiologie – II 
(SNAP-II score) overleving en ECMO behoefte kon voorspellen. Deze analyses werden 
gecorrigeerd voor kant van het defect, de lever positie, initiële beademingsstrategie, 
zwangerschapsduur, centrum van geboorte en O/E LHR. Dit simpele en snelle scorings-
systeem geeft inzicht in de prognose binnen één dag na de geboorte.
Sphingolipiden profielen werden onderzocht in hoofdstuk 4. Trachea aspiraten wer-
den verzameld op de dagen 1, 3, 7 en 14 na de geboorte in 72 CDH patiënten, geboren 
in totaal vier centra. In de multivariable logistische regressie analyse gecorrigeerd voor 
kant van het defect, lever positie en O/E LHR, bleek dat geen van de veranderingen van 
de sphingolipiden waardes significant geassocieerd was met mortaliteit/ ontwikkeling 
van bronchopulmonale dysplasie. Op dag 14 bleek dat enkel de lange keten ceramides 
18:1 en 24:0 significant verhoogd waren in patiënten die initieël beademd werden 
middels conventionele mechanische beademing ten opzichte van patiënten die initieël 
met hoog-frequente oscillatie beademd werden. Dit zou verklaard kunnen worden door 
hoge piek inspiratoire drukken en remodelling van de alveolair membraan.
In hoofdstuk 5 werd de waarde van hoog-sensitieve Troponine T (hsTnT) en N-terminal 
pro-brain natriuretic peptide (NT-proBNP) als predictieve biomarker onderzocht op de 
dagen 1, 3, 7 en 14. In de multivariable analyse met correctie voor multiple testen bleek 
dat geen van de waarden kon voorspellen of er sprake was van ernstige pulmonale hy-
pertensie, overlijden, ECMO behoefte of ontwikkeling van bronchopulmonale dysplasie. 
Toekomstig onderzoek zou zich daarom moeten richten of biomarker waarden bepaald 
voor en na de start van klinische interventies, zoals de start van iNO of start van ECMO, 
beter uitkomst zou kunnen voorspellen.
DEEl iii – BEHAnDElinG
In hoofdstuk 6 wordt een multicenter internationaal gerandomiseerd klinisch onder-
zoek beschreven over initiële beademingsstrategie. In dit onderzoek werden 171 prena-
taal gediagnosticeerde CDH kinderen, die geboren werden na een zwangerschapsduur 
van meer dan 34 weken, geïncludeerd. Zij werden gerandomiseerd voor hoog-frequente 
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oscillatie (HFO) of conventionele mechanische beademing (CMV). De primaire uitkomst-
maat was bronchopulmonale dysplasia (BPD) of overlijden op dag 28. Eénenveertig 
(45.1%) van de 91 patiënten gerandomiseerd voor CMV overleden/ ontwikkelden BPD 
vergeleken met 42 (53.8%) van de 80 patiënten in de HFO groep. De odds ratio voor 
overlijden/ BPD voor CMV versus HFO was 0.62 na correctie voor centrum van geboorte, 
LHR, kant van het defect en lever positie. Wij vonden dat patiënten die initieël beademd 
werden met CMV korter werden beademd, minder vaak ECMO nodig hadden, minder 
vaak iNO en sildenafil nodig hadden, korter vasoactieve medicatie nodig hadden en 
minder vaak falen van behandeling ondervonden in vergelijking met patiënten die 
initieel met HFO waren beademd. De belangrijkste beperking van het onderzoek was 
dat de van tevoren berekende steekproefgrootte niet gehaald werd vanwege beperkte 
financiële middelen en een gebrek aan een onderzoeksinfrastructuur in één groot 
centrum.
Een editorial over vloeibare beademing wordt beschreven in hoofdstuk 7. Dit 
editorial was gebaseerd op een laboratoriumonderzoek waarbij foetale instillatie van 
perfluorocarbon bij konijnen met geïnduceerde CDH onderzocht werd. Wij hebben 
verschillende studies over vloeibare beademing bij CDH bestudeerd. We concludeerden 
dat zodra er bewijs is dat er geen negatieve lange termijn effecten zijn van deze vorm 
van beademing, een gerandomiseerd onderzoek specifiek voor de meest ernstige CDH 
patiënten mogelijk een volgende stap zou kunnen zijn.
In hoofdstuk 8 wordt het prenatale en postnatale beloop van vijf neonaten met een 
prenataal gediagnosticeerde CDH beschreven. Deze patiënten werden niet routinema-
tig onmiddellijk na de geboorte geïntubeerd. Wij concludeerden dat deze methode 
toe te passen is in een selectie van CDH kinderen (LHR >2.5 of O/E LHR >50% en lever 
gepositioneerd in het abdomen), afhankelijk van het beloop van de transitionele fase.
Pulmonale hypertensie is de belangrijkste oorzaak van overlijden in kinderen met 
CDH. In hoofdstuk 9 hebben we de farmacodynmiek van medicamenten beschreven 
welke gebruikt worden in de behandeling van pulmonale hypertensie bij kinderen. Wij 
concludeerden dat betrouwbare data van de farmacodynamiek onderzocht in onder-
zoeken met grote patiëntenaantallen of gerandomiseerd gecontroleerd onderzoek in 
kinderen nog steeds ontbreekt voor de meeste medicamenten.
Hoofdstuk 10 beschrijft een update van het originele gestandaardiseerde neonatale 
behandelingsprotocol welke in 2010 gepubliceerd werd. Consensus werd bereikt in 
22 centra van het CDH EURO Consortium. Vijf experts hebben individueel het niveau 
van het beschikbare bewijs beoordeeld. Verschillen in mening werden bediscussieerd 
totdat volledige consensus bereikt werd. De belangrijkste nieuwe aanbevelingen zijn: 
1) geplande geboorte na een zwangerschapsduur van 39 weken in een groot tertiair 
centrum; 2) neuromusculaire blokkade zou vermeden moeten worden tijdens de initiële 
behandeling in de opvangkamers; 3) preductale saturatie tussen 80-95% en postductale 
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saturatie >70% zou moeten worden nagestreefd middels het aanpassen van de behan-
deling; 4) streef naar PaCO2 waarden tussen 50- 70 mmHg; 5) conventionele mechani-
sche beademing is de optimale initiële beademingsstrategie; en 6) intraveneus sildenafil 
moet overwogen bij CDH patiënten met ernstige pulmonale hypertensie.
DEEl iV – UitKomSt
In een observationale, prospectieve cohort studie, beschreven in hoofdstuk 11, is 
de neuropsychologische uitkomst bestudeerd in 88 hoog-risico CDH patiënten. Deze 
patiënten werden behandeld volgens het gestandaardiseerde neonatale behandelings-
protocol. Patiënten geboren in twee centra van het CDH EURO Consortium (Rotterdam 
of Rome) konden geïncludeerd worden. Cognitie en motoriek werden onderzocht met 
behulp van de Bayley Scales of Infant Development (BSID) test. In Rotterdam werd de 
BSID-II versie met Nederlandse normaalwaarden gebruikt en in Rome werd de BSID-III 
versie met Amerikaanse normaalwaarden gebruikt. Op de leeftijd van 12 maanden was 
de cognitie normaal in 77.8% van de kinderen uit Rotterdam en in 94.8% van de kinde-
ren uit Rome. Op de leeftijd van 24 maanden was dat in respectievelijk 70.7% en 97.4% 
het geval. Motoriek was normaal gescoord in 64.3% van de kinderen uit Rotterdam en 
in 81.6% van de kinderen uit Rome op de leeftijd van 12 maanden. Op de leeftijd van 24 
maanden was dat in respectievelijk 45.7% en 89.8% het geval. Deze opvallende verschil-
len in uitkomsten tussen de twee centra laten zien dat de resultaten voorzichtig geïnter-
preteerd moeten worden voor andere centra. Toekomstige multicenter samenwerking 
zou zich daarom ook niet alleen moeten richten op standaardisatie van postnatale 
behandeling maar ook op internationale standaardisatie van de follow-up met als doel 
om risicofactoren te identificeren en daarmee de morbiditeit te verminderen.
DEEl V – BESCHoUWinG
In hoofdstuk 12 worden verschillen tussen patiëntpopulaties van vier grote centra, 
waarvan twee met beschikbaarheid van ECMO, retrospectief geëvalueerd. In deze studie 
werden 975 CDH patiënten geboren tussen 2004 en 2013 geïncludeerd. Wij vonden dat 
de overleving significant varieerde over de jaren en tussen centra. De karakteristieken 
van de patiëntenpopulaties waren zeer verschillend tussen de centra en dit was van 
invloed op de toekomst. Daarom zijn we van mening dat in toekomstige multicenter 
onderzoeken uitkomsten geëvalueerd zouden moeten worden over een lange tijd en 
dat daarnaast de analyses gecorrigeerd moeten worden voor het centrum van geboorte.
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DEEl Vi – AlGEmEnE DiSCUSSiE
In de algemene discussie in hoofdstuk 13 worden verbanden tussen het beschreven 
onderzoek uit dit proefschrift en de literatuur gelegd. Daarnaast worden implicaties 
voor toekomstig multicenter onderzoek gegeven. Zowel de sterke punten als de limita-
ties van de beschreven studies worden bediscussieerd. De belangrijkste bevindingen en 
aanbevelingen zijn de volgende:
– Multicenter samenwerking is essentieel in een relatief zeldzaam aangeboren afwij-
king zoals CDH.
– Gestandaardiseerde behandeling tussen centra is essentieel om patiëntenpopula-
ties te evalueren.
– Cruciaal voor multicenter onderzoek is een goede onderzoek infrastructuur waar 
financiële ondersteuning en databeheer ook bij hoort.
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DAnKWoorD
Na afgelopen jaren met veel plezier aan dit promotieonderzoek te hebben gewerkt, ben 
ik nu toegekomen aan het schrijven van het laatste gedeelte van mijn proefschrift: het 
dankwoord. Dit onderzoek is tot stand gekomen met de hulp van velen, van wie ik er 
een aantal in het bijzonder wil bedanken.
Allereerst alle ouders van de patiënten met een congenitale hernia diafragmatica die 
meegedaan hebben aan de VICI-trial. Ik heb niet alleen bewondering voor het feit dat 
jullie besloten om mee te willen doen aan dit onderzoek in een zeer spannende en 
moeilijke periode, maar ook voor jullie interesse in het onderzoek.
Mijn promotoren; Prof. Dr. D. Tibboel en Prof. Dr. R.M.H. Wijnen.
Allereerst prof. Tibboel, beste Dick, toen ik als medisch student met u sprak over de 
mogelijkheden van een promotie op de ICK, werd ik direct enthousiast toen u me ver-
telde over de VICI-trial. Ik ben heel dankbaar dat ik het vertrouwen heb gekregen om 
dit mooie project met nieuwe energie voort te zetten. Ik denk dat we er het maximale 
uit hebben gehaald, mede door de goede werkflow met in sommige periodes praktisch 
dagelijks overleg. Ik bewonder uw passie en immer aanwezige enthousiasme voor het 
onderzoek, wat ook bij mij altijd aanstekelijk werkte. Ik ben er dan ook heel trots op de 
eer te hebben uw 100e promovenda te zijn.
Mijn tweede promotor, prof. Wijnen. Beste René, ik ben je bovenal dankbaar voor je 
vertrouwen in mij en de mogelijkheid om naast dit onderzoek ook mijn klinische vaar-
digheden te ontwikkelen als arts-assistent kinderchirurgie. Ik kijk met veel plezier terug 
op onze gezamenlijke diensten, die we ook altijd gebruikten om de voortgang van mijn 
promotie te bespreken. 
Mijn copromotor, dr. H. IJsselstijn. Hanneke, wat ben ik blij dat ik met al mijn vragen heel 
laagdrempelig bij jou terecht kon. En ook dat je altijd in recordtijd reageerde op elke 
mail, of het nu een korte vraag was of een volgende versie van een artikel. Je neemt 
echt de tijd voor de promovendi die je begeleidt. Vooral de laatste maanden heb je me 
erg geholpen met de planning van het laatste deel, waarin in korte tijd nog veel gedaan 
moest worden, wat ik erg waardeer. 
Prof. Dr. I.K.M. Reiss, beste Irwin, na het moment dat ik toevallig van jou mijn geneeskunde-
diploma uitgereikt heb gekregen, hebben we voor de VICI-trial veel samengewerkt. Al 
ben je officieel niet mijn promotor, in de praktijk voelde dat de afgelopen jaren soms wel 
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zo. Je bent altijd erg betrokken geweest en ik kon altijd bij je aankloppen voor een vraag, 
dilemma of een discussie over de resultaten. Je sloot standaard af met de woorden “alles 
kommt gut” en je hebt gelijk gekregen!
My PhD project could not have been successful without the great collaboration within 
the CDH EURO Consortium. I feel honoured to have been part of this consortium for the 
last few years. All your hard work for the VICI-trial has led to the first successful collabora-
tive papers, and hopefully many other research projects will follow. A special thanks to 
some of you. First Dr. I. Capolupo and Dr. A. di Pede, dear Irma and Alessandra, thank you 
for your continuous interest, warm welcome and nice dinners during my visits to Rome. 
Prof. A. Greenough, dear Anne, I feel honoured that you are a member of the committee. 
I have always much appreciated your critical revisions on the papers. Prof. Dr. L.M. Wes-
sel, beste Lucas, hartelijk dank voor alle hulp afgelopen jaren en deelname in de kleine 
commissie. Dr. A. van Heijst, beste Arno, hartelijk dank voor de prettige samenwerking. 
Wat leuk dat je nu ook bij het laatste stukje van mijn promotie betrokken bent als lid van 
de grote commissie. 
Prof. Dr. J.C. de Jongste, dank voor uw bereidwilligheid om de rol van secretaris binnen 
de kleine commissie te vervullen. Prof. Dr. A.P. Bos, dank voor uw deelname in de grote 
commissie. 
Alle co-auteurs, hartelijk dank voor de prettige samenwerking. Een speciale dank voor 
Martin Post, ik heb je hulp bij het onderzoek naar de sphingolipiden erg gewaardeerd. 
Joost, dank je wel voor je hulp bij de statistiek. Ulrike, wat was het leuk om samen twee 
artikelen te schrijven. Je warme persoonlijkheid en betrokkenheid hebben me goed 
gedaan. Beste Ko, wat fijn dat je altijd en snel de manuscripten van commentaar op het 
Engels hebt willen voorzien, ik heb veel van je geleerd. Ook vind ik het erg leuk dat ik je 
huis in Bali heb gezien.
De VICI-trial draaide al een aantal jaren voordat ik het stokje over heb mogen nemen. 
Lieke, dank je wel voor het opzetten van deze prachtige trial en het eerste deel van de 
inclusieperiode. Sanne, dank je voor je inzet voor het tweede deel van de inclusieperi-
ode. Alle stafartsen, fellows en verpleegkundigen van de ICK wil ik ook hartelijk danken 
voor hun hulp bij de inclusie, telefoontjes over nieuw geboren patiënten en hulp bij 
afname van bloed-, urine- en trachea aspiraat-samples. 
Annemarie, Karin, Marie-Louise en Marja, veel dank voor alle hulp bij het inplannen van 
afspraken, verzamelen van handtekeningen, hulp bij praktische zaken maar vooral ook 
alle leuke praatjes tussendoor. 
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Joke, wat was het fijn dat ik altijd bij je mocht aankloppen als ik weer iets nodig had 
aan materialen toen de VICI nog liep. Fijn ook dat je me geholpen hebt met de vriezer-
perikelen, maar bovenal wil ik je bedanken voor je hulp bij het organiseren van al het 
papierwerk van de VICI-trial.
Dr. M. van Dijk, Monique, wat heb ik geboft dat ik onder jouw fantastische begeleiding 
mijn keuze-onderzoek in Kaapstad heb mogen doen. Ik heb toen als beginnend onder-
zoeker, die nog van niets wist, heel veel van je geleerd, maar bovenal heb je me erg 
enthousiast gemaakt voor onderzoek. Ik ben er dan ook van overtuigd dat ik zonder jou 
niet was begonnen aan een promotietraject! 
Juist ook de combinatie met het klinische werk maakte dat ik de afgelopen jaren als 
beginnend arts veel geleerd heb. Alle (fellow) kinderchirurgen; Claudia, Conny, Hester, 
John, Kees, Marco, Pim, René en Sheila, tijdens de diensten heb ik veel opgestoken van 
jullie kennis, aanpak en enthousiasme. Daarbij was humor altijd aanwezig. Verpleegkun-
dig specialisten en verpleegkundigen van de kinderchirurgie, dank voor jullie interesse 
en gezelligheid tijdens de diensten! 
Collega arts-assistenten; Daphne, Desiree, Lisette, Rhiana en Willem, ondanks dat we 
elkaar als groep niet heel vaak zagen, kijk ik met veel plezier terug op de etentjes! 
Daphne, de congressen in Canada vorig jaar waren ontzettend leuk. Desiree, wat een 
eer om van zo dichtbij jouw promotie mee te hebben gemaakt. Je bent een geweldige 
arts en verdient die felbegeerde plek zo! Rhiana, ik heb respect voor hoe je thuis en werk 
combineert, ik hoop van harte dat je je opleidingsplek binnensleept.  
Alle kamergenoten van de afgelopen jaren. Alexandra, wat heb jij hard gewerkt terwijl je 
ook altijd voor anderen klaar stond, nu volop genieten van een prachtige reis en daarna 
blijven we toch nog collega’s. Annelieke, Bianca, Manuel en Tanja; nog niet zo heel lang 
bij ons op de kamer maar vanaf de eerste dag was het gezellig en zijn jullie altijd in voor 
een goede lunch, AH koffie en natuurlijk het “nieuwe foute uur van Sp-2430”. Lisette, wat 
werk je hard! Fijn ook om af en toe ons hart te kunnen luchten als het onderzoek even 
tegen zat. Ik ben zo benieuwd naar jouw uiteindelijke boekje. Miriam, je promotie zit er 
op, je hebt het gedaan. Nu kan je je vol op je droomopleiding tot kinderarts gaan richten. 
Nienke, het was gezellig, die maanden dat je tegenover me zat. Marlous en Raisa, de psy-
chologen van de groep. Dank jullie wel voor alle leuke gesprekken, het lachen en altijd 
luisterende oor. Willem, met veel verschillende technische projecten tegelijkertijd bezig 
en een ware “Adobe Illustrator master”. Aangezien je ook vaak ’s avonds nog aan het 
werk was, waren rustige avonddiensten nooit saai. Navin, hoewel geen kamergenoot, je 
was altijd geïnteresseerd in iedereen om je heen en bracht veel gezelligheid, waar je ook 
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kwam. Ook alle andere onderzoekers van het Sophia bedankt voor de SOV-weekenden, 
borrels en gezelligheid. Veel succes met het afronden van jullie promotie!
Lieve schoonfamilie, met veel plezier reis ik altijd af naar het gezellige Brabant. Dank 
jullie wel dat jullie me vanaf het eerste moment zo warm en enthousiast ontvangen 
hebben. Een schoonfamilie “krijg je er altijd bij”, maar ik heb het met jullie getroffen. 
Lieve vriendinnen, waar ik in het eerste jaar altijd moest zeggen “in principe kan ik wel, 
tenzij er een hernia patiënt geboren wordt “ en de laatste tijd wat minder vaak kon 
omdat “het boekje” afgeschreven moest worden, hoop ik dat komende tijd weer in te 
kunnen halen. Ik kijk uit naar nog heel veel leuke afspraken en gezellige etentjes!
Mijn twee lieve paranimfen, Dorian en Joreintje.
Dor, wat ben ik blij en trots dat je op die spannende dag achter me wil staan! Heel leuk dat 
je zo goed als alle ins en outs van mijn promotie weet en alle hoogte- en dieptepunten 
hebt meegemaakt, inclusief mijn eerste VICI-patiëntinclusie. Ik vind het heel leuk dat we 
allebei in Utrecht onze carrière voort gaan zetten. Dank je wel voor alles afgelopen jaren 
en ik kijk ook al uit naar jouw promotie! 
Jorein, dat ik jou als paranimf wilde vragen, wist ik bijna al vanaf het moment dat ik 
hieraan begon. Niets is je teveel gevraagd, je kunt heel goed organiseren en bent heel 
precies. Daarnaast weet je als geen ander wat promoveren inhoudt. Nu nog de laatste 
loodjes en dan heb je ook jouw prachtige (en enorm dikke) boekje echt in handen!
Lieve opa en oma, alles wat jullie voor ons gedaan hebben en nog steeds doen vind ik 
heel bijzonder. Ik ken niemand die letterlijk altijd zo vanzelfsprekend klaar staan voor 
iedereen als jullie. Of ik nu midden in de nacht met autopech in het Sophia sta en jullie 
kan bellen, of allerlei lekkere dingen meekrijg voor tijdens m’n diensten, jullie zijn zo 
betrokken. Daarom hoop ik dan ook dat jullie nog heel lang zo vitaal mogen blijven als 
nu en ook de altijd leuke etentjes in Utrecht nog lange tijd door kunnen gaan. 
Katinka en Kasper, m’n “kleine broertje en zusje”. Kaat, redelijk in hetzelfde voetpad 
tredend, is het fijn dat je altijd goed begrijpt waar ik mee bezig ben. Een jurk uitzoeken 
voor mijn promotie was heel leuk, samen shoppen moeten we ook maar weer eens wat 
vaker gaan inplannen hè?! Kas, nog heerlijk van het studentenleven aan het genieten. 
Toch moeten we altijd weer hard lachen tijdens alle familiedingen. Ik ben benieuwd 
welke richting je uiteindelijk op zal gaan! Lieve mam, hoewel je soms bezorgd was als 
ik weer eens moest werken, kan je nu zien waarvoor ik het gedaan heb en wat een 
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promotie inhoudt. Ik ga de gezellige ochtendjes voor mijn diensten waarin we konden 
bijkletsen met cappuccino en zon in de tuin, of wandelen met Vita missen! 
Lieve, lieve Dennis, wat ben ik gelukkig met jou. Hoewel afgelopen jaar “lekker druk” 
was voor ons allebei waardoor we heel wat weekenddagen samen werkend/ studerend 
hebben doorgebracht, hebben we ons er met daarnaast veel leuke dingen meer dan 
goed doorheen geslagen. Ik kijk dan ook uit naar een prachtige toekomst samen!
